Patent Application
20250034150
Provided are certain agents that inhibit Bruton's tyrosine kinase (Btk), and methods of making and using such agents.
Protein kinases are a large multigene family consisting of more than 500 proteins which play a critical role in the development and treatment of a number of human diseases in oncology, neurology and immunology.
The Tec kinases are non-receptor tyrosine kinases which consists of five members (Tec (tyrosine kinase expressed in hepatocellular carcinoma), Btk (Bruton's tyrosine kinase), Itk (interleukin-2 (IL-2)-inducible T-cell kinase; also known as Emt or Tsk), Rlk (resting lymphocyte kinase; also known as Txk) and Bmx (bone-marrow tyrosine kinase gene on chromosome X; also known as Etk)) and are primarily expressed in haematopoietic cells, although expression of Bmx and Tec has been detected in endothelial and liver cells. Tec kinases (Itk, Rlk and Tec) are expressed in T cell and are all activated downstream of the T-cell receptor (TCR). Btk is a downstream mediator of B cell receptor (BCR) signaling which is involved in regulating B cell activation, proliferation, and differentiation. More specifically, Btk contains a PH domain that binds phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 binding induces Btk to phosphorylate phospholipase C (PLCy), which in turn hydrolyzes PIP2 to produce two secondary messengers, inositol triphosphate (IP3) and diacylglycerol (DAG), which activate protein kinase PKC, which then induces additional B-cell signaling. Mutations that disable Btk enzymatic activity result in XLA syndrome (X-linked agammaglobulinemia), a primary immunodeficiency. Given the critical roles which Tec kinases play in both B-cell and T-cell signaling, Tec kinases are targets of interest for autoimmune disorders.
Given that Btk plays an important role in B-cell signaling, there is a great need in the art for effective inhibitors of Btk.
One aspect of the disclosure is a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
In a second aspect, the present disclosure provides a pharmaceutical composition comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
In a third aspect, the present disclosure provides methods of treating a disorder responsive to inhibition of Btk in a subject. The methods comprise administering to the subject an effective amount of at least one compound described herein, or a pharmaceutically acceptable salt thereof. The present disclosure also includes the use of at least one compound described herein, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disorder responsive to inhibition of Btk. Also provided is a compound described herein, or a pharmaceutically acceptable salt thereof for use in treating a disorder responsive to inhibition of Btk.
Other features or advantages will be apparent from the following detailed description of several embodiments, and also from the appended claims.
The compounds or pharmaceutically acceptable salts thereof, as described herein, can have activity as Btk modulators. In particular, compounds or pharmaceutically acceptable salts thereof, as described herein, can be Btk inhibitors.
The terms “a” and “an” do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item. Recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The endpoints of all ranges are included within the range and independently combinable. All methods described herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of examples, or exemplary language (e.g., “such as”), is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed.
The suffix “yl” added to the end of a chemical name indicates that the named moiety is bonded to the molecule at point. The suffix “ene” added to the end of a chemical name indicates that the named moiety is bonded to the molecule at two points. Examples include azetidinylene, pyrrolindinylene, piperidinylene, azapanylene or oxazapanylene, which indicates that an azetidine, pyrrolidine, piperidine, azapane or oxazapane is bonded to the remainder of the compound at two points.
As used herein, the term “alkyl” refers to a fully saturated branched or unbranched hydrocarbon moiety. In some embodiments, the alkyl comprises 1 to 20 carbon atoms, 1 to 10 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms. In some embodiments, an alkyl comprises from 6 to 20 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl.
“Alkenyl” refers to an unsaturated hydrocarbon group which may be linear or branched and has at least one carbon-carbon double bond. In some embodiments, alkenyl groups have 2 to 20 carbon atoms, 2 to 10 carbon atoms or 2-6 carbon atoms. The alkenyl group may contain 1, 2 or 3 carbon-carbon double bonds, or more. Examples of alkenyl groups include ethenyl, n-propenyl, iso-propenyl, n-but-2-enyl, n-hex-3-enyl and the like.
“Alkynyl” refers to an unsaturated hydrocarbon group which may be linear or branched and has at least one carbon-carbon triple bond. In some embodiments, alkynyl groups have 2 to 20 carbon atoms, 2 to 10 carbon atoms or 2-6 carbon atoms can be preferred. The alkynyl group may contain 1, 2 or 3 carbon-carbon triple bonds, or more. Examples of alkynyl groups include ethynyl, n-propynyl, n-but-2-ynyl, n-hex-3-ynyl and the like.
As used herein, the term “alkoxy” refers to a fully saturated branched or unbranched alkyl moiety attached through an oxygen bridge (i.e. a —O— C1-4 alkyl group wherein C1-4 alkyl is as defined herein). Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy and the like. In some embodiments, alkoxy groups have about 1-4 carbons, more preferably about 1-2 carbons.
As used herein, the term “aryl” is defined to include all-carbon monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups having a completely conjugated pi-electron system. An aryl group may have 6, 8, 9 or 10 carbon atoms in the ring(s). In some embodiments, an aryl group may have 6 or 10 carbon atoms in the ring(s). For example, as used herein, the term “(C6-C10)aryl” aromatic radicals containing from 6 to 10 carbon atoms such as phenyl, naphthyl, tetrahydronaphthyl, anthracenyl, indanyl and the like. An aryl group having 6 carbon atoms in the ring(s) may be optionally substituted by 1 to 5 suitable substituents.
In some embodiments, the number of carbon atoms in a group is specified herein by the prefix “Cx-xx” or “Cx-Cxx”, wherein x and xx are integers. For example, “C1-4alkyl” is an alkyl group which has from 1 to 4 carbon atoms.
As used herein, the term “carbocyclyl”, “carbocycle” or “carbocyclic ring” refers to a saturated or partially unsaturated monocyclic or bicyclic (e.g., fused, bridged or spiro ring systems) ring system which has from 4- to 12-ring members, all of which are carbon. The term “carbocyclyl” encompasses cycloalkyl groups and cycloalkenyl groups.
In one embodiment, the carbocyclyl is a 3- to 7-membered monocyclic carbocyclyl.
Exemplary 3- to 7-membered monocyclic carbocyclyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropenyl, cyclobutenyl, cyclopenentyl, cyclohexenyl, cycloheptenyl, cyclobutadienyl, cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, phenyl and cycloheptatrienyl.
In one embodiment, the carbocyclyl is a 7- to 10-membered bicyclic carbocyclyl. Exemplary 7- to 10-membered bicyclic carbocyclyls include, but are not limited to, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[2.2]pentanyl, spiro[3.3]heptanyl, bicyclo[3.3.0]octanyl, bicyclo[2.2.2]octanyl, bicyclo[3.3.1] nonanyl, bicyclo[3.3.2]decanyl, decalinyl, naphthyl and indanyl.
A fused bicyclic carbocyclyl has a 4 to 7 membered carbocyclyl fused to a 3 to 7 membered non-aromatic carbocyclyl. Examples include decahydronaphthalene, octahydro-1H-indene, octahydropentalene, decahydroazulene, decahydro-1H-annulene, bicycle[4.2.0]octane, bicycle[3.2.0]heptane and the like.
A bridged bicyclic carbocyclyl comprises a non-aromatic 5 to 7 membered carbocyclyl which shares three ring atoms with a 5 to 7 membered non-aromatic carbocyclyl.
Examples of bridged bicyclics carbocycles include bicyclo[2.2.1]hepantyl, bicyclo[3.2.1]octanyl, and bicyclo[3.3.1]nonanyl.
“Cycloalkyl” refers to completely saturated monocyclic hydrocarbon groups of 3-7 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclopentyl; and “cycloalkyenyl” refers to unsaturated non-aromatic monocyclic hydrocarbon groups of 3-7 carbon atoms, including cyclopentenyl, cyclohexenyl and cyclopentenyl. The term “cycloalkyl” includes completely saturated monocyclic or bicyclic or spiro hydrocarbon groups of 3-7 carbon atoms, 3-6 carbon atoms, or 5-7 carbon atoms. In some embodiments, cycloalkyl is a 3- to 6-membered monocyclic cycloalkyl.
“Halogen” or “halo” may be fluoro, chloro, bromo or iodo.
The term “haloalkyl” or “halo-substituted alkyl” or refers to an alkyl group having at least one halogen substitution.
“Haloalkoxy” is a haloalkyl group which is attached to another moiety via an oxygen atom such as, e.g., but are not limited to —OCHCF2 or —OCF3.
“Heteroaryl” refers to an aromatic 5- to 6-membered monocyclic ring system, having 1 to 4 heteroatoms independently selected from O, N and S, and wherein N can be oxidized (e.g., N(O)) or quaternized, and S can be optionally oxidized to sulfoxide and sulfone.
Examples of 5- to 6-membered monocyclic heteroaryls include, but are not limited to, pyrrolyl, furanyl, thiophenyl (or thienyl), imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, furazanyl, oxadiazolyl, thiadiazolyl, dithiazolyl, triazolyl, tetrazolyl, pyridinyl, pyranyl, thiopyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl, dioxinyl, dithianyl, oxathianyl, triazinyl, tetrazinyl, and the like. In one embodiment, a heteroaryl is a 5-membered heteroaryl. Examples of a 5-membered heteroaryl include, but are not limited to, pyrazolyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, and tetrazolyl.
“Heterocyclyl” refers to a saturated or partially unsaturated monocyclic or bicyclic (e.g., fused, bridged or spiro ring systems) ring system which has from 3- to 12-ring members, at least one of which is a heteroatom, and up to 4 (e.g., 1, 2, 3, or 4) of which may be heteroatoms, wherein the heteroatoms are independently selected from O, S and N, and wherein C can be oxidized (e.g., C(O)), N can be oxidized (e.g., N(O)) or quaternized, and S can be optionally oxidized to sulfoxide and sulfone. In some embodiments, the heterocyclyl is a 4- to 6-membered or 3- to 7-membered monocyclic heterocyclyl. In some embodiments, the heterocyclyl is a 7- to 10-membered bicyclic heterocyclyl, which can be fused, bridged or spiro bicyclic heterocyclyl. In some embodiments, the bicyclic heterocyclyl may include a non-aromatic heterocycle fused to a heteroaromatic ring.
Examples of monocyclic heterocyclyl include, but are not limited to, oxetanyl, thietanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, thiolanyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dithiolanyl, oxathiolanyl, piperidinyl, tetrahydropyranyl, thianyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl, trioxanyl, trithianyl, azepanyl, oxepanyl, thiepanyl, dihydrofuranyl, imidazolinyl, and dihydropyranyl.
A “fused ring system” has from 8 to 12 members (ring atoms) and two rings which share two adjacent ring atoms. A fused bicyclic heterocyclyl has a 4 to 7 membered heterocycyl fused to a 4 to 7 membered heterocycyl or a 3 to 7 membered carbocyclyl. A fused bicyclic heterocyclyl can also have a 4 to 7 membered heterocycyl fused to a 5 to 6 membered heteroaryl. Examples include cyclopentapyrrolidinyl, cyclopentapiperidinyl, cyclopentaazapanyl, cyclohexapyrrolidinyl, cyclohexapiperidinyl, cyclohexaazapanyl, cycloheptapyrrolidinyl, cycloheptapiperidinyl, cycheptaazapanyl, pyrrolopyrrolidinyl, pyrrolopiperidinyl, pyrroloazapanyl, furanopyrrolidinyl, furanopiperidinyl, furanoazapanyl, pyranopyrrolidinyl, pyranopiperidinyl, pyranoazapanyl, dihydropyrrolo[3,4-d]thiazoyl and the like.
A “bridged bicyclic ring system” (also referred to herein as a “bridged bicyclic” or “bridged ring system”) has 7 to 10 members (ring atoms) and two rings which share three adjacent ring atoms. A bridged bicyclic heterocyclyl comprises a 5 to 7 membered heterocycyl which shares three ring atoms with a 5 to 7 membered heterocycyl or a 5 to 7 membered carbocyclyl. Examples nitrogen containing bridged bicyclics include azabicyclo[2.2.1]hepantyl, azabicyclo[3.2.1]octanyl, azabicyclo[3.3.1]nonanyl, diazabicyclo[2.2.1]hepantyl, diazabicyclo[3.2.1]octanyl and diazabicyclo[3.3.1]nonanyl.
Examples of oxygen containing bridged bicyclics include oxobicyclo[2.2.1]hepantyl, oxobicyclo[3.2.1]octanyl, oxobicyclo[3.3.1]nonanyl, oxa-azabicyclo[2.2.1]hepantyl, oxa-azabicyclo[3.2.1]octanyl and oxa-azabicyclo[3.3.1]nonanyl.
A “spiro ring system” (also referred to herein as a “spirocycle”) has 8 to 12 members (ring atoms) and two rings which share one ring atom. A spirobicyclic heterocyclyl comprises a 4 to 7 membered heterocycyl which shares one atom with a 4 to 7 membered heterocycyl or a 4 to 7 membered non-aromatic carbocyclyl. Examples of 8 to 12 nitrogen containing spiro rings systems include 3,4-azabicyclooctanyl, 4,4-azabicyclononanyl, 3,5-azabicyclononanyl, 3,6-azabicyclodecanyl, 4,5-azabicyclodecanyl, 3,7-azabicycloundecanyl, 4,6-azabicycloundecanyl and 5,5-azabicycloundecanyl. Examples of 8-12 oxygen containing spiro ring systems include 3,4-oxobicyclooctanyl, 4,4-oxobicyclononanyl, 3,5-oxobicyclononanyl, 3,6-oxobicyclodecanyl, 4,5-oxobicyclodecanyl, 3,7-oxobicycloundecanyl, 4,6-oxobicycloundecanyl and 5,5-xobicycloundecanyl.
The term “oxo” refers to the diradical ═O.
In cases where a compound provided herein is sufficiently basic or acidic to form stable nontoxic acid or base salts, preparation and administration of the compounds as pharmaceutically acceptable salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α-ketoglutarate, or α-glycerophosphate. Inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
Pharmaceutically-acceptable base addition salts can be prepared from inorganic and organic bases. Salts from inorganic bases, can include but are not limited to, sodium, potassium, lithium, ammonium, calcium or magnesium salts. Salts derived from organic bases can include, but are not limited to, salts of primary, secondary or tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines, substituted cycloalkyl amines, disubstituted cycloalkyl amine, trisubstituted cycloalkyl amines, cycloalkenyl amines, di(cycloalkenyl) amines, tri(cycloalkenyl) amines, substituted cycloalkenyl amines, disubstituted cycloalkenyl amine, trisubstituted cycloalkenyl amines, aryl amines, diaryl amines, triaryl amines, heteroaryl amines, diheteroaryl amines, triheteroaryl amines, heterocycloalkyl amines, diheterocycloalkyl amines, triheterocycloalkyl amines, or mixed di- and tri-amines where at least two of the substituents on the amine can be different and can be alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, or heterocycloalkyl and the like. Also included are amines where the two or three substituents, together with the amino nitrogen, form a heterocycloalkyl or heteroaryl group. Non-limiting examples of amines can include, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, trimethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, or N-ethylpiperidine, and the like. Other carboxylic acid derivatives can be useful, for example, carboxylic acid amides, including carboxamides, lower alkyl carboxamides, or dialkyl carboxamides, and the like.
The compounds or pharmaceutically acceptable salts thereof as described herein, can contain one or more asymmetric centers in the molecule. In accordance with the present disclosure any structure that does not designate the stereochemistry is to be understood as embracing all the various stereoisomers (e.g., diastereomers and enantiomers) in pure or substantially pure form, as well as mixtures thereof (such as a racemic mixture, or an enantiomerically enriched mixture). It is well known in the art how to prepare such optically active forms (for example, resolution of the racemic form by recrystallization techniques, synthesis from optically-active starting materials, by chiral synthesis, or chromatographic separation using a chiral stationary phase).
When a particular stereoisomer of a compound is depicted by name or structure, the stereochemical purity of the compounds is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99%, 99.5% or 99.9%. “Stereochemical purity” means the weight percent of the desired stereoisomer relative to the combined weight of all stereoisomers.
When a particular enantiomer of a compound is depicted by name or structure, the stereochemical purity of the compounds is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99%, 99.5% or 99.9%. “Stereochemical purity” means the weight percent of the desired enantiomer relative to the combined weight of all stereoisomers.
When the stereochemistry of a disclosed compound is named or depicted by structure, and the named or depicted structure encompasses more than one stereoisomer (e.g., as in a diastereomeric pair), it is to be understood that one of the encompassed stereoisomers or any mixture of the encompassed stereoisomers are included. It is to be further understood that the stereoisomeric purity of the named or depicted stereoisomers is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99%, 99.5% or 99.9%. The stereoisomeric purity the weight percent of the desired stereoisomers encompassed by the name or structure relative to the combined weight of all of the stereoisomers.
When a disclosed compound is named or depicted by structure without indicating the stereochemistry, and the compound has one chiral center, it is to be understood that the name or structure encompasses one enantiomer of compound in pure or substantially pure form, as well as mixtures thereof (such as a racemic mixture of the compound and mixtures enriched in one enantiomer relative to its corresponding optical isomer).
When a disclosed compound is named or depicted by structure without indicating the stereochemistry and, e.g., the compound has at least two chiral centers, it is to be understood that the name or structure encompasses one stereoisomer in pure or substantially pure form, as well as mixtures thereof (such as mixtures of stereoisomers, and mixtures of stereoisomers in which one or more stereoisomers is enriched relative to the other stereoisomer(s)).
The disclosed compounds may exist in tautomeric forms and mixtures and separate individual tautomers are contemplated. In addition, some compounds may exhibit polymorphism.
In one embodiment, the invention provides deuterated compounds disclosed herein, in which any or more positions occupied by hydrogen can include enrichment by deuterium above the natural abundance of deuterium. For example, one or more hydrogen atoms are replaced with deuterium at an abundance that is at least 3340 times greater than the natural abundance of deuterium, which is 0.015% (i.e., at least 50.1% incorporation of deuterium), at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). In one embodiment, hydrogen is present at all positions at its natural abundance. The compounds or pharmaceutically acceptable salts thereof as described herein, may exist in tautomeric forms and mixtures and separate individual tautomers are contemplated.
In a first embodiment, the compound of the invention is represented by Formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables are as described above.
In a second embodiment of the disclosure, for compounds of formula (I), or a pharmaceutically acceptable salts thereof, X3 is —OR5, —N(R5)2, 5- to 6-membered heteroaryl, or 4- to 7-membered monocyclic heterocyclyl, wherein the 5- to 6-membered heteroaryl and the 4- to 7-membered monocyclic heterocyclyl are optionally substituted with one or more (e.g., 1 to 6, 1 to 3, or 1, 2, 3, 4, 5 or 6) R50, and the remaining variables are as described in the first embodiment.
In a third embodiment of the present disclosure, for compounds of formula (I), or a pharmaceutically acceptable salts thereof, R0 is H; and the remaining variables are as described in the first or second embodiment.
In a fourth embodiment of the present disclosure, for compounds of formula (I), or a pharmaceutically acceptable salt thereof, the compound is represented by the following formula:
or pharmaceutically acceptable salts thereof; and the remaining variables are as described in the first or second embodiment.
In a fifth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or a pharmaceutically acceptable salts thereof, X3 is —OR5, —N(R5)2, 5-membered heteroaryl, or 4- to 6-membered monocyclic heterocyclyl, wherein the 5-membered heteroaryl and the 4- to 6-membered monocyclic heterocyclyl are optionally substituted with one to three R50; and R5 is C1-6 alkyl optionally substituted with C1-6 alkoxy; and the remaining variables are as described in the first, second, third or fourth embodiment.
In a sixth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, X3 is selected from phenyl, azetidine, morpholine, oxadiazole, piperazine, pyrazole, tetrazole, each optionally substituted with one or two R50; and the remaining variables are as described in the first, second, third, fourth or fifth embodiment.
In a seventh embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, X3 is selected from:
and m is 0, 1 or 2; and the remaining variables are as described in the first, second, third, fourth or fifth embodiment.
In an eighth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, X3 is selected from —O—CH2—CH2—OCH3, —N(CH3)2,
wherein represents a bond to Ring B; and the remaining variables are as described in the
first, second, third, fourth or fifth embodiment.
In a ninth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R50 for each occurrence, is independently C1-6 alkyl or a 4- to 6-membered monocyclic heterocyclyl, wherein the C1-6alkyl represented by R50 is optionally substituted with halo or CN; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh or eighth embodiment.
In a tenth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R50, for each occurrence, is independently selected from —CH3, —CH2—CN and
and the remaining variables are as described in the ninth embodiment.
In an eleventh embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R50 is —CH3; and the remaining variables are as described in the ninth embodiment.
In a twelfth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, Ring A is phenyl, 5 or 6-membered heteroaryl or 5 to 10-membered monocyclic or bicyclic heterocyclyl, each or which is optionally substituted with one to three R4; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth or eleventh embodiment.
In a thirteenth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, Ring A is selected from 3-azabicyclo[3.2.1]octane, azepane, phenyl, piperidine, pyridine and pyrrolidine, each of which is optionally substituted with one to three R4; and the remaining variables are as described in the twelfth embodiment.
In a fourteenth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, A is selected from:
wherein represents a bond to Ring B, and -* represents bond to
and the remaining variables are as described in the twelfth embodiment.
In a fifteenth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, n is 0, 1, 2; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth or fourteenth embodiment.
In a sixteenth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, Ring A is selected from:
wherein represents a bond to Ring B, and -* represents bond to
and the remaining variables are as described in the twelfth embodiment.
In a seventeenth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R4 is selected from halogen, C1-6 alkyl and C1-6 haloalkyl; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth or sixteenth embodiment.
In an eighteenth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R4 is selected from Cl, F, —CH3 and —CHF2; and the remaining variables are as described in the seventeenth embodiment.
In eighteenth nineteenth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R1 is 5-membered heteroaryl optionally substituted with one or two R10; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth or eighteenth embodiment.
In a twentieth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R1 is selected from oxazole, oxadiazole, pyrazole, tetrazole and triazole, each of which is optionally substituted with one or two R10; and the remaining variables are as described in the nineteenth embodiment.
In a twenty-first embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R1 is selected from:
and the remaining variables are as described in the nineteenth embodiment.
In a twenty-second embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R10, for each occurrence, is independently selected from C1-6 alkyl and C3-6 cycloalkyl, each of which is optionally substituted with one to three R15; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth or twenty-first embodiment.
In a twenty-third embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R10, for each occurrence, is independently selected from C1-4 alkyl and cyclopropyl, each of which is optionally substituted with one or three R15; and the remaining variables are as described in the twenty-second embodiment.
In a twenty-fourth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R15, for each occurrence, is independently selected from halogen, C1-4 alkyl and C1-4 haloalkyl; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second or twenty-third embodiment.
In a twenty-fifth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R15, for each occurrence, is independently selected from F, —CH3 and —CH2F; and the remaining variables are as described in the twenty-fourth embodiment.
In a twenty-sixth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R10, for each occurrence, is independently selected from —C(CH3)3, —C(CH3)2—CH2F,
and CH3; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth or twenty-first embodiment.
In a twenty-seventh embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R2 is H; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth or twenty-sixth embodiment.
In a twenty-eighth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R1 and R2, together with their intervening atoms, form a Ring D selected from 5- to 7-membered monocyclic heterocyclyl and 7- to 10-membered bicyclic heterocyclyl, wherein Ring D is optionally substituted with one or more (e.g., 1 to 6, 1 to 3, or 1, 2, 3, 4, 5 or 6) R100; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth or eighteenth embodiment.
In a twenty-ninth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, Ring D is selected from piperazinone and dihydropyrrolo[3,4-d]thiazolone, wherein Ring D is optionally substituted with one or two R100; and the remaining variables are as described in the twenty-eighth embodiment.
In a thirtieth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, Ring D is selected from:
wherein represents a bond to —C(R3)—Ring A; and the remaining variables are as described in the twenty-eighth embodiment.
In a thirty-first embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R100, for each occurrence, is independently selected from C1-6 alkyl and 4- to 6-membered monocyclic heterocyclyl, each of which is optionally substituted with one or two R150; and R150, for each occurrence, is independently selected from C3-6 cycloalkyl and 4- to 6-membered monocyclic heterocyclyl; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth or thirtieth embodiment.
In a thirty-second embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R100, for each occurrence, is independently selected from C1-6 alkyl and oxetanyl, wherein the C1-6 alkyl represented by R100 is optionally substituted with R150; and R150, for each occurrence, is independently selected from cyclobutyl and oxetanyl; and the remaining variables are as described in the thirty-first embodiment.
In a thirty-third embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R100, for each occurrence, is independently selected from —CH3, —CH2—CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH2—CH(CH3)2, —CH2—C(CH3)3,
and the remaining variables are as described in the thirty-first embodiment.
In a thirty-fourth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV), (V) or (VI), or pharmaceutically acceptable salts thereof, R3 is selected from H and C1-6 alkyl; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, thirty-second or thirty-third embodiment.
In a thirty-fifth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV) or (V), or pharmaceutically acceptable salts thereof, R3 is H or —CH3; and the remaining variables are as described in the thirty-fourth embodiment.
In a thirty-sixth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV) or (V), or pharmaceutically acceptable salts thereof, R3 and R4, together with their intervening atoms, form a Ring E, wherein Ring E is selected from 4- to 7-membered monocyclic carbocycle and 4- to 7-membered monocyclic heterocycle, wherein Ring E is optionally substituted with R300; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, thirty-second or thirty-third embodiment.
In a thirty-seventh embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV) or (V), or pharmaceutically acceptable salts thereof, Ring E is 5- to 7-membered monocyclic heterocycle optionally substituted with R300; and the remaining variables are as described in the thirty-sixth embodiment.
In a thirty-eighth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV) or (V), or pharmaceutically acceptable salts thereof, Ring E is represented by the following structural formula:
wherein represents a point of fusion to Ring A and -* represents a bond to —N(R2)—C(O)—R1; and the remaining variables are as described in the thirty-sixth embodiment.
In a thirty-ninth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV) or (V), or pharmaceutically acceptable salts thereof, R300, for each occurrence, is independently selected from C1-6 alkyl and 4- to 6-membered monocyclic heterocyclyl, wherein the C1-6 alkyl and 4- to 6-membered monocyclic heterocyclyl represented by R300 are each optionally substituted with one to three R350; and R350, for each occurrence, is independently halogen; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-ninth, thirtieth, thirty-first, thirty-second, thirty-third, thirty-fourth, thirty-fifth, thirty-sixth, thirty-seventh or thirty-eighth embodiment.
In a fortieth embodiment of the present disclosure, for compounds of formula (I), (II), (III), (IV) or (V), or pharmaceutically acceptable salts thereof, R300, for each occurrence, is independently selected from —CH2—CF3 and
and the remaining variables are as described in the thirty-ninth embodiment.
In a forty-first embodiment of the present disclosure, the compound is represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein: R1 is a 5-membered heteroaryl optionally substituted with R10; R10 is C1-4 alkyl, C1-4 haloalkyl or C3-6 cycloalkyl optionally substituted with C1-3 alkyl; X3 is a 5-membered heteroaryl or a 6-membered monocyclic saturated heterocyclyl, each of which is optionally substituted with R50; R50 is C1-3 alkyl or C1-3 haloalkyl; Ring A is phenyl, 6-membered heteroaryl or 6-membered monocyclic saturated heterocyclyl; R4, for each occurrence, is independently selected from halogen, C1-3 alkyl and C1-3 haloalkyl; and n is 0, 1 or 2.
In a forty-second embodiment of the present disclosure, for compounds of formula (IIA) or (IIIA), or pharmaceutically acceptable salts thereof, R1 is selected from oxadiazole, triazole and tetrazole, each of which is optionally substituted with R10; X3 is pyrazole or piperazine, each of which is optionally substituted with R50; and Ring A is phenyl, pyridine or piperidine; and the remaining variables are as described in the forty-first embodiment.
In a forty-third embodiment of the present disclosure, for compounds of formula (IIA) or (IIIA), or pharmaceutically acceptable salts thereof:
and
wherein represents a bond to Ring B, and -* represents bond to
and the remaining variables are as described in the forty-first embodiment.
In a forty-fourth embodiment of the present disclosure, for compounds of formula (IIA) or (IIIA), or pharmaceutically acceptable salts thereof, ring A is selected from:
wherein represents a bond to Ring B, and -* represents bond to
and the remaining variables are as described in the forty-third embodiment.
In a forty-fifth embodiment of the present disclosure, for compounds of formula (IIA) or (IIIA), or pharmaceutically acceptable salts thereof, R10 is
R4, for each occurrence, is independently selected from F, —CH3 and —CHF2; and R50 is —CH3; and the remaining variables are as described in the forty-first, forty-second, forty-third or forty-fourth embodiment.
The invention also includes both the neutral form and pharmaceutically acceptable salts of the compounds disclosed in the exemplification (e.g., compounds of Examples 1-174).
Another embodiment is a pharmaceutical composition comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
The compounds, or pharmaceutically acceptable salts thereof described herein may be used to decrease the activity of Btk, or to otherwise affect the properties and/or behavior of Btk, e.g., stability, phosphorylation, kinase activity, interactions with other proteins, etc.
In some embodiments, the present invention provides methods of decreasing Btk enzymatic activity. In some embodiments, such methods include contacting a Btk with an effective amount of a Btk inhibitor. Therefore, the present invention further provides methods of inhibiting Btk enzymatic activity by contacting a Btk with a Btk inhibitor of the present invention.
One embodiment of the invention includes a method of treating a disorder responsive to inhibition of Btk in a subject comprising administering to the subject an effective amount of at least one compound described herein, or a pharmaceutically acceptable salt thereof.
In one embodiment, the present invention provides methods of treating autoimmune disorders, inflammatory disorders, and cancers in a subject in need thereof comprising administering to the subject an effective amount of at least one compound described herein, or a pharmaceutically acceptable salt thereof.
The term “autoimmune disorders” includes diseases or disorders involving inappropriate immune response against native antigens, such as acute disseminated encephalomyelitis (ADEM), Addison's disease, alopecia areata, antiphospholipid antibody syndrome (APS), autoimmune hemolytic anemia, autoimmune hepatitis, bullous pemphigoid (BP), Coeliac disease, dermatomyositis, diabetes mellitus type 1, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's disease, idiopathic thrombocytopenic purpura, lupus erythematosus, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, pernicious anaemia, polymyositis, primary biliary cirrhosis, Sjogren's syndrome, temporal arteritis, and Wegener's granulomatosis. The term “inflammatory disorders” includes diseases or disorders involving acute or chronic inflammation such as allergies, asthma, prostatitis, glomerulonephritis, pelvic inflammatory disease (PID), inflammatory bowel disease (IBD, e.g., Crohn's disease, ulcerative colitis), reperfusion injury, rheumatoid arthritis, transplant rejection, and vasculitis. In some embodiments, the present invention provides a method of treating rheumatoid arthritis or lupus. In some embodiments, the present invention provides a method of treating multiple sclerosis.
The term “cancer” includes diseases or disorders involving abnormal cell growth and/or proliferation, such as glioma, thyroid carcinoma, breast carcinoma, lung cancer (e.g. small-cell lung carcinoma, non-small-cell lung carcinoma), gastric carcinoma, gastrointestinal stromal tumors, pancreatic carcinoma, bile duct carcinoma, ovarian carcinoma, endometrial carcinoma, prostate carcinoma, renal cell carcinoma, lymphoma (e.g., anaplastic large-cell lymphoma), leukemia (e.g. acute myeloid leukemia, T-cell leukemia, chronic lymphocytic leukemia), multiple myeloma, malignant mesothelioma, malignant melanoma, and colon cancer (e.g. microsatellite instability-high colorectal cancer). In some embodiments, the present invention provides a method of treating leukemia or lymphoma.
As used herein, the term “subject” and “patient” may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like). Typically, the subject is a human in need of treatment.
As used herein, the term “treating” or “treatment” refers to obtaining desired pharmacological and/or physiological effect. The effect can be therapeutic, which includes achieving, partially or substantially, one or more of the following results: partially or totally reducing the extent of the disease, disorder or syndrome; ameliorating or improving a clinical symptom or indicator associated with the disorder; or delaying, inhibiting or decreasing the likelihood of the progression of the disease, disorder or syndrome.
The effective dose of a compound provided herein, or a pharmaceutically acceptable salt thereof, administered to a subject can be 10 μg-500 mg.
Administering a compound described herein, or a pharmaceutically acceptable salt thereof, to a mammal comprises any suitable delivery method. Administering a compound described herein, or a pharmaceutically acceptable salt thereof, to a mammal includes administering a compound described herein, or a pharmaceutically acceptable salt thereof, topically, enterally, parenterally, transdermally, transmucosally, via inhalation, intracisternally, epidurally, intravaginally, intravenously, intramuscularly, subcutaneously, intradermally or intravitreally to the mammal. Administering a compound described herein, or a pharmaceutically acceptable salt thereof, to a mammal also includes administering topically, enterally, parenterally, transdermally, transmucosally, via inhalation, intracisternally, epidurally, intravaginally, intravenously, intramuscularly, subcutaneously, intradermally or intravitreally to a mammal a compound that metabolizes within or on a surface of the body of the mammal to a compound described herein, or a pharmaceutically acceptable salt thereof.
Thus, a compound or pharmaceutically acceptable salt thereof as described herein, may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the compound or pharmaceutically acceptable salt thereof as described herein may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, or wafers, and the like. Such compositions and preparations should contain at least about 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions can be such that an effective dosage level will be obtained.
The tablets, troches, pills, capsules, and the like can include the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; or a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent.
The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant.
Exemplary pharmaceutical dosage forms for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation can be vacuum drying and the freeze drying techniques, which can yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
Exemplary solid carriers can include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the compounds or pharmaceutically acceptable salts thereof as described herein can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
Useful dosages of a compound or pharmaceutically acceptable salt thereof as described herein can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949, which is incorporated by reference in its entirety.
The amount of a compound or pharmaceutically acceptable salt thereof as described herein, required for use in treatment can vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and can be ultimately at the discretion of the attendant physician or clinician. In general, however, a dose can be in the range of from about 0.1 to about 10 mg/kg of body weight per day.
The a compound or pharmaceutically acceptable salt thereof as described herein can be conveniently administered in unit dosage form; for example, containing 0.01 to 10 mg, or 0.05 to 1 mg, of active ingredient per unit dosage form. In some embodiments, a dose of 5 mg/kg or less can be suitable.
The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals.
The disclosed method can include a kit comprising a compound or pharmaceutically acceptable salt thereof as described herein and instructional material which can describe administering a compound or pharmaceutically acceptable salt thereof as described herein or a composition comprising a compound or pharmaceutically acceptable salt thereof as described herein to a cell or a subject. This should be construed to include other embodiments of kits that are known to those skilled in the art, such as a kit comprising a (such as sterile) solvent for dissolving or suspending a compound or pharmaceutically acceptable salt thereof as described herein or composition prior to administering a compound or pharmaceutically acceptable salt thereof as described herein or composition to a cell or a subject. In some embodiments, the subject can be a human.
The invention is illustrated by the following examples, which are not intended to be limiting.
According to a first process, wherein the A ring is phenyl or 5 or 6-membered heteroaryl, compounds of Formula (I), may be prepared from compounds of Formulae (II′), (III′), (IV′) and (V′) as shown in Scheme 1.
PG is a suitable N protecting group, typically a carbamate and preferable tert-butyl carbamate. LG is a leaving group, typically a halide, mesylate or triflate and preferably Br, Cl or triflate.
The compound of Formula (IV′) may be prepared from the compounds of Formulae (II′) and (III′) by process step a) a palladium catalysed, cross-coupling reaction, such as a Suzuki reaction. Typical cross-coupling reaction conditions comprise a palladium catalyst containing suitable phosphine ligands, in the presence of an inorganic base, in a suitable aqueous solvent at between RT and the reflux temperature of the reaction. Preferred conditions comprise, reaction of the compounds of Formulae (II′) and (III′), in the presence of tBuXPhos PdG3, Pd(t-Bu3P)2, Pd(dppf)Cl2, or RuPhos in combination with Pd2(dba)3 and a suitable base such as Na2CO3, K2CO3, Cs2CO3, K3PO4 or KF in a suitable solvent such as aqueous dioxane at between 40° C. and 100° C.
The compound of Formula (V′) may be prepared from the compound of Formula (IV′) according to process step b) de-protection of a N protecting group, under acidic conditions. Preferred conditions comprise, reaction of the compound of Formula (IV′) with HCl or TFA in a suitable solvent such as MeOH, dioxane, EtOAc or DCM at between RT and 50° C.
The compound of Formula (I) may be prepared according to process step c) an amide bond formation, from the amine of Formula (V′) and R1CO2H, in the presence of a suitable coupling agent and organic base, in a suitable polar aprotic solvent. Preferred conditions comprise the reaction of the acid, R1CO2H with the amine of Formula (V′) in the presence of coupling agent, T3P®, HATU or CDI, in the presence of an organic base such as TEA or DIPEA, in a solvent, such as DMF, EtOAc, dioxane or MeCN at between RT and the reflux temperature of the reaction.
Alternatively, the compounds of Formula (I) may be prepared according to process step d), an amide bond formation, by reaction of the amine of Formula (V′) with R1CO2(C1-C4 alkyl) in the presence of DABAL-Me3, according to the method described by Novak et al. (Tet. Lett. 2006, 47, 5767). Preferred conditions comprise reaction of the ester, R1CO2(C1-C4 alkyl) with the amine of Formula (V′) in the presence of DABAL-Me3, in a suitable solvent such as THF or dioxane at between RT and 45° C.
According to a second process, wherein A ring is phenyl or 5 or 6-membered heteroaryl, compounds of Formula (IV′), may be prepared from compounds of Formulae (II′), (VI′) and (VII′) as shown in Scheme 2.
Hal is halogen, preferably Cl or Br, and W is a boronic acid or boronate ester.
The compound of Formula (VII′) may be obtained from the compounds of Formulae (II′) and (VI′) according to process step (a), a Suzuki reaction, as previously described in Scheme 1.
When X3 is 5- to 6-membered heteroaryl, the compound of Formula (IV) may be obtained from the compounds of Formula (VII′) and X3—W according to process step (a), a Suzuki reaction, as previously described in Scheme 1.
When X3 is —N(R5)2, or an N-linked 4- to 7-membered monocyclic heterocyclyl, the compound of Formula (IV′) may be obtained by process step d) a Buchwald-Hartwig cross-coupling reaction. Typical conditions comprise, reaction of X3H with the compound of Formula (VII′) in the presence of a suitable inorganic base, a suitable palladium catalyst in the presence of suitable phosphine ligands, in a suitable solvent at elevated temperature. Preferred conditions comprise, reaction of the compounds of Formulae (VII′) and X3H in the presence of RuPhos in combination with Pd2(dba)3, in the presence of a suitable base such as K2CO3, K3PO4 or Cs2CO3 in a suitable solvent such as dioxane or toluene at between 70° C. and 110° C.
According to a third process, wherein the A ring is linked to the B ring through a N atom, the compound of Formula (IV′), may be prepared from compounds of Formulae (III′) and (VIII′) as shown in Scheme 3.
The compound of Formula (IV′) may be prepared according to process step e) an amination reaction. Typical conditions comprise reaction of the amine of Formula (VIII′) with the compound of Formula (III′), optionally in the presence of an organic or inorganic base, such as DIPEA or Cs2CO3 in IPA or DMF at RT.
According to a fourth process, the compound of Formula (I), may be prepared from the compounds of Formulae (II′), (VI′), (X′), (XI′) and (XII′) as shown in Scheme 4.
The compound of Formula (II′) may be prepared from the compound of Formula (XI′), according to process step (f), a boronate ester formation achieved by treatment with a suitable boronate such as (BPin)2, in the presence of a suitable inorganic base, such as K2CO3 or KOAc and a suitable catalyst, such as, Pd(dppf)Cl2 in a suitable non-polar solvent at between RT and elevated temperature. Preferred conditions comprise, treatment of the compound of Formula (II′) with (BPin)2 in the presence of Pd(dppf)Cl2 in the presence of KOAc in dioxane, at between RT and 90° C.
The compound of Formula (X′) may be prepared from the compound of Formula (II′) according to process step b) a deprotection reaction, as previously described in Scheme 1.
The compound of Formula (XI′) may be prepared from the compound of Formula (X′) and R1CO2H according to process step c) or R1CO2 (C1-C4)alkyl according to process step d) as previously described in Scheme 1.
The compound of Formula (XII′) may be prepared from the compounds of Formulae (XI′) and (VI′) according to process step a) as previously described in Scheme 1.
The compound of Formula (I) may be prepared from the compound of Formula (XII′) and X3H according to process steps a) or e) as previously described.
According to a fifth process, the compounds of Formula (XI′) may be prepared from the compound of Formula (XII′) as shown in Scheme 5.
The compound of Formula (XI′) may be prepared from the compound of Formula (XII′) according to process step f) as previously described in Scheme 4.
According to a sixth process, wherein the A ring is linked to the B ring through a N atom, the compounds of Formula (XI′) may be prepared from the compound of Formula (XII′) as shown in Scheme 6.
The compound of Formula (XV′) may be prepared from the compound of Formula (X′) and R1CO2H according to process step c) or R1CO2 (C1-C4)alkyl according to process step d) as previously described in Scheme 1.
The compound of Formula (XVI′) may be obtained from the compound of Formula (XVI′) according to process step b) as previously described in Scheme 1.
The compound of Formula (I) may be obtained from the compounds of Formulae (III′) and (XVI′) according to process step (e) as previously described in Scheme 3.
Compounds of Formulae (I) may be converted to alternative compounds of Formulae (I), by standard chemical transformations such as for example, alkylation of a heteroatom such as N, via reductive amination, or alkylation in the presence of an organic or inorganic base in a suitable solvent such as MeCN, using methods well known to those skilled in the art.
The compounds of Formulae (II′), (III′), (VI′), (VIII′), (XI′), (XIII′) and (XIV′) are commercially available, may be prepared by analogy to methods known in the literature, or the methods described in the Experimental section below.
It will be appreciated by those skilled in the art that it may be necessary to utilize a suitable protecting group strategy for the preparation of compounds of Formula (I). Typical protecting groups may comprise, carbamate and preferably Boc for the protection of amines.
It will be further appreciated that it may be necessary or desirable to carry out the transformations in a different order from that described in the schemes, or to modify one or more of the transformations, to provide the desired compound of the invention.
Preparative HPLC conditions
In the Example described below, the following preparative HPLC methods were used.
C.1 Preparation of [1,5-a]pyrazines
Diethyl 1H-pyrazole-3,5-dicarboxylate (69.6 g, 328 mmol) and Cs2CO3 (126 g, 388 mmol) were added to a solution of 2-bromo-1-(1-methyl-1H-pyrazol-4-yl)ethan-1-one (60.6 g, 298 mmol) in DMF (900 mL) and the reaction was stirred at RT overnight. The reaction mixture was diluted with water and extracted with DCM. The organic layer was dried (Na2SO4) and concentrated in vacuo. The crude product was suspended in heptanes: EtOAc 1:1 (50-100 mL) and filtered. The solid was washed with EtOAc and heptanes to give the product (68.5 g) as a white solid. The mother liquor was concentrated and purified by column chromatography (heptanes: EtOAc gradient 0 to 100%) to give additional product (9.7 g) to provide, 78.2 g (78% yield) of diethyl 1-(2-(1-methyl-1H-pyrazol-4-yl)-2-oxoethyl)-1H-pyrazole-3,5-dicarboxylate as a white solid. LCMS m/z=335.2 [M+H]+
A mixture of diethyl 1-(2-(1-methyl-1H-pyrazol-4-yl)-2-oxoethyl)-1H-pyrazole-3,5-dicarboxylate (15.0 g, 44.9 mmol) and NH4OAc (10.4 g, 135 mmol) in EtOH (150 mL) was heated at 130° C. for 24 h in a Berghoff reactor. The resulting suspension was filtered, the solid washed with water, and dried to give ethyl 4-hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (11.8 g, 92%) as a white solid. This reaction was performed batchwise on a total amount of 78.2 g of starting material, to provide a total of 66.6 g of product (92% yield). LCMS mz=288.3 [M+H]+
Ethyl 4-hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (66.6 g, 232 mmol) was suspended in MeOH (1.2 L), 1M NaOH (696 mL, 696 mmol) was added and the reaction stirred at RT overnight. The mixture was acidified to pH 2 with conc. HCl and filtered. The solid was washed with MeOH, transferred to a round bottom flask and azeotroped with MeCN. The solid was split in two portions and the hydrolysis was repeated. Methyl 4-hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (46.0 g, 116 mmol) was suspended in MeOH (1.2 L) and 1 M NaOH (348 mL, 348 mmol) and water (10 mL) were added and the reaction was stirred at RT overnight. The mixture was neutralized with conc. HCl, filtered and the solid was washed with MeCN, dioxane and dried under vacuum to give 4-hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylic acid (71.0 g, crude) containing a lot of salts. The reaction was then repeated with the second portion to provide an additional 60 g of crude product. LCMS m/z=258.0 [M+H]+
A three-necked flask was charged with pre-heated sulfolane (0.24 kg, 2.0 mol), which was heated to 50° C. 4-Hydroxy-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylic acid (41.8 g, 68 mmol) and a few drops of conc. sulfuric acid were added portion-wise and the reaction mixture was heated at 350° C. (external) for 4 h. The reaction was cooled to RT, diluted with DCM and purified by filtration through a short plug of silica eluting with 3 L of heptanes (fr1), 6 L heptanes: EtOAc 1:1 (fr2-3), 6 L EtOAc (fr4-5), 4 L DCM (fr6), 6 L DCM: MeOH 9:1 (fr7-8). The product (containing byproduct) (2.88 g, 20% yield) was isolated from fr7 as a brown solid. LCMS m/z=214.1 [M+H]+.
6-(1-Methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-ol (2.88 g, 13.4 mmol) was suspended in POCl3 (19.9 mL, 214 mmol) and the reaction was heated at 80° C. overnight. The mixture was diluted with MeCN and concentrated, the residue was suspended in DCM, and the mixture was washed with sat. NaHCO3 and brine, dried over Na2SO4 and concentrated. The crude product was purified by column chromatography (DCM: EtOAc/TEA(5%); gradient 0 to 25%) to give 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (1.35 g, 43% yield) as a yellow solid. LCMS m/z=234.0 [M+H]+.
A mixture of tert-butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (300 mg, 900 μmol), 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (210 mg, 900 μmol), K2CO3 (373 mg, 2.70 mmol) and Pd(dppf)Cl2•DCM (74 mg, 90 μmol) were dissolved in dioxane (7.2 mL) and water (1.8 mL) and N2 was bubbled through the mixture for 5 min. The reaction was heated to 100° C. under N2 and stirred at 100° C. for 3 h. The cooled reaction was concentrated and loaded directly onto a silica gel column. The crude material was purified via column chromatography (gradient: 0-75% [3:1 EtOAc/EtOH]: heptane) to afford tert-butyl (4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate as a white solid (264 mg, 73% yield). LCMS m/z=405.0 [M+H]+. 7. Synthesis of(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride
To a solution of tert-butyl (4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (264 mg, 653 μmol) in EtOAc (1 mL) was added 1M HCl in EtOAc (6.53 mL, 6.53 mmol) and the reaction stirred for 3 days at ambient temperature. The reaction mixture was concentrated to dryness to give (4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride, which was used without further purification (246 mg, crude). LCMS m/z=305.0 [M+H]+
To a solution of 1-(tert-butyl)-1H-pyrazole-3-carboxylic acid (21 mg, 123 μmol) in THF (2 mL) in an ice water cooling bath was added TEA (33 mg, 329 μmol) and HATU (63 mg, 164 μmol). The mixture was stirred at 0° C. for 10 min, then (4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (25 mg, 82 μmol) was added. The reaction mixture was warmed to 23° C. and stirred for 24 h. The reaction was quenched with water (5 mL) then extracted with EtOAc (3×5 mL). The organic phases were combined, washed with brine, dried (Na2SO4), filtered and concentrated. The crude material was purified by reverse phase HPLC (Method A, 5-60% gradient) to give 1-(tert-butyl)-N-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1H-pyrazole-3-carboxamide as a beige solid (14.6 mg, 39% yield). LCMS m/z=455.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.12 (s, 1H), 8.66 (t, J=6.4 Hz, 1H), 8.33 (s, 1H), 8.18 (d, J=2.4 Hz, 1H), 8.15-8.08 (m, 3H), 7.92 (d, J=2.4 Hz, 1H), 7.54 (d, J=8.5 Hz, 2H), 7.22-7.13 (m, 1H), 6.66 (d, J=2.4 Hz, 1H), 4.55 (d, J=6.7 Hz, 2H), 3.95-3.83 (m, 3H), 1.57 (s, 9H).
1-(Tert-butyl)-N-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1H-pyrazole-4-carboxamide was obtained as a beige solid (15.7 mg, 42% yield), from (4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 1, step 7) and 1-(tert-butyl)-1H-pyrazole-4-carboxylic acid following a similar method to that described for Example 1, Step 8. The crude material was purified by reverse phase HPLC (Method A, 5-55% gradient). LCMS m/z=455.1 [M+H]+1H NMR (500 MHz, DMSO-d6) δ: 9.13 (s, 1H), 8.67 (t, J=5.8 Hz, 1H), 8.34-8.32 (m, 2H), 8.18 (d, J=2.4 Hz, 1H), 8.13-8.10 (m, 3H), 7.92 (s, 1H), 7.52 (d, J=8.5 Hz, 2H), 7.15 (d, J=1.8 Hz, 1H), 4.54 (d, J=6.1 Hz, 2H), 3.90 (s, 3H), 1.53 (s, 9H).
2-(tert-Butyl)-N-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-2H-tetrazole-5-carboxamide was obtained as a beige solid (17.7 mg, 47% yield) from (4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 1, step 7) and 2-(tert-butyl)-2H-tetrazole-5-carboxylic acid following a similar method to that of Example 1, step 8. The crude material was purified by reverse phase HPLC (Method A, 5-55% gradient). LCMS m/z=457.1 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ: 9.67 (t, J=6.1 Hz, 1H), 9.13 (s, 1H), 8.33 (s, 1H), 8.18 (d, J=2.5 Hz, 1H), 8.14-8.10 (m, 3H), 7.56 (d, J=7.9 Hz, 2H), 7.16 (d, J=2.6 Hz, 1H), 4.60 (d, J=6.1 Hz, 2H), 3.90 (s, 3H), 1.74 (s, 9H).
1-(tert-Butyl)-N-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1H-1,2,3-triazole-4-carboxamide was obtained as a beige solid (18.2 mg, 49% yield), from (4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 1, step 7) and 1-(tert-butyl)-1H-1,2,3-triazole-4-carboxylic acid following a similar procedure to that of Example 1, Step 8. The crude material was purified by reverse phase HPLC (Method A, 5-55% gradient). LCMS m/z=456.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.18 (t, J=6.0 Hz, 1H), 9.12 (s, 1H), 8.71 (s, 1H), 8.33 (s, 1H), 8.19-8.18 (m, 1H), 8.12-8.09 (m, 3H), 7.54 (d, J=8.5 Hz, 2H), 7.15 (d, J=2.7 Hz, 1H), 4.57 (d, J=6.1 Hz, 2H), 3.90 (s, 3H), 1.64 (s, 9H).
N-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide was obtained as a yellow solid (13.2 mg, 35% yield) from (4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 1, step 7) and potassium 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate following a similar procedure to that Example 1, step 8. The crude material was purified by reverse phase HPLC (Method A, 5-60% gradient). LCMS m/z=455.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.54 (t, J=6.1 Hz, 1H), 9.13 (s, 1H), 8.34 (s, 1H), 8.19 (d, J=2.7 Hz, 1H), 8.13-8.11 (m, 3H), 7.54 (d, J=8.5 Hz, 2H), 7.16 (d, J=1.8 Hz, 1H), 4.56 (d, J=6.1 Hz, 2H), 3.90 (s, 3H), 1.54 (s, 3H), 1.41-1.37 (m, 2H), 1.18-1.16 (m, 2H).
A mixture of tert-butyl (2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (200 mg, 569.4 μmol), 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 133.06 mg, 569.4 μmol), K2CO3 (236.11 mg, 1.71 mmol), and Pd(dppf)Cl2 (20.83 mg, 28.5 μmol) were dissolved in dioxane (4.56 mL) and water (1.14 mL) and N2 was bubbled through the mixture for 5 min. The reaction was heated to 100° C. under an atmosphere of N2 and stirred at 100° C. overnight. The cooled reaction was concentrated and purified by silica gel column chromatography (gradient elution 0-100% EtOAc:Heptane) to afford tert-butyl (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (218 mg, 90.6% yield) as a light yellow solid. LCMS m/z=432.2 [M+H]+.
tert-Butyl (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (218 mg, 516.0 μmol) was dissolved in MeOH (5.16 mL) and HCl solution (1.25M in MeOH, 4.13 mL, 5.17 mmol) added and the reaction was stirred overnight at 50° C. The reaction was concentrated under vacuum and dried to afford (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (208 mg, crude) as a yellow solid. LCMS m/z=323.1 [M+H]+.
A stock solution of (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (320 mg), DCM (8 mL), and DIPEA (1.5 mL) was prepared. The stock solution (1.2 mL) was added to a vial containing potassium 5-tert-butyl-1,3,4-oxadiazole-2-carboxylate (25 mg, 121.4 μmol) which was then cooled to 0° C. HATU (52 mg) was added, and the reaction stirred overnight at RT. The reaction mixture was diluted with DCM (2 mL) and water (2 mL), the vials shaken, and the layers separated. The aqueous layer was extracted with DCM (2 mL) and the combined organic extracts evaporated. The residue was purified by prep-HPLC (Method B1, 5-60% gradient) to give 5-(tert-butyl)-N-(2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,3,4-oxadiazole-2-carboxamide. LCMS m/z=475.1 [M+H]+. 1H NMR (DMSO-d6) δ: 9.91 (t, J=6.1 Hz, 1H), 9.18 (d, J=1.2 Hz, 1H), 8.37 (s, 1H), 8.21 (d, J=2.4 Hz, 1H), 8.13 (s, 1H), 7.98 (s, 1H), 7.88-7.97 (m, 1H), 7.62 (s, 1H), 7.21 (d, J=2.4 Hz, 1H), 4.62 (d, J=6.1 Hz, 2H), 3.91 (s, 3H), 1.40 (s, 9H).
2-(tert-Butyl)-N-(2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-2H-tetrazole-5-carboxamide was obtained from 2-tert-butyltetrazolo-5-carboxylic acid and (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 6, step 2) following a similar procedure to that described in Example 6, step 3. The crude product was purified by prep HPLC (Method B1, 5-60% gradient). LCMS m/z=475.1 [M+H]+ 1H NMR (DMSO-d6) δ: 9.66 (t, J=6.1 Hz, 1H), 9.18 (d, J=1.2 Hz, 1H), 8.37 (s, 1H), 8.25-8.20 (m, 1H), 8.13 (s, 1H), 7.99 (dd, J=7.9, 1.8 Hz, 1H), 7.94 (dd, J=11.0, 1.8 Hz, 1H), 7.64-7.55 (m, 1H), 7.25-7.19 (m, 1H), 4.65 (d, J=6.1 Hz, 2H), 3.91 (s, 3H), 1.74 (s, 9H).
N-(2-Fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide was prepared from (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 6, step 2) and potassium 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate using a similar method to that used for Example 6, step 3. The crude material was purified by prep-HPLC (Method B1, gradient 5-60%). LCMS m/z=473.0 [M+H]+. 1H NMR (DMSO-d6) δ: 9.54 (t, J=5.8 Hz, 1H), 9.18 (s, 1H), 8.37 (s, 1H), 8.21 (d, J=2.4 Hz, 1H), 8.13 (s, 1H), 8.00 (dd, J=7.9, 1.8 Hz, 1H), 7.94 (dd, J=11.0, 1.2 Hz, 1H), 7.57 (t, J=7.9 Hz, 1H), 7.22 (d, J=2.4 Hz, 1H), 4.60 (d, J=6.1 Hz, 2H), 3.91 (s, 3H), 1.55 (s, 3H), 1.44-1.32 (m, 2H), 1.25-1.08 (m, 2H).
The compounds in the following table were prepared from (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 6, step 2) and the appropriate carboxylic acid, following a similar procedure to that described in Example 6, step 3.
Carboxylic Acid: 1-tert-butyltriazole-4-carboxylic acid Prep-HPLC (Method B1, 5-60% gradient) LCMS m/z = 474.1 [M + H]+. 1H NMR (DMSO-d6) δ: 9.24-9.11 (m, 2H), 8.72 (s, 1H), 8.37 (s, 1H), 8.20 (d, J = 2.4 Hz, 1H), 8.12 (s, 1H), 7.98 (d, J = 1.2 Hz, 1H), 7.93 (dd, J = 11.3, 1.5 Hz, 1H), 7.56 (s, 1H), 7.19-7.25 (m, 1H), 4.61 (d, J = 6.1 Hz, 2H), 3.91 (s, 3H), 1.64 (s, 9H).
Carboxylic acid: 1-tert-butylpyrazole-4-carboxylic acid Prep-HPLC (Method B1, 5-60% gradient) LCMS m/z = 473.1 [M + H]+. 1H NMR (DMSO-d6) δ: 9.17 (s, 1H), 8.66 (t, J = 5.8 Hz, 1H), 8.37 (s, 1H), 8.34 (s, 1H), 8.21 (d, J = 2.4 Hz, 1H), 8.13 (s, 1H), 7.99 (dd, J = 7.9, 1.8 Hz, 1H), 7.93 (s, 1H), 7.63-7.53 (m, 1H), 7.21 (d, J = 2.4 Hz, 1H), 4.56 (d, J = 6.1 Hz, 2H), 3.91 (s, 3H), 1.53 (s, 9H).
Carboxylic Acid: 1-tert-butylpyrazole-3-carboxylic acid Prep-HPLC (Method B1, 5-60% gradient) LCMS m/z = 473.1 [M + H]+1H NMR (DMSO-d6) δ: 9.17 (s, 1H), 8.65 (t, J = 6.1 Hz, 1H), 8.37 (s, 1H), 8.20 (d, J = 2.4 Hz, 1H), 8.13 (s, 1H), 7.99 (dd, J = 8.2, 1.5 Hz, 1H), 7.96-7.86 (m, 2H), 7.56 (t, J = 7.9 Hz, 1H), 7.22 (d, J = 2.4 Hz, 1H), 6.67 (d, J = 2.4 Hz, 1H), 4.59 (d, J = 6.1 Hz, 2H), 3.91 (s, 3H), 1.57 (s, 9H).
Carboxylic Acid: 2-tert-butyloxazole-4-carboxylic acid Prep-HPLC (Method B1, 5-60% gradient) LCMS m/z = 474.0 [M + H]+. 1H NMR (DMSO-d6) δ: 9.17 (s, 1H), 8.75 (t, J = 6.1 Hz, 1H), 8.56 (s, 1H), 8.37 (s, 1H), 8.20 (d, J = 2.4 Hz, 1H), 8.13 (s, 1H), 7.99 (dd, J = 7.9, 1.8 Hz, 1H), 7.93 (dd, J = 11.0, 1.2 Hz, 1H), 7.54 (t, J = 7.9 Hz, 1H), 7.21 (d, J = 1.8 Hz, 1H), 4.58 (d, J = 6.1 Hz, 2H), 3.91 (s, 3H), 1.48-1.27 (m, 9H).
Carboxylic acid: 3-(1-fluoro-2-methylpropan-2-yl)-1,2,4-oxadiazole-5- carboxylic acid (Example 71, step 6) Prep-HPLC (Method B1, 5-60% gradient) LCMS mz = 493.0 [M + H]+. 1H NMR (DMSO-d6) δ: 10.01 (t, J = 6.1 Hz, 1H), 9.18 (d, J = 1.2 Hz, 1H), 8.37 (s, 1H), 8.21 (d, J = 2.4 Hz, 1H), 8.13 (s, 1H), 8.00 (dd, J = 7.9, 1.8 Hz, 1H), 7.95 (dd, J = 11.3, 1.5 Hz, 1H), 7.63 (t, J = 7.9 Hz, 1H), 7.21 (dd, J = 2.4, 1.2 Hz, 1H), 4.71-4.57 (m, 3H), 4.53 (s, 1H), 3.91 (s, 2H), 1.38 (d, J = 1.8 Hz, 6H).
To a solution of tert-butyl (4-bromo-2-methylbenzyl)carbamate (80 g, 266.50 mmol) and (BPin)2 (81.21 g, 319.80 mmol) in dioxane (1 L) were added KOAc (78.46 g, 799.5 mmol) and Pd(dppf)Cl2 (9.75 g, 13.32 mmol) and the mixture was stirred at 90° C. for 16 h under a N2 atmosphere. The reaction mixture was diluted with H2O (600 mL) and extracted with EtOAc (3×500 mL). The combined organic layer was dried over Na2SO4 and filtered. The filtrate was concentrated in vacuo and the residue was purified by column chromatography on silica gel (PE/EtOAc=20/1) to give tert-butyl (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (85 g, 91.9% yield) as a yellow solid. 1HNMR (400 MHz, CDCl3) δ: 7.69-7.58 (m, 2H), 7.30-7.26 (m, 1H), 4.72 (br s, 1H), 4.36 (d, J=4.8 Hz, 2H), 2.35 (s, 3H), 1.48 (m, 9H), 1.38 (s, 12H). 2. Preparation of tert-butyl(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate
A mixture of 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 500 mg, 2.14 mmol), tert-butyl (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (900 mg, 2.59 mmol), K2CO3 (700 mg, 5.06 mmol), and Pd(dppf)Cl2 (30 mg, 41.0 μmol) was degassed under N2, then dioxane (10 mL) and water (2 mL) added and the reaction stirred at 90° C. in a sealed vessel for 20 mins. The reaction was removed from heating, allowed to cool to RT, then diluted with water (10 mL) and EtOAc (10 mL). The phases were allowed to separate, the aqueous layer was extracted with EtOAc (2×10 mL) and the organic layers combined and evaporated to dryness. The crude material was purified on silica gel (50% to 100% EtOAc in heptane) to give tert-butyl(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate as a light yellow solid, (830 mg, 92.7% yield). LCMS m/z=419.3 [M+H]+
A solution of tert-butyl(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (830 mg, 1.98 mmol) in 1.25M methanolic HCl (16 mL) was stirred at RT for 16 h. The mixture was heated to vigorous reflux for 1 h, then concentrated in vacuo to give 2-(tert-butyl)-N-(2-methyl-4-(5-(piperazin-1-yl)pyrimidin-4-yl)benzyl)-2H-tetrazole-5-carboxamide dihydrochloride as a light yellow solid. LCMS m/z=319.2 [M+H]+
SUBSTRATE STOCK SOLUTION—To an 8 mL vial was added 2-(tert-butyl)-N-(2-methyl-4-(5-(piperazin-1-yl)pyrimidin-4-yl)benzyl)-2H-tetrazole-5-carboxamide dihydrochloride (175 mg) and DIPEA (250 μL) in DMF (2.5 mL) and the mixture stirred for 10 mins.
To a vial containing potassium 5-tert-butyl-1,3,4-oxadiazole-2-carboxylate (20 mg, 96.03 μmol) was added 600 μL of the substrate stock solution followed by T3P® (125.0 mg, 196.43 μmol, 50% purity). and the reaction stirred at RT for 2 h. The reaction was quenched by the addition of satd. NaHCO3 (3 mL) and extracted with EtOAc (3 mL). The resulting aqueous slurry was extracted further with EtOAc (3×3 mL) and the combined organic layers were concentrated to dryness. The residue was diluted with DMSO (2 mL) and passed through a 0.2 um syringe filter. The product was isolated by prep-HPLC (Method B1, 5-60% gradient). LCMS m/z=471.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.85 (t, J=6.10 Hz, 1H) 9.13 (s, 1H) 8.34 (s, 1H) 8.19 (d, J=2.44 Hz, 1H) 8.12 (s, 1H) 7.95 (s, 2H) 7.50 (s, 1H) 7.15 (d, J=2.44 Hz, 1H) 4.56 (d, J=6.10 Hz, 2H) 3.92 (s, 3H) 2.49 (s, 3H) 1.41 (s, 9H).
2-(tert-Butyl)-N-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-2H-tetrazole-5-carboxamide was prepared from 2-tert-butyl-2H-1,2,3,4-tetrazole-5-carboxylic acid and 2-(tert-butyl)-N-(2-methyl-4-(5-(piperazin-1-yl)pyrimidin-4-yl)benzyl)-2H-tetrazole-5-carboxamide dihydrochloride (Example 14, step 3) following the method used in Example 14, step 4. LCMS m/z=471.3 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.58 (s, 1H) 9.13 (s, 1H) 8.34 (s, 1H) 8.19 (d, J=2.44 Hz, 1H) 8.12 (s, 1H) 7.95 (s, 2H) 7.51-7.43 (m, 1H) 7.18-7.12 (m, 1H) 4.59 (d, J=6.10 Hz, 2H) 3.91 (s, 3H) 2.50-2.48 (s, 3H) 1.75 (s, 9H).
1-(tert-Butyl)-N-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1H-1,2,3-triazole-4-carboxamide was prepared from 1-tert-butyltriazole-4-carboxylic acid and 2-(tert-butyl)-N-(2-methyl-4-(5-(piperazin-1-yl)pyrimidin-4-yl)benzyl)-2H-tetrazole-5-carboxamide dihydrochloride (Example 14, step 3) following the method used in Example 14, step 4. LCMS m/z=470.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.12 (s, 1H) 9.07 (s, 1H) 8.73 (s, 1H) 8.34 (s, 1H) 8.18 (d, J=2.44 Hz, 1H) 8.12 (s, 1H) 7.94 (s, 2H) 7.50-7.40 (m, 1H) 7.16 (d, J=2.44 Hz, 1H) 4.55 (d, J=6.10 Hz, 2H) 3.91 (s, 3H) 2.49-2.47 (m, 3H) 1.65 (s, 9H).
1-(tert-Butyl)-N-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1H-pyrazole-4-carboxamide was prepared from 1-tert-butylpyrazole-4-carboxylic acid and 2-(tert-butyl)-N-(2-methyl-4-(5-(piperazin-1-yl)pyrimidin-4-yl)benzyl)-2H-tetrazole-5-carboxamide dihydrochloride (Example 14, step 3) following the method used in Example 14, step 4. LCMS m/z=469.3 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.13 (d, J=1.22 Hz, 1H) 8.58-8.47 (m, 2H) 8.35 (d, J=5.49 Hz, 2H) 8.19 (d, J=2.44 Hz, 1H) 8.12 (s, 1H) 7.94 (s, 4H) 7.45 (d, J=8.55 Hz, 1H) 7.15 (d, J=2.44 Hz, 1H) 4.51 (d, J=5.49 Hz, 2H) 3.92 (s, 3H) 2.47 (s, 3H) 1.59-1.48 (m, 9H).
1-(tert-Butyl)-N-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1H-pyrazole-3-carboxamide was prepared from 1-tert-butylpyrazole-3-carboxylic acid and 2-(tert-butyl)-N-(2-methyl-4-(5-(piperazin-1-yl)pyrimidin-4-yl)benzyl)-2H-tetrazole-5-carboxamide dihydrochloride (Example 14, step 3) following the method used in Example 14, step 4. LCMS m/z=469.3 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.12 (d, J=1.22 Hz, 1H) 8.54 (t, J=6.10 Hz, 1H) 8.34 (s, 1H) 8.18 (d, J=2.44 Hz, 1H) 8.12 (s, 1H) 8.01-7.86 (m, 2H) 7.49-7.40 (m, 1H) 7.16 (s, 1H) 6.72-6.62 (m, 1H) 4.53 (d, J=6.10 Hz, 2H) 3.91 (s, 3H) 2.48 (s, 3H) 1.58 (s, 9H).
To a solution of (4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 1, step 7, 30 mg, 99 μmol) and ethyl 3-(tert-butyl)-1,2,4-oxadiazole-5-carboxylate (29 mg, 148 μmol) in THF (1.5 mL) was added DABAL-Me3 (38 mg, 148 μmol) and the reaction was heated to 45° C. and stirred at that temperature for 18 h. The reaction mixture was cooled to ambient temperature and diluted with water (1 mL), 1M HCl solution (1 mL) and EtOAc (5 mL). The layers were separated, and the aqueous phase was extracted with additional portions of EtOAc. The combined organic phase was washed with brine, dried (Na2SO4), filtered and concentrated. The crude material was purified by reverse phase HPLC (Method A, 5-65% gradient) to give 3-(tert-butyl)-N-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-5-carboxamide as a beige solid (4.7 mg, 10% yield). LCMS m/z=457.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.98 (t, J=6.2 Hz, 1H), 9.13 (s, 1H), 8.34 (s, 1H), 8.19 (d, J=2.4 Hz, 1H), 8.14-8.11 (m, 3H), 7.57 (d, J=7.9 Hz, 2H), 7.16 (s, 1H), 4.58 (d, J=6.1 Hz, 2H), 3.90 (s, 3H), 1.37 (s, 9H).
5-(1-(Fluoromethyl)cyclopropyl)-N-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide was obtained (29.6 mg, 47% yield) from (4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 1, step 7) and ethyl 5-(1-(fluoromethyl)cyclopropyl)-1,2,4-oxadiazole-3-carboxylate following a similar method to that of Example 19. The crude material was purified by reverse phase HPLC (Method C, 5-55% gradient). LCMS m/z=473.1 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ: 9.60 (t, J=6.4 Hz, 1H), 9.13 (s, 1H), 8.34 (s, 1H), 8.19 (d, J=2.4 Hz, 1H), 8.16-8.08 (m, 3H), 7.54 (d, J=7.9 Hz, 2H), 7.20-7.13 (m, 1H), 4.83 (s, 1H), 4.73 (s, 1H), 4.57 (d, J=6.1 Hz, 2H), 3.90 (s, 3H), 1.60-1.52 (m, 2H), 1.51-1.44 (m, 2H).
2-(tert-Butyl)-N-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-2H-1,2,3-triazole-4-carboxamide was obtained (23.8 mg, 39% yield) from (4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 1, step 7) and ethyl 2-(tert-butyl)-2H-1,2,3-triazole-4-carboxylate (Journal of Medicinal Chemistry (2018), 61(8), 3370-3388), following a similar method to that of Example 19. The crude material was purified by reverse phase HPLC (Method C, 5-60% gradient). LCMS m/z=456.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.13 (s, 1H), 9.05 (t, J=6.1 Hz, 1H), 8.33 (s, 1H), 8.18 (d, J=2.4 Hz, 1H), 8.16 (s, 1H), 8.14-8.10 (m, 3H), 7.55 (d, J=7.9 Hz, 2H), 7.19-7.14 (m, 1H), 4.57 (d, J=6.1 Hz, 2H), 3.90 (s, 3H), 1.69-1.62 (m, 9H).
To a solution of ethyl carbonocyanidate (10 g, 101 mmol) in EtOH (75 mL) and H2O (25 mL) was added Na2CO3 (10.7 g, 101 mmol) and hydroxylamine hydrochloride (7.0 g, 101 mmol) and the reaction mixture was stirred at 25° C. for 12 h. The mixture was poured into EtOAc (100 mL), filtered, and the filtrate was concentrated in vacuo. The residue was re-dissolved in EtOAc (100 mL), filtered, and the filtrate was concentrated in vacuo to give ethyl (E)-2-amino-2-(hydroxyimino)acetate as a yellow solid (10 g, crude), which was carried forward without further purification. 1H NMR (400 MHz, CDCl3) δ: 4.37-4.32 (m, 2H), 1.38-1.30 (m, 3H).
A mixture of ethyl (E)-2-amino-2-(hydroxyimino)acetate (500 mg, 3.8 mmol), 3-hydroxy-2,2-dimethylpropanoic acid (447 mg, 3.8 mmol), HATU (2.9 g, 7.6 mmol), and DIPEA (977 mg, 7.6 mmol) in DCM (10 mL) was stirred at 25° C. for 1 h. An additional volume of DCM (30 mL) was added and the organic phase was washed with H2O (10 mL×3). The organic phase was dried (Na2SO4), filtered, and concentrated in vacuo. The crude product was purified by silica-gel column chromatography (PE/EtOAc, 5:1 to 0:1) to give ethyl (E)-2-(3-hydroxy-2,2-dimethylpropanamido)-2-(hydroxyimino)acetate as a white solid (500 mg, yield: 57%). LCMS m/z=233.1 [M+H]+.
A solution of ethyl (E)-2-(3-hydroxy-2,2-dimethylpropanamido)-2-(hydroxyimino)acetate (500 mg, 2.2 mmol) in pyridine (10 mL) was heated to 80° C. and was stirred at that temperature for 12 h. The reaction mixture was concentrated in vacuo and the residue was purified by silica-gel column chromatography (PE/EtOAc, 10:1 to 1:1) to give ethyl 5-(1-hydroxy-2-methylpropan-2-yl)-1,2,4-oxadiazole-3-carboxylate as a colorless oil (250 mg, yield: 54%). LCMS m/z=215.1 [M+H]+.
To a solution of ethyl 5-(1-hydroxy-2-methylpropan-2-yl)-1,2,4-oxadiazole-3-carboxylate (430 mg, 2.0 mmol) and DIPEA (390 mg, 3.0 mmol) in DCM (10 mL) at 0° C. was added Tf2O (566 mg, 2.0 eq) and the reaction mixture was stirred at 25° C. for 2 h. An additional volume of DCM (40 mL) was added and the organic phase was washed with H2O (20 mL×3). The organic phase was dried (Na2SO4), filtered, and concentrated in vacuo. The crude product was purified by silica-gel column chromatography (PE/EtOAc, 10:1 to 1:1) to give ethyl 5-(2-methyl-1-(((trifluoromethyl)sulfonyl)oxy)propan-2-yl)-1,2,4-oxadiazole-3-carboxylate as a colorless oil (600 mg, yield: 86%). LCMS m/z=347.1 [M+H]+.
A solution of ethyl 5-(2-methyl-1-(((trifluoromethyl)sulfonyl)oxy)propan-2-yl)-1,2,4-oxadiazole-3-carboxylate (600 mg, 1.7 mmol) and tetrabutylammonium bifluoride (536 mg, 1.9 mmol) in THF (30 mL) was heated to 40° C. and stirred at that temperature for 12 h. The reaction mixture was cooled to ambient temperature and was concentrated in vacuo. The crude product was purified by silica-gel column chromatography (PE/EtOAc, 10:1 to 3:1) to give ethyl 5-(1-fluoro-2-methylpropan-2-yl)-1,2,4-oxadiazole-3-carboxylate as a colorless oil (330 mg, yield: 88%). LCMS m/z=217.1 [M+H]+.
5-(1-Fluoro-2-methylpropan-2-yl)-N-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide was obtained (37.6 mg, 60% yield) from ethyl 5-(1-fluoro-2-methylpropan-2-yl)-1,2,4-oxadiazole-3-carboxylate and (4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 1, step 7) following a similar method to that of Example 19. The crude material was purified by reverse phase HPLC (Method C, gradient 5-55%). LCMS m/z=475.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ=9.65 (t, J=6.1 Hz, 1H), 9.13 (d, J=1.2 Hz, 1H), 8.34 (s, 1H), 8.19 (d, J=2.4 Hz, 1H), 8.16-8.08 (m, 3H), 7.55 (d, J=8.5 Hz, 2H), 7.19-7.13 (m, 1H), 4.68 (s, 1H), 4.63-4.53 (m, 4H), 3.90 (s, 3H), 1.45 (d, J=1.2 Hz, 9H)
A mixture of tert-butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (350 mg, 1.05 mmol), 4,6-dichloropyrazolo[1,5-a]pyrazine (200 mg, 1.06 mmol), K3PO4 (2.0 M, 824.4 uL) and dioxane (5.0 mL) was stirred at RT and degassed for 10 mins by bubbling N2 through. Pd(t-Bu3P)2 (15 mg, 29.35 μmol) was added, the vial sealed, and the reaction stirred at 40° C. for 72 h. The reaction was diluted with water (10 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were concentrated to dryness and purified by silica gel column chromatography (heptanes to EtOAc) to give tert-butyl (4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate as a light yellow solid (290 mg, 76.3% yield). LCMS m/z=359.1 [M+H]+. 2. Preparation of tert-butyl (4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate
To a vial containing tert-butyl (4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (160 mg, 445.9 μmol) was added Pd2(dba)3 (20 mg, 21.8 μmol), Cs2CO3 (450 mg, 1.38 mmol) and RuPhos (20 mg, 42.9 μmol), the vial sealed and degassed under N2. Dioxane (5.04 mL) and morpholine (65 mg, 746.1 μmol) were added and the reaction stirred at 100° C. for 4 h. The cooled reaction was diluted with water (10 mL), extracted with EtOAc (3×10 mL) and the combined organic layers were concentrated to dryness to give a bright orange solid. This was purified by silica gel chromatography (heptanes to EtOAc) to give tert-butyl (4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate as a light yellow solid (150 mg, 82.2% yield). LCMS m/z=410.2 [M+H]+
A solution of tert-butyl (4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (150 mg, 366.3 μmol) and 4M HCl (500 uL) in dioxane (5.00 mL) was stirred at 50° C. for 16 h. The reaction mixture was concentrated in vacuo and azeotroped with MeOH to give (4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride as a tan solid (148 mg, crude). LCMS m/z=310.1 [M+H]+
To a vial was added (4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine hydrochloride (20 mg, 57.8 μmol), DABAL-Me3 (15 mg, 58.5 μmol) and ethyl 5-tert-butyl-1,2,4-oxadiazole-3-carboxylate (20 mg, 100.9 μmol) in dioxane (500 uL), the vial sealed and stirred at 120° C. for 10 min. Celite® (250 mg) was added to the cooled mixture, followed by water (0.5 mL) and EtOH (2 mL) and the mixture stirred for 15 mins. The slurry was centrifuged and mother liquor decanted. The remaining solids were extracted with EtOH (2×5 mL), repeating centrifugation and mother liquor collection. The combined mother liquors were concentrated to dryness to give a bright yellow solid. This was purified by prep-HPLC (Method C2, 5-60% gradient) to provide 5-(tert-butyl)-N-(4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide. LCMS m/z=462.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.59 (br t, J=6.10 Hz, 1H) 8.16 (s, 1H) 8.11-7.98 (m, 2H) 7.53 (d, J=8.55 Hz, 1H) 7.12-7.02 (m, 1H) 4.65-4.45 (m, 2H) 3.87-3.70 (m, 3H) 1.44 (s, 9H).
3-(tert-Butyl)-N-(4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-5-carboxamide was prepared from 5-tert-butyl-1,2,4-oxadiazole-2-carboxylate and (4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine hydrochloride (Example 23, step 3), following the method used in Example 23, step 4. LCMS m/z=462.2 [M+H]+. 1H NMR (DMSO-d6) δ: 10.04-9.92 (m, 1H), 8.16 (s, 1H), 8.11-8.04 (m, 2H), 8.03 (d, J=2.4 Hz, 1H), 7.53 (d, J=8.55 Hz, 2H), 7.12-7.02 (m, 1H), 4.65-4.45 (m, 2H), 3.87-3.70 (m, 4H), 1.44 (s, 9H).
SUBSTRATE STOCK SOLUTION—To a vial containing (4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 23, step 3, 105 mg, 0.339 mmol) was added DMF (5 mL) followed by DIPEA (130 mg) and the mixture stirred.
T3P® (50% purity) was added to a mixture of 2-(tert-butyl)-2H-tetrazole-5-carboxylic acid (80 μmol) and substrate stock solution (1 mL) and the reaction stirred at 50° C. for 3 h. The reaction was allowed to cool to RT, diluted with water (6 mL) and left to stand overnight. The vials were centrifuged, mother liquor decanted and discarded. The solids were slurried in water (5 mL), vortexed, centrifuged, mother liquor decanted and discarded. The crude material was dissolved in DMSO (2.2 mL) and purified by prep-HPLC (Method C2, gradient 5-60%) to afford 2-(tert-butyl)-N-(4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)benzyl)-2H-tetrazole-5-carboxamide. LCMS m/z=462.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.66 (t, J=6.41 Hz, 1H) 8.15 (d, J=1.22 Hz, 1H) 8.06 (d, J=7.94 Hz, 1H) 8.03 (d, J=2.44 Hz, 1H) 7.54 (d, J=8.55 Hz, 1H) 7.10-7.00 (m, 1H) 4.59 (d, J=6.10 Hz, 2H), 3.86-3.72 (m, 4H) 1.74 (s, 9H).
The compounds in the following table were prepared from (4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 23, step 3) and the appropriate carboxylic acid, following the method described in Example 25.
Carboxylic Acid: 1-tert-butyltriazole-4-carboxylic acid Prep-HPLC (Method C2, 5-60% gradient) LCMS m/z = 461.3 [M + H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.17 (t, J = 6.10 Hz, 1 H) 8.70 (s, 1 H) 8.14 (s, 1 H) 8.10-7.97 (m, 2 H) 7.52 (d, J = 8.55 Hz, 2 H) 7.11-7.01 (m, 1 H) 4.56 (d, J = 6.10 Hz, 2 H) 3.84-3.73 (m, 4 H) 1.64 (s, 9 H).
Carboxylic acid: 1-tert-butylpyrazole-4-carboxylic acid Prep HPLC (Method C2, 5-60% gradient) LCMS m/z = 460.2 [M + H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.66 (t, J = 5.80 Hz, 1 H) 8.32 (s, 1 H) 8.15 (d, J = 1.22 Hz, 1 H) 8.08-7.99 (m, 2 H) 7.92 (s, 1 H) 7.50 (d, J = 8.55 Hz, 2 H) 7.05 (d, J = 1.83 Hz, 1 H) 4.52 (d, J = 6.10 Hz, 2 H) 3.85-3.73 (m, 4 H) 1.53 (s, 9 H)
Carboxylic acid: 1-tert-butylpyrazole-3-carboxylic acid Prep-HPLC (Method C2, 5-60% gradient). LCMS m/z = 460.2 [M + H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.65 (t, J = 6.10 Hz, 1 H) 8.14 (s, 1 H) 8.09-7.97 (m, 2 H) 7.92 (d, J = 2.44 Hz, 1 H) 7.52 (d, J = 7.94 Hz, 2 H) 7.05 (d, J = 2.44 Hz, 1 H) 6.66 (d, J = 2.44 Hz, 1 H) 4.53 (d, J = 6.10 Hz, 2 H) 3.85-3.72 (m, 4 H) 1.73-1.46 (m, 9 H).
Carboxylic acid: potassium 5-tert-butyl-1,3,4-oxadiazole-2-carboxylate Prep-HPLC (Method C2, 5-60% gradient). LCMS m/z = 462.2 [M + H]+
PBr3 (0.95 mL, 10 mmol) was added dropwise to a solution of (4-bromo-2-methylphenyl)methanol (1.3 g, 6.7 mmol) in DCM (50 mL) at 0° C., the reaction was stirred at RT for 1 h, then quenched with ice-water (50 mL). The pH was adjusted to 7.0 with 50% aq. NaOH solution and the mixture was extracted with EtOAc (100 mL×2). The combined organic layers were washed with water (50 mL), dried (Na2SO4) and concentrated to give 4-bromo-1-(bromomethyl)-2-methylbenzene (1.56 g, yield: 89%) as a white solid which was used in the next step without further purification.
To a solution of tert-butyl 3-oxopiperazine-1-carboxylate (1.2 g, 6.0 mmol) in THF (200 mL) was added NaH (320 mg, 8.1 mmol) in an ice-bath and the mixture stirred at 0° C. for 1 h. A solution of 4-bromo-1-(bromomethyl)-2-methylbenzene (1.42 g, 5.4 mmol) in THF (5 mL) was added dropwise over a period of 10 min, the ice-bath was removed and the mixture stirred at RT for 2 h. The mixture was diluted with ice-water (50 mL) and extracted with EtOAc (100 mL×2). The combined organic phases were washed with brine (50 mL), dried (Na2SO4) and concentrated in vacuo. The residue was purified by silica gel column (PE/EtOAc=5:1) to give tert-butyl 4-(4-bromo-2-methylbenzyl)-3-oxopiperazine-1-carboxylate (1.6 g, yield: 77%) as white solid. LCMS m/z=327.0[M+H]+.
A mixture of tert-butyl 4-(4-bromo-2-methylbenzyl)-3-oxopiperazine-1-carboxylate (500 mg, 1.30 mmol), (BPin)2 (330.12 mg, 1.30 mmol), Pd(dppf)Cl2 (95.12 mg, 130 μmol) and KOAc (382.75 mg, 3.90 mmol) in dioxane (8.0 mL) was degassed and heated to 95° C. for 16 h. After cooling to RT, the crude was filtered through Celite® and the filtrate concentrated. The residue was chromatographed on silica gel (Heptanes/EtOAc 0-100%) to give tert-butyl 4-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-3-oxopiperazine-1-carboxylate (598 mg, crude). LCMS m/z=375.3 [M+H]+.
A mixture of tert-butyl 4-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-3-oxopiperazine-1-carboxylate (238 mg, 553.05 μmol), 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 129.23 mg, 553.05 μmol), Pd(dppf)Cl2 (40.47 mg, 55.30 μmol) and K2CO3 (229.31 mg, 1.66 mmol) in dioxane (3.0 mL) and water (1.0 mL) was degassed and heated to 95° C. for 16 h. The cooled mixture was filtered through Celite® and concentrated in vacuo. The residue was chromatographed on silica gel (Heptanes/EtOAc 0-100%) to give tert-butyl 4-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-3-oxopiperazine-1-carboxylate (136 mg, 49% yield). LCMS m/z=502.3 [M+H]+.
HCl (4 M, 203.36 uL) was added to a solution of tert-butyl 4-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-3-oxopiperazine-1-carboxylate (136 mg, 271.14 μmol) in MeOH (2.0 mL) and the reaction stirred at RT for 16 h. The reaction mixture was evaporated under reduced pressure to give 1-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)piperazin-2-one hydrochloride (114 mg, crude) which was used without further purification. LCMS m/z=402.3 [M+H]+
NaBH(OAc)3 (62.09 mg, 292.94 μmol) was added to a solution of 1-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)piperazin-2-one hydrochloride (58.80 mg, 146.47 μmol), isobutyraldehyde (25.23 mg, 351.53 μmol) and AcOH (8.80 mg, 146.47 μmol) in DCM (2.0 mL) and the reaction stirred at RT for 16 h. The mixture was quenched with MeOH and concentrated in vacuo. The residue was purified by prep HPLC to give 4-isobutyl-1-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)piperazin-2-one (53 mg, 75% yield). LCMS m/z=458.3 [M+H]+. 1H NMR (400 MHz, MeOH-d4) δ: 8.84-8.75 (m, 1H), 8.24-8.17 (m, 1H), 8.13-8.04 (m, 2H), 8.00-7.88 (m, 2H), 7.51-7.41 (m, 1H), 7.09-7.02 (m, 1H), 4.85 (br s, 2H), 4.13-4.05 (m, 2H), 4.01-3.92 (m, 3H), 3.70-3.57 (m, 4H), 3.18-3.08 (m, 2H), 2.54-2.45 (m, 3H), 2.29-2.14 (m, 1H), 1.08 (d, J=6.78 Hz, 6H).
1-(2-Methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-4-neopentylpiperazin-2-one was obtained (25.1 mg, 40% yield) from 1-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)piperazin-2-one hydrochloride (Example 30, step 4) and pivaldehyde following the method described in Example 30, step 5. LCMS m/z=472.2 [M+H]+. 1H NMR (400 MHz, MeOH-d4) δ: 8.87-8.79 (m, 1H), 8.26-8.19 (m, 1H), 8.12-8.06 (m, 2H), 8.01-7.91 (m, 2H), 7.50-7.41 (m, 1H), 7.10-7.02 (m, 1H), 4.85-4.80 (m, 2H), 4.10-4.03 (m, 2H), 4.00-3.94 (m, 3H), 3.67-3.53 (m, 4H), 3.14-3.04 (m, 2H), 2.53-2.46 (m, 3H), 1.14 (s, 9H).
1-(2-Methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-4-(oxetan-3-ylmethyl)piperazin-2-one was obtained (19.2 mg, 52% yield) from 1-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)piperazin-2-one hydrochloride (Example 30, step 4) and oxetane-3-carbaldehyde following the method described in Example 30, step 5. LCMS m/z=472.1 [M+H]+. 1H NMR (400 MHz, MeOH-d4) δ: 8.84-8.78 (m, 1H), 8.23-8.19 (m, 1H), 8.12-8.05 (m, 2H), 8.00-7.91 (m, 2H), 7.48-7.39 (m, 1H), 7.08-7.03 (m, 1H), 4.96-4.91 (m, 1H), 4.83 (br s, 2H), 4.55-4.49 (m, 2H), 4.14-4.09 (m, 1H), 4.00-3.98 (m, 5H), 3.74 (dd, J=4.6, 10.7 Hz, 1H), 3.64-3.44 (m, 6H), 2.47 (br s, 3H).
NaH (57.60 mg, 2.40 mmol) was added to a solution of tert-butyl 3-oxopiperazine-1-carboxylate (400 mg, 2.0 mmol) in THF (4.0 mL) at 0° C., the mixture stirred for 1 h, 1-bromo-4-(chloromethyl)benzene (410.96 mg, 2.0 mmol) was added and the reaction stirred at RT for 2 h. The reaction was quenched with aq. NaHCO3, extracted with EtOAc, the organic layer was dried over Na2SO4 and concentrated in vacuum. The residue was chromatographed on silica gel (Heptanes/EtOAc 0-100%) to give tert-butyl 4-(4-bromobenzyl)-3-oxopiperazine-1-carboxylate (54.50 mg, 7.4% yield). 2. Preparation of tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-3-oxopiperazine-1-carboxylate
A mixture of tert-butyl 4-((4-bromophenyl)methyl)-3-oxo-piperazine-1-carboxylate (54.30 mg, 147.05 μmol), (BPin)2 (37.34 mg, 147.05 μmol), KOAc (43.29 mg, 441.15 μmol) and Pd(dppf)Cl2·DCM (12.01 mg, 14.71 μmol) in dioxane (2.0 mL) was degassed and heated at 95° C. for 16 h. The cooled mixture was filtered through Celite® and the filtrate concentrated. The residue was chromatographed on silica gel (Heptanes/EtOAc 0-100%) to give tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-3-oxopiperazine-1-carboxylate (53.30 mg, 87.1% yield).
tert-Butyl 4-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-3-oxopiperazine-1-carboxylate was obtained (31.3 mg, 50.1% yield) from tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-3-oxopiperazine-1-carboxylate and 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5), following a similar method to that used in Example 30, step 3. LCMS m/z=488.4 [M+H]+
1-(4-(6-(1-Methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)piperazin-2-one hydrochloride was obtained crude, from tert-butyl 4-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-3-oxopiperazine-1-carboxylate following the method used in Example 30, Step 4. LCMS m/z=388.3 [M+H]+.
1-(4-(6-(1-Methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-4-neopentyl piperazin-2-one was obtained (14 mg, 95% purity) from 1-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)piperazin-2-one hydrochloride and pivaldehyde, following a similar method to that used for Example 30, step 5. LCMS m/z=458.3 [M+H]+. 1H NMR (400 MHz, CDCl3) δ: 8.58 (s, 1H), 8.11-8.04 (m, 3H), 8.02-7.93 (m, 2H), 7.50-7.40 (m, 2H), 7.00-6.92 (m, 1H), 4.83-4.73 (m, 2H), 4.07-3.99 (m, 3H), 3.94-3.86 (m, 2H), 3.60-3.53 (m, 2H), 3.39-3.32 (m, 2H), 2.85-2.78 (m, 2H), 1.12 (s, 9H).
tert-Butyl 4-(4-bromo-2-fluorobenzyl)-3-oxopiperazine-1-carboxylate was obtained (420 mg, 20.7% yield) from 4-bromo-1-(chloromethyl)-2-fluorobenzene and tert-butyl 3-oxopiperazine-1-carboxylate, following a similar method to that used in Example 33, step 1. 1H NMR (400 MHz, CDCl3) δ: 7.31-7.27 (m, 2H), 7.26-7.22 (m, 1H), 4.63 (s, 2H), 4.14-4.12 (m, 2H), 3.65-3.60 (m, 2H), 3.36-3.31 (m, 2H), 1.47 (s, 9H).
tert-Butyl 4-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-3-oxopiperazine-1-carboxylate was obtained (235 mg crude) from tert-butyl 4-(4-bromo-2-fluorobenzyl)-3-oxopiperazine-1-carboxylate following a similar method to that used in Example 33, step 2. 3. Preparation of tert-butyl 4-(2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-3-oxopiperazine-1-carboxylate
tert-Butyl 4-(2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-3-oxopiperazine-1-carboxylate was obtained (54 mg, 19.7% yield) from tert-butyl 4-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-3-oxopiperazine-1-carboxylate and 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5), following a similar method to that used in Example 30, step 3. LCMS m/z=506.3 [M+H]+.
1-(2-Fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl) piperazin-2-one hydrochloride was obtained crude, from tert-butyl 4-(2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-3-oxopiperazine-1-carboxylate following the method used in Example 30, Step 4. LCMS m/z=406.3 [M+H]+
1-(2-Fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-4-isobutylpiperazin-2-one was obtained (4 mg, 95% purity) from 1-(2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)piperazin-2-one hydrochloride and isobutyraldehyde following a similar method to that used for Example 30, step 5. LCMS m/z=462.3 [M+H]+ 1H NMR (400 MHz, CDCl3, d): 8.61-8.53 (m, 1H), 8.09-8.03 (m, 1H), 8.00-7.94 (m, 2H), 7.90-7.86 (m, 1H), 7.85-7.79 (m, 1H), 7.58-7.51 (m, 1H), 6.99-6.94 (m, 1H), 4.80-4.70 (m, 2H), 4.00 (s, 3H), 3.41-3.33 (m, 2H), 3.24-3.18 (m, 2H), 2.70-2.62 (m, 2H), 2.20-2.13 (m, 2H), 1.87-1.73 (m, 1H), 0.92 (d, J=6.5 Hz, 6H).
1-(2-Fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-4-neopentylpiperazin-2-one was obtained (15 mg) from 1-(2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)piperazin-2-one hydrochloride (Example 34, step 4) and pivaldehyde, following a similar method to that used for Example 30, step 5. LCMS m/z=476.4 [M+H]+. 1H NMR (400 MHz, CDCl3, d): 8.62-8.57 (m, 1H), 8.11-8.05 (m, 1H), 8.03-7.96 (m, 2H), 7.93-7.79 (m, 2H), 7.63-7.49 (m, 1H), 7.04-6.92 (m, 1H), 4.88-4.75 (m, 2H), 4.03 (s, 3H), 3.93-3.86 (m, 2H), 3.72-3.64 (m, 2H), 3.45-3.36 (m, 2H), 2.88-2.79 (m, 2H), 1.12 (s, 9H).
A mixture of 4-bromo-1-(chloromethyl)-2-methyl-benzene (1.02 g, 4.67 mmol), tert-butyl 2-methyl-3-oxo-piperazine-1-carboxylate (1.00 g, 4.67 mmol) and sodium tert-butoxide (1.35 g, 14.0 mmol) in dioxane (5.0 mL) was heated at 95° C. overnight. The cooled mixture was diluted with EtOAc, washed with water and dried over Na2SO4. The concentrated residue was chromatographed on silica gel (Heptanes/EtOAc 0-100%) to give tert-butyl 4-((4-bromo-2-methyl-phenyl)methyl)-2-methyl-3-oxo-piperazine-1-carboxylate (1.37 g, 70% yield). LCMS m/z=297.0 [M+H]+
tert-Butyl 2-methyl-4-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-3-oxopiperazine-1-carboxylate was obtained (1.41 g, 92% yield) from tert-butyl 4-((4-bromo-2-methyl-phenyl)methyl)-2-methyl-3-oxo-piperazine-1-carboxylate, following a similar method to that used in Example 30, step 2.
tert-Butyl 2-methyl-4-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-3-oxopiperazine-1-carboxylate was obtained (198.3 mg, 43% yield) from tert-butyl 4-((4-bromo-2-methyl-phenyl)methyl)-2-methyl-3-oxo-piperazine-1-carboxylate and 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5), following a similar method to that described in Example 30 step 3. LCMS m/z=516.3 [M+H]+
3-Methyl-1-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)piperazin-2-one hydrochloride was obtained, crude, from tert-butyl 2-methyl-4-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-3-oxopiperazine-1-carboxylate, following the procedure described in Example 30, step 4. LCMS m/z=416.2 [M+H]+
4-Isobutyl-3-methyl-1-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)piperazin-2-one was obtained (39.5 mg, 30% yield) from 3-methyl-1-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)piperazin-2-one hydrochloride and isobutyraldehyde following a similar method to that used in Example 30, step 5. LCMS m/z=472.3 [M+H]+. 1H NMR (400 MHz, CDCl3) δ: 8.60 (s, 1H), 8.09-8.05 (m, 1H), 8.04 (s, 1H), 8.00 (s, 1H), 7.93-7.86 (m, 2H), 7.32 (d, J=7.8 Hz, 1H), 6.99-6.95 (m, 1H), 4.89 (d, J=15.1 Hz, 1H), 4.70 (d, J=15.1 Hz, 1H), 4.08 (br s, 1H), 4.03 (s, 3H), 3.72-3.39 (m, 4H), 3.11 (dd, J=8.4, 12.9 Hz, 1H), 2.94 (dd, J=5.5, 13.1 Hz, 1H), 2.43 (s, 3H), 2.23-2.10 (m, 1H), 1.79 (d, J=7.3 Hz, 3H), 1.12 (d, J=6.5 Hz, 3H), 1.10-1.07 (m, 3H).
3-Methyl-1-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-4-(oxetan-3-yl)piperazin-2-one was obtained (67.4 mg, 46% yield) from 3-methyl-1-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)piperazin-2-one hydrochloride (Example 36, step 5) and oxetan-3-one, following a similar method to that used for Example 30, step 5. LCMS m/z=472.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ: 8.64 (d, J=1.0 Hz, 1H), 8.10-8.08 (m, 1H), 8.08-8.07 (m, 1H), 8.03-8.01 (m, 1H), 7.92-7.87 (m, 2H), 7.31 (d, J=7.8 Hz, 1H), 7.00 (dd, J=1.0, 2.5 Hz, 1H), 4.93-4.68 (m, 6H), 4.31-4.22 (m, 1H), 4.05 (s, 3H), 3.77 (q, J=7.2 Hz, 1H), 3.50-3.43 (m, 2H), 3.40-3.30 (m, 1H), 3.16-3.04 (m, 1H), 2.43 (s, 3H), 1.53 (d, J=7.0 Hz, 3H).
To a solution of 4-bromo-2-methylbenzyl amine hydrochloride (1.68 g, 6.82 mmol) in DMF (15 mL) were added DIPEA (3.0 mL, 22.8 mmol) and 4-(bromomethyl)-2-(tert-butyl)thiazole-5-carboxylate (1.39 g, 4.54 mmol) in DMF (10 mL) at 0° C. The reaction was allowed to warm to RT and stirred for 12 h. The mixture was diluted with water (40 mL) and extracted with EtOAc (100 mL×2). The organic phase was washed with water (60 mL×2), dried and concentrated. The residue was purified by silica gel column chromatography (EtOAc/PE=1/4) to give 4-(((4-bromo-2-methylbenzyl)amino)methyl)-2-(tert-butyl)thiazole-5-carboxylic acid as a yellow oil (850 mg, 44%). LCMS m/z=425.1 [M+H]+
To a solution of 4-(((4-bromo-2-methylbenzyl)amino)methyl)-2-(tert-butyl)thiazole-5-carboxylic acid (850 mg, 2.0 mmol) in MeOH (10 mL) and H2O (5 mL) was added NaOH (320 mg, 8.0 mmol) and the reaction mixture was stirred at RT for 16 h. After removal of MeOH, the residue was diluted with water (10 mL) and the pH adjusted to 5-6 with HCl (1 N). The mixture was extracted with EtOAc (50 mL×3). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to give 5-((4-bromo-2-methyl-phenyl)methyl)-2-tert-butyl-4H-pyrrolo[3,4-d]thiazol-6-one as a yellow solid (760 mg, yield: 96%), which was used in the next step without further purification. LCMS m/z=379.1 [M+H]+.
2-tert-Butyl-5-((2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) methyl])-4H-pyrrolo[3,4-d]thiazol-6-one was obtained (24.1 mg, 88% yield) from 5-((4-bromo-2-methyl-phenyl)methyl)-2-tert-butyl-4H-pyrrolo[3,4-d]thiazol-6-one, following a similar method to that used for Example 30, step 2. LCMS m/z=427.3 [M+H]+
A mixture of 2-tert-butyl-5-((2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methyl])-4H-pyrrolo[3,4-d]thiazol-6-one (24.0 mg, 56.29 μmol), 5-chloro-7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidine (Example 1, step 5, 13.15 mg, 56.29 μmol), Pd(dppf)Cl2 (4.12 mg, 5.63 μmol) and K2CO3 (23.34 mg, 168.87 μmol) in dioxane (2.0 mL) and water (199.98 uL) was degassed and heated at 95° C. for 16 h. The cooled mixture was diluted with EtOAc, filtered through Celite®, and the filtrate concentrated in vacuo. The residue was purified by chromatography on silica gel (DCM/MeOH 0-30%) to give 2-tert-butyl-5-((2-methyl-4-[7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl]phenyl)methyl)-4H-pyrrolo[3,4-d]thiazol-6-one (20.0 mg, 68% yield). LCMS m/z=498.2 [M+H]+. 1H NMR (400 MHz, MeOH-d4) δ: 8.24-6.63 (m, 8H), 4.47-4.36 (m, 2H), 4.01-3.75 (m, 5H), 2.45 (s, 3H), 1.54-1.41 (m, 9H).
A mixture of tert-butyl (R)-5-(1-(tert-butyl)-1H-1,2,3-triazole-4-carboxamido)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-carboxylate (WO2018/191577, Example 23, step 2, 500 mg, 926.8 μmol), 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 259.9 mg, 1.11 mmol), K2CO3 (384.29 mg, 2.78 mmol), and Pd(dppf)Cl2 (33.91 mg, 46.34 μmol) was dissolved in dioxane (4.94 mL) and water (1.24 mL). N2 was bubbled through the mixture for 5 min and the reaction was heated to 100° C. overnight. The cooled reaction was diluted with EtOAc and water, the layers separated, the organic layer was washed with brine and concentrated in vacuo. The material was used in the next step as crude assuming 100% yield. LCMS m/z=611.0 [M+H)]+. 2. Synthesis of (R)-1-(tert-butyl)-N-(8-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide hydrochloride
To a solution of tert-butyl (R)-5-(1-(tert-butyl)-1H-1,2,3-triazole-4-carboxamido)-8-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-carboxylate (488 mg, 0.80 mmol) in dioxane (7.99 mL) was added HCl (4 M, 1.20 mL) and the reaction was stirred at RT overnight. The resulting solids were filtered off, washed with EtOAc and air dried to afford (R)-1-(tert-butyl)-N-(8-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide hydrochloride (110 mg, 25.2% yield) as an orange solid. 1H NMR (500 MHz, DMSO-d6) δ: 9.41 (br d, J=7.94 Hz, 1H), 9.16 (s, 1H), 8.82 (s, 1H), 8.36 (s, 1H), 8.30-8.18 (m, 2H), 8.14 (s, 1H), 7.53 (br d, J=7.94 Hz, 1H), 7.31 (br d, J=2.44 Hz, 1H), 5.65 (t, J=1.00 Hz, 1H), 4.74-4.54 (m, 2H), 4.43-4.18 (m, 2H), 3.91 (s, 3H), 2.38-2.14 (m, 2H), 1.67 (s, 9H).
To a solution of (R)-1-(tert-butyl)-N-(8-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide hydrochloride (55 mg, 96.95 μmol) in MeOH (1.94 mL) was added oxetan-3-one (34.9 mg, 485 μmol) and NaCNBH3 (18.3 mg, 291 μmol) and the reaction mixture was stirred at RT overnight. The material was concentrated and purified by reverse phase purification (Method B2, 5-45% gradient) to afford (R)-1-(tert-butyl)-N-(8-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide, (26.4 mg, 45.7% yield) as a pale yellow solid. LCMS m/z=567.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.49 (s, 1H), 9.19 (s, 1H), 8.81 (s, 1H), 8.34 (s, 1H), 8.30-8.18 (m, 2H), 8.14 (s, 1H), 7.56 (d, J=1.00 Hz, 1H), 7.21 (br d, J=1.83 Hz, 1H), 5.71 (s, 1H), 5.01-4.45 (m, 8H), 3.92 (s, 2H), 3.54 (s, 1H), 2.43-2.25 (m, 2H), 1.68 (s, 9H)
To a solution of (R)-1-(tert-butyl)-N-(8-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide hydrochloride (Example 39, step 2, 55.0 mg, 101 μmol) in MeCN (1.01 mL) was added 2,2,2-trifluoroethyl trifluoromethanesulfonate (46.7 mg, 201 μmol) and K2CO3 (41.7 mg, 302 μmol) and the reaction mixture was stirred under N2 at 80° C. overnight. The material was filtered through Celite®, concentrated, and purified by reverse phase HPLC (Method B2, 5-45% gradient) to afford (R)-1-(tert-butyl)-N-(8-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide, 16.9 mg (27.8% yield) as brown solid. LCMS m/z=593.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.14 (s, 1H), 9.09 (br d, J=7.94 Hz, 1H), 8.77 (s, 1H), 8.33 (s, 1H), 8.20 (d, J=2.44 Hz, 1H), 8.12 (s, 1H), 8.03 (dd, J=7.94, 1.83 Hz, 1H), 7.96 (d, J=1.83 Hz, 1H), 7.46 (br d, J=8.55 Hz, 1H), 7.17 (dd, J=2.44, 1.22 Hz, 1H), 5.51 (t, J=1.00 Hz, 1H), 4.35 (br d, J=15.26 Hz, 2H), 4.10 (br d, J=15.26 Hz, 2H), 3.91 (s, 3H), 3.26-3.21 (m, 2H), 2.20-2.12 (m, 2H), 1.67 (s, 9H)
tert-Butyl N-((4-methyl-4-piperidyl)methyl)carbamate (296.83 mg, 1.30 mmol) followed by Cs2CO3 (521.31 mg, 1.60 mmol) were added to a solution of 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 233.66 mg, 1.00 mmol) in DMF (3.0 mL) and the reaction stirred at RT overnight. The reaction was diluted with water (10 mL) and extracted with EtOAc (2×10 mL). The combined organic phases were dried over Na2SO4, filtered and evaporated to dryness. The residual material was purified by silica gel column chromatography (1:1 heptane:EtOAc) to give tert-butyl ((4-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)carbamate (430 mg, 90% yield) as a dark brown gum. LCMS m/z=426.1 [M+H]+.
To a solution of tert-butyl ((4-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)carbamate (429.79 mg, 1.01 mmol) in DCM (3.0 mL) was added TFA (2.30 g, 20.20 mmol) and the reaction stirred at RT overnight. The mixture was diluted with MeOH and purified on a 5 g SCX column where the product eluted with 2M NH3-MeOH to give (4-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine (260 mg, 71.2% yield) as a beige solid. LCMS m/z=326.1 [M+H]+.
DIPEA (24 mg, 185 μmol) was added to a mixture of (4-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine (40.0 mg, 122.92 μmol) and 5-tert-butyl-1,2,4-oxadiazole-3-carboxylic acid (23 mg, 135.2 μmol) in DMF (1 mL) and the mixture stirred for 5 mins at RT. T3P® (120 mg, 185 μmol, 50% purity) was added and the reaction stirred at RT overnight. The mixture was diluted with EtOAc (3 mL) and water (3 mL) and the mixture stirred vigorously. The aqueous phase was discarded, the remaining organic phase dried over Na2SO4, and filtered. The filtrate was evaporated, the residual material was re-dissolved in DMSO and the product was purified by prep-HPLC (Method A, 5-60% gradient). LCMS mz=478.1 [M+H]+. 1H NMR (DMSO-d6) δ: 8.96-8.87 (m, 1H), 8.44 (s, 1H), 8.14 (s, 1H), 7.94 (s, 1H), 7.93 (d, J=2.4 Hz, 1H), 6.97-6.88 (m, 1H), 4.08-3.98 (m, 2H), 3.87 (s, 3H), 3.69-3.59 (m, 2H), 3.31-3.25 (m, 2H), 1.66-1.57 (m, 2H), 1.49-1.35 (m, 11H), 1.02 (s, 3H).
tert-Butyl ((3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)pyrrolidin-3-yl)methyl)carbamate was obtained (300 mg, 65.6% yield) as a dark brown gum, from 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5) and tert-butyl N-((3-methylpyrrolidin-3-yl)methyl)carbamate, following a similar method to that described in Example 41, step 1. LCMS m/z=412.1 [M+H]+.
(3-Methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)pyrrolidin-3-yl)methanamine was obtained (210 mg, 83.2% yield) as a pale yellow solid, from tert-butyl ((3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)pyrrolidin-3-yl)methyl)carbamate following a similar method to that described in Example 41, step 2. LCMS m/z=312.1 [M+H]+.
5-(tert-Butyl)-N-((3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)pyrrolidin-3-yl)methyl)-1,2,4-oxadiazole-3-carboxamide was obtained from (3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)pyrrolidin-3-yl)methanamine and 5-tert-butyl-1,2,4-oxadiazole-3-carboxylic acid following the method used in Example 41, step 3. LCMS m/z=464.0 [M+H]+. 1H NMR (DMSO-d6) δ: 9.11 (t, J=6.4 Hz, 1H), 8.29 (s, 1H), 8.10 (s, 1H), 7.92 (s, 1H), 7.89 (d, J=2.4 Hz, 1H), 7.04-6.92 (m, 1H), 3.86 (s, 5H), 3.64-3.39 (m, 2H), 2.09-1.92 (m, 1H), 1.84-1.67 (m, 1H), 1.41 (s, 9H), 1.13 (s, 3H).
The compounds in the following table were prepared from (4-methyl-1-(6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl])-4-piperidyl)methanamine (Example 41, step 2) or (3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)pyrrolidin-3-yl)methanamine (Example 42, step 2) and the appropriate carboxylic acid, following a similar method to that used for Example 41, step 3.
Carboxylic acid: 2-tert-butyltetrazole-5-carboxylic acid Prep-HPLC (Method A, 5-60% gradient) LCMS m/z = 478.1 [M + H]+. 1H NMR (DMSO-d6) 8: 8.95 (s, 1H), 8.43 (s, 1H), 8.14 (s, 1H), 7.94 (s, 1H), 7.93 (d, J = 2.4 Hz, 1H), 6.95-6.90 (m, 1H), 4.09-3.99 (m, 2H), 3.86 (s, 3H), 3.70-3.60 (m, 2H), 1.79-1.68 (m, 9H), 1.68-1.57 (m, 2H), 1.51-1.38 (m, 2H), 1.03 (s, 3H).
Carboxylic acid: 1-tert-butyltriazole-4-carboxylic acid Prep-HPLC (Method A, 5-60% gradient) LCMS m/z = 477.1 [M + H]+1H NMR (DMSO-d6) δ: 8.66 (s, 1H), 8.43 (s, 1H), 8.42-8.35 (m, 1H), 8.14 (s, 1H), 7.94 (s, 1H), 7.93 (d, J = 2.4 Hz, 1H), 6.91 (d, J = 2.4 Hz, 1H), 4.03 (ddd, J = 13.3, 6.6, 4.0 Hz, 2H), 3.87 (s, 3H), 3.70-3.61 (m, 2H), 1.62 (s, 11H), 1.49-1.37 (m, 2H), 1.02 (s, 3H).
Carboxylic acid: 2-(tert-butyl)oxazole-5-carboxylic acid Prep-HPLC (Method C2, 5-60% gradient) LCMS m/z = 477.1 [M + H]+. 1H NMR (DMSO-d6) δ: 8.43 (s, 2H), 8.14 (s, 1H), 7.94 (s, 1H), 7.93 (d, J = 2.4 Hz, 1H), 7.67 (s, 1H), 6.92 (d, J = 2.4 Hz, 1H), 4.09- 3.98 (m, 2H), 3.87 (s, 3H), 3.70-3.60 (m, 2H), 3.29-3.20 (m, 2H), 1.65-1.54 (m, 2H), 1.49-1.39 (m, 2H), 1.38-1.29 (m, 9H), 1.02 (s, 3H).
Carboxylic acid: 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylic acid Prep HPLC (Method A, 5-60% gradient) LCMS m/z = 476.1 [M + H]+. 1H NMR (DMSO-d6) δ: 8.85 (s, 1H), 8.44 (s, 1H), 8.14 (s, 1H), 7.94 (s, 1H), 7.93 (d, J = 2.4 Hz, 1H), 6.96-6.90 (m, 1H), 4.08-3.98 (m, 2H), 3.86 (s, 3H), 3.67-3.59 (m, 2H), 3.29-3.23 (m, 2H), 1.65-1.56 (m, 2H), 1.53 (s, 3H), 1.47-1.39 (m, 2H), 1.36 (d, J = 2.4 Hz, 2H), 1.15 (d, J = 3.1 Hz, 2H), 1.01 (s, 3H).
Carboxylic acid: 3-tert-butyl-1,2,4-oxadiazole-5-carboxylic acid Prep-HPLC (Method C2, 5-60% gradient) LCMS m/z = 478.1 [M + H]+. 1H NMR (DMSO-d6) δ: 9.36-9.29 (m, 1H), 8.44 (s, 1H), 8.14 (s, 1H), 7.95 (s, 1H), 7.93 (d, J = 2.4 Hz, 1H), 6.96-6.90 (m, 1H), 4.08-3.98 (m, 2H), 3.87 (s, 3H), 3.68-3.60 (m, 2H), 3.31-3.25 (m, 2H), 1.63 (ddd, J = 13.3, 9.3, 3.7 Hz, 2H), 1.46 (br d, J = 2.4 Hz, 2H), 1.40-1.30 (m, 9H), 1.03 (s, 3H)
Carboxylic acid: 2-tert-butyltetrazole-5-carboxylic acid Prep-HPLC (Method A, 5-60% gradient) LCMS m/z = 464.0 [M + H]+. 1H NMR (DMSO-d6) 8: 9.18 (t, J = 6.4 Hz, 1H), 8.28 (s, 1H), 8.09 (s, 1H), 7.92 (s, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.05-6.93 (m, 1H), 4.08-3.78 (m, 5H), 3.61-3.40 (m, 2H), 2.11-1.93 (m, 1H), 1.82-1.60 (m, 10H), 1.15 (s, 3H).
Carboxylic acid: 1-tert-butyltriazole-4-carboxylic acid Prep-HPLC (Method A, 5-60% gradient) LCMS m/z = 463.0 [M + H]+. 1H NMR (DMSO-d6) δ: 8.66 (s, 1H), 8.28 (s, 1H), 8.10 (s, 1H), 7.92 (s, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.01-6.93 (m, 1H), 3.86 (s, 5H), 2.06-1.95 (m, 1H), 1.80-1.69 (m, 1H), 1.62 (s, 9H), 1.13 (s, 3H).
Carboxylic acid: 2-tert-butyloxazole-5-carboxylic acid Prep HPLC (Method C2, 5-60% gradient) LCMS m/z = 463.0 [M + H]+1H NMR (DMSO-d6) δ: 8.63-8.55 (m, 1H), 8.33- 8.26 (m, 1H), 8.13-8.07 (m, 1H), 7.93-7.91 (m, 1H), 7.90-7.87 (m, 1H), 7.66 (s, 1H), 6.97-6.94 (m, 1H), 3.86 (s, 7H), 3.32-3.24 (m, 1H), 2.07-1.92 (m, 2H), 1.82-1.67 (m, 2H), 1.34 (s, 9H), 1.14 (s, 3H).
Carboxylic acid: 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylic acid Prep-HPLC (Method C2, 5-60% gradient) LCMS m/z = 462.0 [M + H]+1H NMR (DMSO-d6) δ: 9.05 (s, 1H), 8.29 (s, 1H), 8.09 (s, 1H), 7.92 (s, 1H), 7.91-7.85 (m, 1H), 6.97-6.93 (m, 1H), 3.86 (s, 5H), 2.06-1.93 (m, 1H), 1.81-1.69 (m, 1H), 1.52 (s, 3H), 1.40-1.31 (m, 2H), 1.12 (s, 5H).
tert-Butyl 2-amino-6-azaspiro[3.4]octane-6-carboxylate (160.0 mg, 706.96 μmol), followed by T3P® (674.83 mg, 1.06 mmol, 50% purity) were added to a solution of lithium 5-(tert-butyl)-1,2,4-oxadiazole-3-carboxylate (373.49 mg, 2.12 mmol) in DMF (1.0 mL) and the reaction warmed to 50° C. and stirred overnight. The mixture was diluted with water (3 mL) and the product was extracted with EtOAc (2×3 mL). The combined organic phases were washed with brine (2 mL), dried over Na2SO4 and filtered. The filtrate was evaporated to dryness and the material was purified on a 5 g SPE column eluting with heptane:EtOAc, to give tert-butyl 2-(5-(tert-butyl)-1,2,4-oxadiazole-3-carboxamido)-6-azaspiro[3.4]octane-6-carboxylate as a white solid. LCMS m/z=313.1 [M-tBu+H]+
To a solution of tert-butyl 2-(5-(tert-butyl)-1,2,4-oxadiazole-3-carboxamido)-6-azaspiro[3.4]octane-6-carboxylate (180.0 mg, 475.61 μmol) in DCM (3.0 mL) was added TFA (1.08 g, 9.51 mmol) and the reaction stirred at RT overnight. The mixture was diluted with MeOH (5.0 mL) and purified on a 5 g SCX column. The desired compound eluted with TEA/MeOH (1 mL/25 mL) to give 5-(tert-butyl)-N-(6-azaspiro[3.4]octan-2-yl)-1,2,4-oxadiazole-3-carboxamide trifluoroacetate (90.0 mg) as a colorless gum. LCMS m/z=279.1 [M+H]+.
N-(6-azaspiro[3.4]octan-2-yl)-5-tert-butyl-1,2,4-oxadiazole-3-carboxamide (42.89 mg, 154.07 μmol), followed by Cs2CO3 (62.75 mg, 192.58 μmol) were added to a solution of 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 30.0 mg, 128.39 μmol) in DMF (2.0 mL) and the reaction stirred at RT overnight. The reaction was diluted with water (10 mL) and extracted with EtOAc (2×15 mL). The combined organic phases were dried over Na2SO4, filtered and evaporated to dryness. The residual material was re-dissolved in DMSO and the product purified by prep-HPLC (Method A, 5-60% gradient) to give 5-(tert-butyl)-N-(6-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-6-azaspiro[3.4]octan-2-yl)-1,2,4-oxadiazole-3-carboxamide. LCMS m/z=476.1 [M+H]+. 1H NMR (DMSO-d6) δ: 9.21 (dd, J=19.2, 7.6 Hz, 2H), 8.29 (s, 1H), 8.18-8.06 (m, 1H), 7.98-7.91 (m, 1H), 7.89 (d, J=1.8 Hz, 1H), 7.04 (s, 1H), 6.96 (d, J=2.4 Hz, 1H), 4.63-4.44 (m, 1H), 3.87 (d, J=1.8 Hz, 8H), 2.33 (br s, 6H), 2.11 (s, 2H), 2.06-1.98 (m, 1H), 1.43 (d, J=1.8 Hz, 9H).
5-(tert-Butyl)-N-(6-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-6-azaspiro[3.4]octan-2-yl)-1,2,4-oxadiazole-3-carboxamide was separated by SFC using a LUX Cellulose-4 LC 30×250 mm, 3 um column, eluting with 45% MeOH w/0.1% DEA in CO2 (flow rate: 100 mL/min, ABPR 120bar, MBPR 40 psi, column temp 40 deg C.) to give, Peak 1: 5-(tert-butyl)-N-((2r,4s)-6-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-6-azaspiro[3.4]octan-2-yl)-1,2,4-oxadiazole-3-carboxamide. LCMS m/z=476.1 [M+H]+. 1H NMR (CDCl3) δ: 8.00 (s, 1H), 7.85 (s, 3H), 7.22-7.10 (m, 1H), 6.79-6.72 (m, 1H), 4.72 (br d, J=8.0 Hz, 1H), 4.02-3.96 (m, 5H), 3.93 (t, J=6.9 Hz, 2H), 2.69-2.56 (m, 2H), 2.19 (br d, J=3.5 Hz, 3H), 2.15-2.06 (m, 3H), 1.48 (s, 10H), 1.21-1.09 (m, 1H) and Peak 2: 5-(tert-butyl)-N-((2s,4r)-6-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-6-azaspiro[3.4]octan-2-yl)-1,2,4-oxadiazole-3-carboxamide. LCMS m/z=476.1 [M+H]+. 1H NMR (CDCl3) δ: 7.98 (d, J=0.8 Hz, 1H), 7.86 (d, J=0.8 Hz, 1H), 7.82 (d, J=2.5 Hz, 1H), 7.80 (s, 1H), 7.22-7.10 (m, 1H), 6.75 (dd, J=2.4, 0.9 Hz, 1H), 4.78-4.63 (m, 1H), 3.96 (s, 5H), 3.90-3.83 (m, 2H), 2.61-2.52 (m, 2H), 2.28-2.20 (m, 2H), 2.17 (s, 2H), 1.48 (s, 9H), 1.30-1.18 (m, 1H).
A solution of tert-butyl (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (WO 2015089327 A1, 35.7 g, 103 mmol) in DCM, was treated with TFA (85 mL, 1110 mmol) and the reaction stirred at RT for 2 h. The mixture was concentrated in vacuo, and the residue azeotroped with toluene. The residue was suspended in sat. NaHCO3soln., the mixture extracted with EtOAc (2×100 mL) and the combined organic extracts were washed with brine, dried over Na2SO4 and filtered. 4M HCl in dioxane (30 mL) was added, the solution concentrated in vacuo and the residue stirred in Et2O (500 mL). The resulting suspension was filtered and the solid dried to afford the title compound as an off-white solid, 23.5 g, 84%. 1H NMR (300 MHz, DMSO-d6) δ: 8.56 (br s, 3H), 7.49-7.52 (m, 2H), 7.41 (dd, 1H), 4.01-4.04 (m, 2H), 2.34 (s, 3H), 1.27 (s, 12H).
To a suspension of (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine dihydrochloride (34 g, 0.12 mol) and 5-(tert-butyl)-1,2,4-oxadiazole-3-carboxylic acid (29.2 g, 0.15 mol) in anhydrous DMF (500 mL) was added DIPEA (62 mL, 0.36 mol). The resulting mixture was cooled to 0° C., T3P® (50% in DMF, 90 mL, 0.15 mol) was added and the reaction allowed to warm to RT and stirred for 2 h. The reaction mixture was partitioned between water (300 mL) and EtOAc (300 mL) and the layers were separated. The aqueous phase was extracted with EtOAc (3×100 mL), the combined organic extracts washed with water (3×50 mL), sat. aq. solution of NaHCO3 (50 mL) and brine (50 mL). The organic layer was dried over Na2SO4, filtered and concentrated in vacuo to give a beige oil. This was purified by column chromatography on silica gel eluting with heptanes/EtOAc, (100/0 to 70/30) to give the title compound as a thick pale-yellow oil which slowly solidified on standing (29.0 g, 60%).
A mixture of 5-(tert-butyl)-N-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (350 mg, 876.56 μmol), 4,6-dichloropyrazolo[1,5-a]pyrazine (329.60 mg, 1.75 mmol), Pd(t-Bu3P)2 (22.40 mg, 43.83 μmol) and K3PO4 (558.20 mg, 2.63 mmol, 1.32 mL) in dioxane (4.40 mL) and water (1.10 mL) was sparged with N2 for 5 min and stirred at RT for 18 h. The mixture was diluted with EtOAc and water, the layers separated and the organic phase washed with brine. The combined aqueous layers were extracted with EtOAc, the combined organic layers were dried (MgSO4), filtered and concentrated in vacuum. The residue was purified by column chromatography (0-100% EtOAc in Hept) to give 5-(tert-butyl)-N-(4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)-2-methylbenzyl)-1,2,4-oxadiazole-3-carboxamide (245 mg, 65.8% yield). LCMS m/z=425.0 [M+H]+.
To a solution of 5-(tert-butyl)-N-(4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)-2-methylbenzyl)-1,2,4-oxadiazole-3-carboxamide (50 mg, 117.68 μmol) and 1-(oxetan-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (35.32 mg, 141.22 μmol) in dioxane (2.10 mL) was added K3PO4 (2 M, 470.72 uL) solution in water and the resulting mixture was sparged with N2 for 5 min. tBuXPhos Pd G3 (18.70 mg, 23.54 μmol) was added and the mixture heated to 60° C. for 17 h, cooled to RT, diluted with EtOAc and washed with water and brine. The organic layer was dried (MgSO4), filtered and concentrated in vacuum. The residue was purified by prep HPLC (Method C2, 5-60% gradient). The product was further purified by preparative TLC (97:3 DCM:MeOH) to give 5-(tert-butyl)-N-(2-methyl-4-(6-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (2 mg, 3.32% yield) as a white solid. LCMS m/z=513.2 [M+H]+ 1H NMR (500 MHz, CDCl3) δ ppm 8.58 (s, 1H), 8.24 (s, 1H), 8.08-8.04 (m, 2H), 7.97-7.90 (m, 2H), 7.52 (d, J=7.9 Hz, 1H), 7.18 (br s, 1H), 6.97 (dd, J=2.4, 1.2 Hz, 1H), 5.60-5.51 (m, 1H), 5.17-5.10 (m, 4H), 4.78 (d, J=6.1 Hz, 2H), 2.53 (s, 3H), 1.50-1.46 (m, 9H).
2-Chloroacetaldehyde (220 g, 0.18 L, 1.28 mol) was added to a solution of 6-chloro-2-(methylthio)pyrimidin-4-amine (150 g, 854 mmol) in dioxane (300 mL) and the reaction stirred at 100° C. for 5 h and then allowed to cool to RT overnight. The suspension was cooled to 0° C. and the solid was filtered off to give 7-chloro-5-(methylthio)imidazo[1,2-c]pyrimidine as a yellow solid (151 g, 75% yield). LCMS m/z=200.1 [M+H]+
7-Chloro-5-(methylthio)imidazo[1,2-c]pyrimidine (52.2 g, 221 mmol) was suspended in MeOH (200 mL) and a solution of KOH (55.9 g, 996 mmol) in water (520 mL) was added slowly. The reaction was heated at reflux for 3 h and then was cooled to RT overnight. The mixture was acidified to pH 6 with 1M HCl and the obtained suspension was filtered. The solid was washed with MeOH then azeotroped with MeCN to provide 7-chloroimidazo[1,2-c]pyrimidin-5(6H)-one as a white solid (28.6 g, 76% yield). LCMS m/z=170.1 [M+H]+
7-Chloroimidazo[1,2-c]pyrimidin-5(6H)-one (40 g, 236 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (73.6 g, 354 mmol) and XPhos (11.2 g, 24 mmol) were dissolved in IPA (1.8 L) and a 2 M solution of K3PO4 (150 g, 0.35 L, 708 mmol) in water was added. The mixture was purged with N2 for 15 min then Pd2(dba)3 (10.8 g, 12 mmol) was added, and the mixture was refluxed overnight. Additional Pd2(dba)3 (5 g) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (25 g) were added and the mixture refluxed for a further 24 h. The reaction mixture was filtered to remove palladium-residues, the organic solvent was evaporated, and the residue was partitioned between water and a 1:1-mixture of heptanes: EtOAc. A white solid precipitated in both the organic and aqueous layer and the solid was filtered off. The solid was washed with water, EtOAc and MeCN and dried in vacuo to give the product (32.8 g). The layers of the filtrate were separated and the aqueous layer was cooled in an ice bath. The solution was treated with concentrated HCl to pH 6 with stirring and the resulting fine precipitate was collected, washed with H2O and Et2O, and dried under vacuum to give further product (9.0 g). A total of 41.8 g of 7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5(6H)-one was obtained as a yellow solid (82% yield). LCMS m/z=215.0 [M+H]+
POCl3 (89.3 g, 54.1 mL, 583 mmol) was added dropwise over 5 min to an ice cooled solution of 7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5(6H)-one (41.8 g, 194 mmol) and DIPEA (126 g, 971 mmol) in dry DCM (300 mL) and the reaction was allowed to warm to RT. The mixture was diluted with DCM (150 mL), then stirred for 24 h at RT. The suspension was diluted with hexanes and the solid was collected by filtration (66.0 g). The collected solid was suspended in DCM: DIPEA (5:1, 500 mL), stirred for 30 min and then a saturated aqueous solution of NaHCO3 was added and the mixture stirred for 1 h. The mixture was filtered through Celite®, the layers were separated, and the aqueous layer extracted with DCM (3×). The organic layers were dried over Na2SO4 and concentrated in vacuo to provide 5-chloro-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidine as a yellow solid (22.5 g, 50% yield). LCMS m/z=234.0 [M+H]+.
tert-Butyl (4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)benzyl)carbamate was obtained as a white solid, 380 mg, 63% yield, from 5-chloro-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidine and tert-butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate following a similar procedure to that described in Example 1, Step 6. LCMS m/z=405.1 [M+H]+
(4-(7-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)phenyl)methanamine dihydrochloride was obtained, crude, 374 mg, from tert-butyl (4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)benzyl)carbamate following a similar procedure to that described in Example 1, step 7. LCMS m/z=305.0 [M+H]+
1-(tert-Butyl)-N-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)benzyl)-1H-pyrazole-3-carboxamide was obtained, (26.2 mg, 58% yield) from (4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)phenyl)methanamine dihydrochloride and 1-(tert-butyl)-1H-pyrazole-3-carboxylic acid, following a similar procedure to that described in Example 1, Step 8. The crude material was purified by reverse phase HPLC (Method A, 5-55% gradient). LCMS m/z=455.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 8.70 (t, J=6.4 Hz, 1H), 8.33 (s, 1H), 8.10 (s, 1H), 7.97-7.92 (m, 4H), 7.83 (s, 1H), 7.63 (s, 1H), 7.57 (d, J=7.9 Hz, 2H), 6.67-6.65 (m, 1H), 4.56 (d, J=6.1 Hz, 2H), 3.88 (s, 3H), 1.57 (s, 9H).
The compounds in the following table were prepared from (4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)phenyl)methanamine dihydrochloride (Example 56, step 6) and the appropriate carboxylic acid, following a similar method to that used for Example 1, step 8.
Carboxylic acid: 1-(tert-butyl)-1H-pyrazole-4-carboxylic acid 26.7 mg, 59% yield, Prep-HPLC (Method A, 5-55% gradient) LCMS m/z = 455.2 [M + H]+. 1H NMR (500 MHz, DMSO-d6) δ: 8.71 (t, J = 6.2 Hz, 1H), 8.33 (d, J = 1.8 Hz, 2H), 8.10 (s, 1H), 7.98-7.92 (m, 4H), 7.83 (s, 1H), 7.64 (d, J = 1.2 Hz, 1H), 7.55 (d, J = 7.9 Hz, 2H), 4.55 (d, J = 6.1 Hz, 2H), 3.94-3.83 (m, 3H), 1.53 (s, 9H).
Carboxylic acid: 2-(tert-butyl)-2H-tetrazole-5-carboxylic acid 13 mg, 29% yield, Prep-HPLC (Method A, 5-50% gradient) LCMS m/z = 457.2 [M + H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.70 (t, J = 6.4 Hz, 1H), 8.35 (s, 1H), 8.11 (s, 1H), 7.98-7.95 (m, 3H), 7.85 (s, 1H), 7.67 (s, 1H), 7.59 (d, J = 8.5 Hz, 2H), 4.62 (d, J = 6.1 Hz, 2H), 3.97-3.84 (m, 3H), 1.74 (s, 9H).
Carboxylic acid: 1-(tert-butyl)-1H-1,2,3-triazole-4-carboxylic acid 26.7 mg, 59% yield, Prep-HPLC (Method A, 5-50% gradient) LCMS m/z = 456.2 [M + H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.22 (t, J = 6.4 Hz, 1H), 8.71 (s, 1H), 8.36 (s, 1H), 8.12 (s, 1H), 7.97-7.94 (m, 3H), 7.85 (s, 1H), 7.68 (s, 1H), 7.57 (d, J = 7.9 Hz, 2H), 4.59 (d, J = 6.1 Hz, 2H), 4.05-3.79 (m, 3H), 1.64 (s, 9H).
Carboxylic acid: 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylic acid 23.1 mg, 51% yield, Prep-HPLC (Method A, 5-50% gradient) LCMS m/z = 455.1 [M + H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.57 (t, J = 6.2 Hz, 1H), 8.33 (s, 1H), 8.10 (s, 1H), 7.99-7.92 (m, 3H), 7.84 (s, 1H), 7.63 (s, 1H), 7.56 (d, J = 7.9 Hz, 2H), 4.57 (d, J = 6.7 Hz, 2H), 3.89 (s, 3H), 1.55 (s, 3H), 1.41-1.37 (m, 2H), 1.19-1.15 (m, 2H).
Carboxylic acid: 5-(tert-butyl)-1,3,4-oxadiazole-2-carboxylic acid 20.8 mg, 46% yield, Prep-HPLC (Method A, 5-50% gradient) LCMS m/z = 457.1 [M + H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.94 (s, 1H), 9.94 (d, J = 12.0 Hz, 1H), 8.33 (s, 1H), 8.10 (s, 1H), 7.99-7.96 (m, 2H), 7.93 (s, 1H), 7.84 (s, 1H), 7.64 (d, J = 1.2 Hz, 1H), 7.59 (d, J = 7.9 Hz, 2H), 4.59 (d, J = 6.7 Hz, 2H), 3.89 (s, 3H), 1.40 (s, 9H).
cis racemic
To a solution of (Z)-but-2-ene (22.5 g, 401 mmol) and Rh(OAc)2 dimer (2.35 g, 5.3 mmol) in DCM (1.5 L) at 0° C. was added ethyl 2-diazoacetate (130 g, 1140 mmol) over 4 h. The mixture was stirred at 20° C. for 16 h. The reaction mixture was filtered through a pad of silica gel and concentrated in vacuo to give ethyl 2,3-cis-dimethylcyclopropane-1-carboxylate as a yellow oil (60 g, crude), which was carried forward without further purification.
A solution of ethyl 2,3-cis-dimethylcyclopropane-1-carboxylate (60 g, 422 mmol) in MeOH (400 mL) was added to KOH (90 g, 1.6 mol) in H2O (200 mL) at RT. After the reaction was completed, the solvent was removed by distillation in vacuo and DCM (700 mL) was added. The aqueous layer was separated and acidified with 4 M aqueous HCl solution until pH=1. The acidic aqueous phase was extracted with EtOAc (3×20 mL). The combined organic extracts were washed with brine (50 mL), dried (Na2SO4), filtered, and concentrated in vacuo to give 2,3-cis-dimethylcyclopropane-1-carboxylic acid (36.1 g, yield: 75% over 2 steps), which was carried forward without further purification. 3. Synthesis of ethyl 5-(2,3-cis-dimethylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate
To a solution of oxalyl chloride (28.2 mL, 328 mmol) in DCM (500 mL) was added 2,3-cis-dimethylcyclopropane-1-carboxylic acid (30 g, 263 mmol), and the reaction mixture was stirred at ambient temperature for 1 h. Excess oxalyl chloride was removed by distillation to give crude 2,3-cis-dimethylcyclopropane-1-carbonyl chloride. To a solution of ethyl (E)-2-amino-2-(hydroxyimino)acetate (34.7 g, 263 mmol) and DIPEA (67.8 g, 526 mmol) in DCM (500 mL) at −15° C. was added dropwise, crude 2,3-cis-dimethylcyclopropane-1-carbonyl chloride. The resulting solution was stirred as it warmed to ambient temperature and continued to stir for 16 h. Water (800 mL) was added, and the layers were separated. The aqueous phase was extracted with DCM (300 mL×3) and the combined organic phases were dried (Na2SO4), filtered, and concentrated in vacuo. To the residue was added pyridine (400 mL) and the mixture heated to 110° C. and stirred for 16 h. The reaction mixture was cooled to ambient temperature and concentrated in vacuo. The crude product was purified by silica-gel column chromatography (EtOAc/hexanes, from 1% to 10%) to give ethyl 5-(2,3-cis-dimethylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate as a yellow oil (9 g, yield: 16%).
A solution of ethyl 5-(2,3-cis-dimethylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate (6 g, 28.5 mmol) in MeOH (40 mL) was added to a solution of KOH (1.75 g, 31.2 mmol) dissolved in H2O (20 mL). When the reaction was complete, the solvent was removed by distillation in vacuo and DCM (70 mL) was added. The aqueous layer was separated and concentrated in vacuo to give potassium 5-(2,3-cis-dimethylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate as a white solid (5.21 g, 82% yield). LCMS m/z=183.0 [M+H]+
5-(−2,3-cis-Dimethylcyclopropyl)-N-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide was obtained (13.1 mg, 28% yield) from potassium 5-(2,3-cis-dimethylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate and (4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)phenyl)methanamine dihydrochloride (Example 56, step 6) using a similar method to that used for Example 1, Step 8. LCMS m/z=469.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.70-9.52 (m, 1H), 8.34 (s, 1H), 8.19-8.07 (m, 1H), 8.05-7.92 (m, 3H), 7.89-7.81 (m, 1H), 7.64 (br d, J=1.2 Hz, 1H), 7.62-7.50 (m, 2H), 4.67-4.45 (m, 2H), 3.96-3.84 (m, 3H), 1.90 (t, J=4.6 Hz, 1H), 1.80-1.63 (m, 2H), 1.23-1.13 (m, 6H).
To a solution of 1-(fluoromethyl)cyclopropane-1-carbonitrile (850 mg, 8.5 mmol) in EtOH (15 mL) and H2O (1 mL) were added Na2CO3 (1.8 g, 17 mmol) and hydroxylamine hydrochloride (1.2 g, 17 mmol) and the reaction was heated at 80° C. and stirred at that temperature for 4 h. The reaction mixture was cooled to ambient temperature, poured into H2O (50 mL) and extracted with EtOAc (150 mL). The organic phase was dried (Na2SO4), filtered, and concentrated in vacuo. The crude product was purified by silica-gel column chromatography to give (E)-1-(fluoromethyl)-N′-hydroxycyclopropane-1-carboximidamide as a white solid (1 g, 90% yield), which was carried forward without further purification.
A solution of (E)-1-(fluoromethyl)-N′-hydroxycyclopropane-1-carboximidamide (5.2 g, 39 mmol) in pyridine (20 mL) was cooled to 0° C. Ethyl chlorooxoacetate (5.3 mL, 47 mmol) was added dropwise and after the addition was complete, the reaction mixture was heated at 80° C. and stirred at that temperature for 2 h. The reaction mixture was poured into ice-water (100 mL) and the aqueous phase was extracted with DCM (30 mL×3). The organic phase was washed with an HCl solution (30 mL, 1 M), followed by brine (30 mL). The organic phase was dried (Na2SO4), filtered and concentrated in vacuo to give ethyl 3-(1-(fluoromethyl)cyclopropyl)-1,2,4-oxadiazole-5-carboxylate (6.1 g, 85% yield), which was carried forward without further purification.
Potassium 3-(1-(fluoromethyl)cyclopropyl)-1,2,4-oxadiazole-5-carboxylate was obtained (4 g, 78% yield over 3 steps) from ethyl 3-(1-(fluoromethyl)cyclopropyl)-1,2,4-oxadiazole-5-carboxylate, following the method described in Example 64, Step 4. LCMS m/z=187.0 [M+H]+
3-(1-(Fluoromethyl)cyclopropyl)-N-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)benzyl)-1,2,4-oxadiazole-5-carboxamide was obtained (7.9 mg, 17% yield) from potassium 3-(1-(fluoromethyl)cyclopropyl)-1,2,4-oxadiazole-5-carboxylate and (4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)phenyl)methanamine dihydrochloride (Example 56, step 6), following a similar method to that used for Example 1, step 8. LCMS m/z=473.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.98 (t, J=6.1 Hz, 1H), 8.33 (s, 1H), 8.10 (s, 1H), 8.00-7.94 (m, 2H), 7.94-7.91 (m, 1H), 7.84 (s, 1H), 7.64 (d, J=1.2 Hz, 1H), 7.59 (d, J=8.5 Hz, 2H), 4.78 (s, 1H), 4.69 (s, 1H), 4.59 (d, J=6.7 Hz, 2H), 3.89 (s, 3H), 1.37-1.28 (m, 4H).
To a solution of (4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)phenyl)methanamine dihydrochloride (Example 56, step 6, 37 mg, 98 μmol) and ethyl 3-(tert-butyl)-1,2,4-oxadiazole-5-carboxylate (29 mg, 148 μmol) in THF (1.5 mL) was added DABAL-Me3 (38 mg, 148 μmol) and the reaction was heated to 45° C. and was stirred at that temperature for 18 h. The reaction mixture was cooled to ambient temperature and diluted with water (1 mL), 1M HCl solution (1 mL) and EtOAc (5 mL). The layers were separated, and the aqueous phase was extracted with additional portions of EtOAc. The combined organic phase was washed brine, dried over Na2SO4, filtered, and concentrated. The crude material was purified by reverse phase HPLC (Method A, 5-55% gradient) to give 3-(tert-butyl)-N-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)benzyl)-1,2,4-oxadiazole-5-carboxamide (5.6 mg, yield 12%).). LCMS m/z=457.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 10.00 (br t, J=6.1 Hz, 1H), 8.35 (s, 1H), 8.12 (s, 1H), 8.02-7.95 (m, 3H), 7.86 (s, 1H), 7.69 (s, 1H), 7.60 (d, J=7.9 Hz, 2H), 4.60 (d, J=6.1 Hz, 2H), 3.89 (s, 3H), 1.41-1.34 (m, 9H).
A solution of 6-bromo-4-methoxypyrazolo[1,5-a]pyridine (300 mg, 1.32 mmol) in aqueous HBr (267 mg, 1.32 mmol, 40% purity, 10 mL) was stirred at 130° C. for 12 h. The reaction mixture was cooled to ambient temperature and a solution of satd. Aq. Na2CO3 was added to adjust the pH to 8. The quenched reaction mixture was concentrated under vacuum to give crude material which was purified by silica gel column chromatography (PE/EtOAc=7:3) to give 6-bromopyrazolo[1,5-a]pyridin-4-ol as a brown solid (150 mg, 51% yield). LCMS m/z=212.9, 214.9 [M+H]+.
To a solution of 6-bromopyrazolo[1,5-a]pyridin-4-ol (100 mg, 0.47 mmol) in DCM (10 mL) was added TEA (143 mg, 1.41 mmol) and the reaction mixture was cooled to 0° C. in an ice-water cooling bath. Triflic anhydride (265 mg, 0.94 mmol) was added and the reaction stirred at 0° C. for 30 mins. The reaction mixture was concentrated and the crude material was purified by prep-TLC (PE/EtOAc=10:1) to give 6-bromopyrazolo[1,5-a]pyridin-4-yl trifluoromethanesulfonate as a clear oil (150 mg, 84% yield). LCMS m/z=344.9, 346.9 [M+H]+.
A mixture of tert-butyl (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (208 mg, 0.60 mmol), 6-bromopyrazolo[1,5-a]pyridin-4-yl trifluoromethanesulfonate (207 mg, 0.60 mmol), K2CO3 (249 mg, 1.80 mmol), and Pd(dppf)Cl2•DCM (49 mg, 60 μmol) were dissolved in dioxane (4.8 mL) and water (1.2 mL) and N2 was bubbled through the mixture for 5 mins. The reaction mixture was heated to 100° C. under an atmosphere of N2 for 1 h. The reaction was cooled to ambient temperature and filtered through Celite®. The filtrate was concentrated and the crude material was purified by silica gel column chromatography (EtOAc/heptanes, from 2% to 100%) to give tert-butyl (4-(6-bromopyrazolo[1,5-a]pyridin-4-yl)-2-methylbenzyl)carbamate as a clear oil (160 mg, 64% yield). LCMS m/z=416.0, 418.0. [M+H]+.
A mixture of tert-butyl (4-(6-bromopyrazolo[1,5-a]pyridin-4-yl)-2-methylbenzyl)carbamate (75 mg, 0.18 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (56 mg, 0.27 mmol), K2CO3 (75 mg, 0.54 mmol), and Pd(dppf)Cl2•DCM (15 mg, 18 μmol) were dissolved in dioxane (1.4 mL) and water (0.4 mL) and N2 was bubbled through the mixture for 5 mins. The reaction mixture was heated to 100° C. under an atmosphere of N2 and stirred for 1 h. The reaction mixture was cooled to ambient temperature and filtered through Celite®. The filtrate was concentrated and the crude material was purified by silica gel column chromatography (EtOAc/heptanes, from 2% to 100%) to give tert-butyl (2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)benzyl)carbamate as a clear oil (44 mg, 59% yield). LCMS m/z=418.1 [M+H]+
To a solution of tert-butyl (2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)benzyl)carbamate (44 mg, 0.11 mmol) in minimal EtOAc was added an HCl solution (1M in EtOAc, 1 mL) and the reaction stirred at ambient temperature for 3 days. The reaction mixture was concentrated to give (2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)phenyl)methanamine dihydrochloride (40 mg, crude), which was carried forward without further purification. LCMS m/z=318.0 [M+H]+
N-(2-Methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)benzyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide was obtained as a white solid (11.3 mg, 47% yield) from (2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)phenyl)methanamine dihydrochloride and potassium 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate following a similar method to that used in Example 5. The crude product was purified by prep-HPLC (Method C1, 5-65% gradient). LCMS m/z=468.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.42 (t, J=6.1 Hz, 1H), 8.99 (s, 1H), 8.32 (s, 1H), 8.06 (s, 1H), 8.01 (d, J=2.4 Hz, 1H), 7.61-7.50 (m, 3H), 7.39 (d, J=7.9 Hz, 1H), 6.67 (dd, J=2.4 Hz, 1.2 Hz, 1H), 4.51 (d, J=6.1 Hz, 2H), 3.88 (s, 3H), 2.43 (s, 3H), 1.55 (s, 3H), 1.42-1.36 (m, 2H), 1.20-1.12 (m, 2H).
1-(tert-Butyl)-N-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)benzyl)-1H-1,2,3-triazole-4-carboxamide was obtained as a pink solid (10.7 mg, 45% yield) from (2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)phenyl) methanamine dihydrochloride (Example 65, step 6) and 1-(tert-butyl)-1H-1,2,3-triazole-4-carboxylic acid following a similar method to that described in Example 4. The crude material was purified by reverse phase HPLC (Method A, 5-60% gradient). LCMS m/z=469.3 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.01 (t, J=6.1 Hz, 1H), 8.99-8.97 (m, 1H), 8.71 (s, 1H), 8.32 (s, 1H), 8.05 (s, 1H), 8.01 (d, J=2.4 Hz, 1H), 7.60-7.54 (m, 2H), 7.51 (d, J=1.2 Hz, 1H), 7.39 (d, J=7.9 Hz, 1H), 6.70-6.64 (m, 1H), 4.52 (d, J=6.1 Hz, 2H), 3.88 (s, 3H), 2.44 (s, 3H), 1.64 (s, 9H).
A mixture of tert-butyl (2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (211 mg, 0.60 mmol), 6-bromopyrazolo[1,5-a]pyridin-4-yl trifluoromethanesulfonate (207 mg, 0.60 mmol), K2CO3 (249 mg, 1.80 mmol), and Pd(dppf)Cl2•DCM (49 mg, 60 μmol) were dissolved in dioxane (4.8 mL) and water (1.2 mL) and N2 was bubbled through the mixture for 5 mins. The reaction mixture was heated to 100° C. under an atmosphere of N2 and was stirred for 1 h. The reaction mixture was cooled to ambient temperature and filtered through Celite®. The filtrate was concentrated and the crude material was purified by silica gel column chromatography (EtOAc/heptanes, from 2% to 100%) to give tert-butyl (4-(6-bromopyrazolo[1,5-a]pyridin-4-yl)-2-fluorobenzyl)carbamate as a white solid (151 mg, 60% yield). LCMS m/z=419.9, 421.9 [M+H]+
A mixture of tert-butyl (4-(6-bromopyrazolo[1,5-a]pyridin-4-yl)-2-fluorobenzyl)carbamate (151 mg, 0.36 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (112 mg, 0.54 mmol), K2CO3 (149 mg, 1.1 mmol), and Pd(dppf)Cl2•DCM (29 mg, 36 μmol) were dissolved in dioxane (2.9 mL) and water (0.7 mL) and N2 was bubbled through the mixture for 5 mins. The reaction was heated to 100° C. under an atmosphere of N2 and was stirred for 1 h. The reaction mixture was cooled to ambient temperature and filtered through Celite®. The filtrate was concentrated and the crude material was purified by silica gel column chromatography (EtOAc/heptanes, from 2% to 100%) to give tert-butyl (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)benzyl)carbamate as an off-white solid (115 mg, 76% yield). LCMS m/z=422.1 [M+H]+
To a solution of tert-butyl (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)benzyl)carbamate (115 mg, 0.27 mmol) in minimal EtOAc was added an HCl solution (1M in EtOAc, 2.7 mL). The reaction mixture was stirred at ambient temperature for 3 days. The reaction mixture was concentrated to give (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)phenyl)methanamine dihydrochloride (115 mg, crude), which was carried forward without further purification. LCMS m/z=322.0 [M+H]+
N-(2-Fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)benzyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide was obtained as a white solid (8.3 mg, 25% yield) from (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)phenyl)methanamine dihydrochloride and potassium 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate, following a similar method to that used for Example 1, step 8. The crude material was purified by prep-HPLC (Method A, 5-60% gradient). LCMS m/z=472.4 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.51 (t, J=6.1 Hz, 1H), 9.03 (s, 1H), 8.34 (s, 1H), 8.07 (s, 1H), 8.04 (d, J=2.4 Hz, 1H), 7.67-7.58 (m, 3H), 7.52 (t, J=7.9 Hz, 1H), 6.71 (d, J=2.4 Hz, 1H), 4.57 (d, J=6.1 Hz, 2H), 3.88 (s, 3H), 1.54 (s, 3H), 1.46-1.35 (m, 2H), 1.22-1.12 (m, 2H).
5-(tert-Butyl)-N-(2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide was obtained as a white solid (7.3 mg, 22% yield) from (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)phenyl)methanamine dihydrochloride (Example 67, step 3) and lithium 5-(tert-butyl)-1,2,4-oxadiazole-3-carboxylate following a similar method to that used in Example 67, step 4. The crude material was purified by prep-HPLC method A, gradient 5-65%. LCMS m/z=474.4 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ: 9.56 (t, J=6.1 Hz, 1H), 9.03 (s, 1H), 8.34 (s, 1H), 8.07 (s, 1H), 8.04 (d, J=1.8 Hz, 1H), 7.70-7.60 (m, 3H), 7.53 (t, J=7.9 Hz, 1H), 6.76-6.67 (m, 1H), 4.58 (d, J=6.1 Hz, 2H), 3.88 (s, 3H), 1.43 (s, 9H).
1-(tert-Butyl)-N-(2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)benzyl)-1H-1,2,3-triazole-4-carboxamide was obtained as a white solid (3.5 mg, 10% yield) from (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)phenyl) methanamine dihydrochloride (Example 67, step 3) and 1-(tert-butyl)-1H-1,2,3-triazole-4-carboxylic acid, following a similar method to that used for Example 1, step 8. The crude material was purified by prep-HPLC (Method A, 5-60% gradient). LCMS m/z=473.5 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.12 (t, J=6.1 Hz, 1H), 9.03 (s, 1H), 8.72 (s, 1H), 8.37-8.30 (m, 1H), 8.07 (s, 1H), 8.03 (d, J=2.4 Hz, 1H), 7.63-7.59 (m, 3H), 7.54-7.47 (m, 1H), 6.71 (d, J=2.4 Hz, 1H), 4.58 (d, J=6.1 Hz, 2H), 3.88 (s, 3H), 1.64 (s, 9H).
1-(tert-Butyl)-N-(2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)benzyl)-1H-pyrazole-3-carboxamide was obtained as a white solid (17.9 mg, 53% yield) from (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)phenyl)methanamine dihydrochloride (Example 67, step 3) and 1-(tert-butyl)-1H-pyrazole-3-carboxylic acid, following a similar method to that described in Example 1, step 8. LCMS m/z=472.5 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.07-8.98 (m, 1H), 8.61 (t, J=6.1 Hz, 1H), 8.33 (s, 1H), 8.07 (s, 1H), 8.03 (d, J=2.4 Hz, 1H), 7.93 (d, J=2.4 Hz, 1H), 7.68-7.57 (m, 3H), 7.56-7.47 (m, 1H), 6.75-6.70 (m, 1H), 6.66 (d, J=2.4 Hz, 1H), 4.56 (d, J=6.1 Hz, 2H), 3.88 (s, 3H), 1.57 (s, 9H).
To a solution of methyl 2-cyano-2-methylpropanoate (100 g, 786 mmol) in THF (800 mL) and water (2 L), NaBH4 (89.3 g, 2.36 mol) was added slowly over 1 h at 15° C. (ice-water bath) and the mixture was stirred at 20° C. for 4 h. The reaction was quenched by slow addition of aqueous HCl solution (6 M) to pH<7. The mixture was extracted with EtOAc (3×) and the organic layer was washed with 2N NaOH and brine. The organic phase was dried over Na2SO4, filtered, and concentrated under vacuum to give a colorless oil (48 g). Heptane was added and mixture concentrated again to remove the volatiles. Crude 3-hydroxy-2,2-dimethylpropanenitrile was obtained as a colorless oil (47 g, 60% yield) and was carried forward without further purification. 1H NMR (300 MHz, CDCl3) δ: 3.56 (s, 2H), 2.51 (br s, 1H), 1.31 (s, 6H).
To a solution of 3-hydroxy-2,2-dimethylpropanenitrile (51.0 g, 515 mmol) in EtOH (800 mL), hydroxylamine (50% weight in water, 120 mL, 2.06 mol) was added at 25° C. and the reaction was stirred at 70° C. overnight. The mixture was cooled and concentrated under vacuum and the water was removed azeotropically with toluene (2×) and THF (1×). The white solid was triturated in Et2O, filtered, and dried again under vacuum to give (E)-N′,3-dihydroxy-2,2-dimethylpropanimidamide as a white solid (62.5 g, 91% yield), which was carried forward without further purification. 1H NMR (300 MHz, DMSO-d6) δ: 8.85 (s, 1H), 5.20 (s, 2H), 4.54 (br s, 1H), 3.31 (s, 2H), 1.03 (s, 6H).
Ethyl 2-chloro-2-oxo-acetate (53.0 mL, 473 mmol) was added to a solution of (E)-N′,3-dihydroxy-2,2-dimethylpropanimidamide (62.5 g, 473 mmol) in pyridine (1 L) cooled with an ice-water bath. After 1 h, the reaction mixture was heated to 80° C. and was stirred at that temperature for 16 h. The mixture was concentrated under vacuum to remove pyridine. The residue was dissolved in EtOAc (400 mL) and water (300 mL) and extracted with EtOAc (3×300 mL). The combined organic phases were washed with water (100 mL) and brine, dried over Na2SO4, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (eluting with DCM/EtOAc, from 10/1 to 1/1) to give a mixture of ethyl 3-(1-hydroxy-2-methylpropan-2-yl)-1,2,4-oxadiazole-5-carboxylate with 20 mol % of 3-hydroxy-2,2-dimethylpropanenitrile. Most of the 3-hydroxy-2,2-dimethylpropanenitrile was removed by Kugelrohr distillation at 90° C. to afford ethyl 3-(1-hydroxy-2-methylpropan-2-yl)-1,2,4-oxadiazole-5-carboxylate as a colorless oil (22.5 g, 22% yield), which was carried forward without further purification.
To a solution of ethyl 3-(1-hydroxy-2-methylpropan-2-yl)-1,2,4-oxadiazole-5-carboxylate (22.2 g, 104 mmol) and DIPEA (35.4 mL, 207.3 mmol) in DCM (600 mL) at 0° C. was added triflic anhydride (21 mL, 124 mmol) and the mixture was stirred overnight at RT. Additional DCM (200 mL) was added, followed by water (100 mL). The phases were separated, and the organic phase was washed with water (100 mL). The organic phase was dried over Na2SO4, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (heptane/EtOAc=5/1 to 3/1) to give ethyl 3-(2-methyl-1-(((trifluoromethyl)sulfonyl)oxy)propan-2-yl)-1,2,4-oxadiazole-5-carboxylate as an orange oil (27.5 g, 76% yield). 1H NMR (300 MHz, CDCl3) δ: 4.71 (s, 2H), 4.53 (q, J=7.3 Hz, 2H), 1.56 (s, 6H), 1.43 (t, J=7.4 Hz, 3H).
A solution of ethyl 3-(2-methyl-1-(((trifluoromethyl)sulfonyl)oxy)propan-2-yl)-1,2,4-oxadiazole-5-carboxylate (27.5 g, 79.4 mmol) and tetrabutylammonium hydrogen difluoride (50% in MeCN, 89.0 g, 159 mmol) in THF (700 mL) was stirred at 40° C. for 48 h. The mixture was concentrated under vacuum. The residue was dissolved in EtOAc (700 mL), washed with water (3×100 mL). The organic phase was dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluting with heptane/EtOAc=5/1 to 3/1) to give ethyl 3-(1-fluoro-2-methylpropan-2-yl)-1,2,4-oxadiazole-5-carboxylate as a colorless oil (11.3 g, 65% yield). 1H NMR (300 MHz, CDCl3) δ: 4.63 (s, 1H), 4.54 (q, J=7.4 Hz, 2H), 4.46 (s, 1H), 1.56-1.38 (m, 9H).
To a cold solution of ethyl 3-(1-fluoro-2-methylpropan-2-yl)-1,2,4-oxadiazole-5-carboxylate (9.70 g, 44.9 mmol) in MeOH (90 mL) was added a solution of LiOH·H2O (3.76 g, 89.7 mmol) in water (15 mL) and the resulting mixture was stirred for 2 h at RT. MeOH was removed under vacuum and the aqueous residue (cooled with ice bath) was acidified with concentrated HCl until pH=2-3. The mixture was concentrated under vacuum to give a white solid. The residue was dried by co-evaporation with toluene (3×10 mL). The white solid obtained was suspended in 5% MeOH in DCM (100 mL), the mixture was filtered, and the filter cake washed with the same mixture (3×10 mL). The filtrates were combined, dried over anhydrous Na2SO4, filtered, and concentrated under vacuum to give 3-(1-fluoro-2-methylpropan-2-yl)-1,2,4-oxadiazole-5-carboxylic acid as white solid (7.0 g, crude), which was carried forward without further purification. LCMS m/z=189.0 [M+H]+
3-(1-Fluoro-2-methylpropan-2-yl)-N-(2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)benzyl)-1,2,4-oxadiazole-5-carboxamide was obtained as a white solid (4.5 mg, 13% yield) from (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl)phenyl)methanamine dihydrochloride (Example 67, step 3) and 3-(1-fluoro-2-methylpropan-2-yl)-1,2,4-oxadiazole-5-carboxylic acid following a similar method to that used for Example 1 step 8. The crude material was purified by reverse phase HPLC (Method A, 5-65% gradient). LCMS m/z=492.4 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ: 9.98 (t, J=5.8 Hz, 1H), 9.04 (s, 1H), 8.34 (s, 1H), 8.07 (s, 1H), 8.04 (d, J=1.8 Hz, 1H), 7.69-7.52 (m, 4H), 6.75-6.67 (m, 1H), 4.62 (s, 1H), 4.60 (d, J=6.1 Hz, 2H), 4.53 (s, 1H), 3.88 (s, 3H), 1.38 (d, J=1.8 Hz, 6H).
C.4 Preparation of [1,2,4]triazolo[1,5-a]pyrazines
A suspension of tert-butyl N-(4-piperidylmethyl)carbamate (500 mg, 2.33 mmol), 6,8-dibromo-[1,2,4]triazolo[1,5-a]pyrazine (647.52 mg, 2.33 mmol) and DIPEA (602.26 mg, 4.66 mmol) in IPA (10 mL) was stirred at RT for 2 h. After 15 min, a copious white solid formed, so additional IPA (10 mL) was added to allow stirring. The mixture was filtered, the solid washed with IPA and dried to give tert-butyl ((1-(6-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)piperidin-4-yl)methyl)carbamate (864 mg, 90.2% yield) as a white solid. 1H NMR (500 MHz, CDCl3) δ ppm: 8.20 (s, 1H), 7.99 (s, 1H), 5.66-5.30 (br s, 2H), 4.64 (br s, 1H), 3.20-3.01 (m, 4H), 1.95-1.80 (m, 3H), 1.46 (s, 9H), 1.39-1.24 (m, 2H).
A mixture of tert-butyl ((1-(6-bromo-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)piperidin-4-yl)methyl)carbamate (150 mg, 364.7 μmol), (1-methylpyrazol-4-yl)boronic acid (91.85 mg, 729.4 μmol) and Cs2CO3 (356.48 mg, 1.09 mmol) in dry dioxane (3.0 mL) was sparged with N2 for 5 min. RuPhos (34.04 mg, 72.94 μmol) and Pd2(dba)3 (33.40 mg, 36.47 μmol) were added and the resulting mixture was heated at 100° C. for 17 h. The cooled mixture was filtered through a pad of Celite® washing through with EtOAc and the filtrate was concentrated in vacuum. The residue was purified by silica gel chromatography (0-100% Heptane in EtOAc) to give tert-butyl ((1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)piperidin-4-yl)methyl)carbamate (116 mg, 77.1% yield) as an orange solid. LCMS m/z=413.2 [M+H]+
A suspension of tert-butyl ((1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)piperidin-4-yl)methyl)carbamate (115 mg, 278.79 μmol) in MeOH (1.0 mL) was treated with 4M HCl in dioxane (975.77 uL) and the reaction stirred at RT for 2 h. The mixture was concentrated to dryness to give (1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)piperidin-4-yl)methanamine dihydrochloride as a white solid. LCMS m/z=313.2 [M+H]+
T3P® (218.91 mg, 344.01 μmol, 50% purity) was added to a solution of 2-tert-butyltetrazole-5-carboxylic acid (43.90 mg, 258.01 μmol), (1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)piperidin-4-yl)methanamine hydrochloride (60 mg, 172 μmol) and DIPEA (111.15 mg, 860.02 μmol) in dry DMF (2.0 mL) and the reaction stirred at RT for 2 days. Additional DIPEA (111.15 mg, 860.02 μmol) and T3P® (218.91 mg, 344.01 μmol, 232.89 uL, 50% purity) were added and stirring continued for 2 h. The reaction was quenched with saturated NaHCO3 solution and extracted with EtOAc. The organic layer was washed with brine (3×) and the combined aqueous layers were extracted with EtOAc. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuum. The crude was purified by prep HPLC (Method C2, 5-60% gradient) to give 2-(tert-butyl)-N-((1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)piperidin-4-yl)methyl)-2H-tetrazole-5-carboxamide (68.40 mg, 81.3% yield) as an orange solid. LCMS m/z=465.2 [M+H]+ 1H NMR (500 MHz, CDCl3) δ ppm: 8.25-8.21 (m, 1H), 8.11-8.08 (m, 1H), 7.87 (s, 1H), 7.84 (s, 1H), 7.34-7.29 (m, 1H), 5.51 (br d, J=13.4 Hz, 2H), 4.00-3.96 (m, 3H), 3.49 (t, J=6.7 Hz, 2H), 3.19-3.11 (m, 2H), 2.14-2.03 (m, 1H), 2.03-1.94 (m, 2H), 1.83-1.81 (m, 9H), 1.52-1.42 (m, 2H).
To a suspension of (1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)piperidin-4-yl)methanamine dihydrochloride (Example 72, step 3, 95.0 mg, 272.34 μmol) and lithium 5-tert-butyl-1,2,4-oxadiazole-3-carboxylate (96.47 mg, 544.68 μmol) in dry DMF (2.0 mL) was added DIPEA (176 mg, 1.36 mmol) followed by T3P® (259.96 mg, 817.02 μmol) and the reaction stirred at RT for 17 h. The reaction was diluted with EtOAc, washed with sat. NaHCO3, water and brine (2×). The combined aq. layers were re-extracted with EtOAc, the combined organic extracts were dried (MgSO4), filtered and concentrated in vacuum. The residue was purified by prep-HPLC (Method C2, 5-60% gradient) to give 5-(tert-butyl)-N-((1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)piperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide (79.9 mg, 60% yield) as an off-white solid. LCMS m/z=465.3 [M+H]+ 1H NMR (500 MHz, CDCl3) δ ppm: 8.24 (s, 1H), 8.09 (s, 1H), 7.92 (s, 1H), 7.84 (s, 1H), 7.12 (br t, J=6.1 Hz, 1H), 5.48 (br d, J=13.4 Hz, 2H), 3.97-4.03 (m, 3H), 3.44 (t, J=6.4 Hz, 2H), 3.18-3.08 (m, 2H), 2.13-2.02 (m, 1H), 1.96 (br d, J=12.8 Hz, 2H), 1.48 (s, 9H), 1.47-1.39 (m, 2H).
1-(tert-Butyl)-N-((1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)piperidin-4-yl)methyl)-1H-1,2,3-triazole-4-carboxamide was obtained as an off-white solid (55.7 mg, 62.9% yield) from (1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)piperidin-4-yl)methanamine dihydrochloride (Example 72, step 3) and 1-tert-butyltriazole-4-carboxylic acid, following the method described in Example 72, step 4. LCMS m/z=464.3 [M+H]+ 1H NMR (500 MHz, CDCl3) δ ppm 8.24 (s, 1H), 8.17-8.13 (m, 1H), 8.09 (s, 1H), 7.90-7.85 (m, 1H), 7.84 (s, 1H), 7.35-7.30 (m, 1H), 5.61-5.43 (m, 2H), 3.99 (s, 3H), 3.44 (t, J=6.4 Hz, 2H), 3.19-3.10 (m, 2H), 2.09-2.02 (m, 1H), 2.02-1.95 (m, 2H), 1.74-1.70 (m, 1H), 1.52-1.40 (m, 2H).
C.5 Preparation of [1,2,4]triazolo[4,3-a]pyridines
A mixture of 7-bromo-5-chloro-[1,2,4]triazolo[4,3-a]pyridine (112 mg, 0.48 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (100 mg, 0.48 mmol), K2CO3 (199 mg, 1.4 mmol), and Pd(dppf)Cl2•DCM (39 mg, 48 μmol) were dissolved in dioxane (3.8 mL) and water (1 mL) and N2 was bubbled through the mixture for 5 mins. The reaction mixture was heated to 100° C. under an atmosphere of N2 and stirred at that temperature for 1 h. The reaction mixture was cooled to ambient temperature and filtered through Celite®. The filtrate was concentrated and the crude material was purified by silica gel column chromatography (3:1 EtOAc/EtOH:heptanes, from 2% to 100%) to give 5-chloro-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine as an off-white solid (84 mg, 75% yield). 1H NMR (500 MHz, MeOH-d4) δ: 9.27 (s, 1H), 8.25 (s, 1H), 8.06 (s, 1H), 7.87 (s, 1H), 7.54-7.50 (m, 1H), 3.96 (s, 3H).
A mixture of tert-butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (120 mg, 0.36 mmol), 5-chloro-7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine (84 mg, 0.36 mmol), K2CO3 (149 mg, 1.1 mmol), and Pd(dppf)Cl2•DCM (29 mg, 36 μmol) were dissolved in dioxane (2.9 mL) and water (0.7 mL) and N2 was bubbled through the mixture for 5 mins. The reaction mixture was heated to 100° C. under an atmosphere of N2 and was stirred for 2 h. The reaction mixture was cooled to ambient temperature and filtered through Celite®. The filtrate was concentrated and the crude material was purified by silica gel column chromatography ([3:1 EtOAc/EtOH]/heptanes from 2% to 100%) to give tert-butyl (4-(7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-yl)benzyl)carbamate as a brown solid (129 mg, 89% yield). LCMS m/z=405.1 [M+H]+
To a solution of tert-butyl (4-(7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-yl)benzyl)carbamate (125 mg, 309 μmol) in EtOAc (1 mL) was added an HCl solution (1 M in EtOAc, 3.09 mL) and the reaction was stirred for 3 days at ambient temperature. The reaction mixture was concentrated, and the crude material was carried forward without further purification (94 mg, crude). LCMS m/z=305 [M+H]+
To a solution of 1-(tert-butyl)-1H-1,2,3-triazole-4-carboxylic acid (13 mg, 75 μmol) in THF (2 mL) in an ice water cooling bath was added TEA (20 mg, 201 μmol) and HATU (38 mg, 101 μmol). The reaction mixture was stirred at 0° C. for 10 min before (4-(7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-yl)phenyl)methanamine dihydrochloride (19 mg, 50 μmol) was added. The reaction mixture was warmed to 23° C. and stirred for 24 h. Water (5 mL) was added to quench the reaction, then EtOAc (5 mL) added and the layers were separated. The aqueous phase was extracted EtOAc (2×5 mL). The organic phases were combined, washed with brine, dried over Na2SO4, filtered, and concentrated. The crude material was purified by reverse phase HPLC (Method C1, 5-45% gradient) to give 1-(tert-butyl)-N-(4-(7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-yl)benzyl)-1H-1,2,3-triazole-4-carboxamide as a white solid (14.7 mg, 51% yield). LCMS m/z=456.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ: 9.29-9.16 (m, 2H), 8.71 (s, 1H), 8.52 (s, 1H), 8.22 (s, 1H), 8.02 (s, 1H), 7.85-7.76 (m, 2H), 7.57 (d, J=8.5 Hz, 2H), 7.41 (s, 1H), 4.58 (d, J=6.7 Hz, 2H), 3.89 (s, 3H), 1.68-1.61 (m, 9H).
N-(4-(7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-yl)benzyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide was obtained (13.8 mg, 48% yield) as a white solid, from potassium 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate and (4-(7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-yl)phenyl)methanamine dihydrochloride (Example 75, step 3) following the method used in Example 75, step 4. LCMS m/z=455.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ: 9.57 (t, J=6.1 Hz, 1H), 9.18 (s, 1H), 8.51 (s, 1H), 8.22 (s, 1H), 8.02 (s, 1H), 7.82 (d, J=8.5 Hz, 2H), 7.57 (d, J=8.5 Hz, 2H), 7.39 (s, 1H), 4.56 (d, J=6.7 Hz, 2H), 3.95-3.84 (m, 3H), 1.59-1.51 (m, 3H), 1.44-1.34 (m, 2H), 1.23-1.13 (m, 2H).
1-(tert-Butyl)-N-(4-(7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-yl)benzyl)-1H-pyrazole-4-carboxamide was obtained as a white solid (19.6 mg, 68% yield) from 1-(tert-butyl)-1H-pyrazole-4-carboxylic acid and (4-(7-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-yl)phenyl)methanamine dihydrochloride (Example 75, step 3), following the method used in Example 75, step 4. LCMS m/z=455.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ: 9.18 (s, 1H), 8.72 (t, J=6.1 Hz, 1H), 8.52 (s, 1H), 8.32 (s, 1H), 8.23 (s, 1H), 8.02 (s, 1H), 7.92 (s, 1H), 7.81 (d, J=8.5 Hz, 2H), 7.55 (d, J=7.9 Hz, 2H), 7.40 (s, 1H), 4.54 (d, J=6.1 Hz, 2H), 3.89 (s, 3H), 1.59-1.49 (m, 9H).
A mixture of 5-(tert-butyl)-N-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (Step 1, Example 55, 100 mg, 250.4 μmol), 5-chloro-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidine (Step 4, Example 56, 58.52 mg, 250.4 μmol), K2CO3 (103.84 mg, 751.3 μmol) and Pd(dppf)Cl2 (9.16 mg, 12.5 μmol) were dissolved in dioxane (2.0 mL) and water (0.5 mL) and N2 was bubbled through the mixture for 5 min. The reaction mixture was heated to 100° C. under N2 and stirred at 100° C. overnight. The cooled reaction was concentrated, dissolved in MeOH, and filtered through at 0.45 μM syringe filter. The filtrate was concentrated and purified by HPLC (Method C3, 5-75%) to afford 5-(tert-butyl)-N-(2-methyl-4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (70 mg, 56.4% yield). LCMS m/z=471.3 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.54 (t, J=6.10 Hz, 1H) 8.33 (s, 1H) 8.10 (s, 1H) 7.93-7.90 (m, 1H) 7.83 (s, 1H) 7.82-7.78 (m, 2H), 7.64-7.61 (m, 1H) 7.48 (d, J=8.55 Hz, 1H) 4.56 (d, J=6.10 Hz, 2H) 3.89 (s, 3H) 2.46 (s, 3H) 1.44 (s, 9H).
To a solution of 4-bromo-3-fluoro-2-methylbenzonitrile (62.2 g, 290 mmol) in THF (150 mL) was added BH3·THF (49.9 g, 581 mmol) and the solution was stirred at 70° C. overnight. The reaction was quenched by cautiously adding MeOH at 0° C., the mixture was concentrated, the residue was dissolved in DCM (1 L) and 36% aqueous HCl (20 mL) slowly added. The mixture was stirred for 30 min, the resulting solid filtered off, washed with DCM and TBME and dried under vacuum to give (4-bromo-3-fluoro-2-methylphenyl)methanamine hydrochloride (58.6 g, 79%) as a grey solid. LCMS m/z=218.2 [M+H]+.
To a suspension of 4-bromo-3-fluoro-2-methylphenyl)methanamine hydrochloride (63.0 g, 247 mmol) in DCM (450 mL), was added TEA (75.1 g, 742 mmol) and (Boc)2O (64.8 g, 297 mmol) and the reaction was stirred at rt overnight. The mixture was washed with water and brine, dried over Na2SO4 and concentrated. The crude product was used as such in the next step.
A solution of tert-butyl (4-bromo-3-fluoro-2-methylbenzyl)carbamate (47.4 g, 149 mmol), bis(pinacolato)diboron (45.4 g, 179 mmol) and KOAc (29.3 g, 298 mmol) in dioxane (600 mL) was stirred under N2 at rt for 10 min. PdCl2(dppf)•DCM (12.2 g, 14.9 mmol) was added and the reaction mixture was stirred at 90° C. for 16 h. The mixture was filtered through Celite®, the filtrate was diluted with EtOAc, then washed with water, aq. NaHCO3 and brine. The organic layer was dried over Na2SO4 and concentrated in vacuo. The crude product was purified by column chromatography (heptane: EtOAc gradient 0 to 30% EtOAc) to give impure product. The solid was triturated with hexane, the solid filtered off and dried to give (tert-butyl (3-fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate. 42.3 g, 78%.
tert-Butyl (3-fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (30.0 g, 82.1 mmol) was suspended in 4 M HCl in dioxane (62 mL, 246 mmol) and the mixture was stirred for 1 h at rt. The mixture was concentrated in vacuum and azeotroped with toluene (5×50 mL) to give (3-fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine hydrochloride (25.8 g, crude) as a light pink solid.
DIPEA (45 mL, 257 mmol) was added to a suspension of (3-fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine hydrochloride (25.8 g, 85.6 mmol) and 5-(tert-butyl)-1,2,4-oxadiazole-3-carboxylic acid (21.8 g, 128 mmol) in anhydrous DMF (500 mL) and the mixture was cooled to 0° C. T3P® (64.7 mL, 111 mmol) was added and the resulting mixture was allowed to warm to rt and stirred for 2 h. The reaction was quenched with water (300 mL) and EtOAc (300 mL) was added. The layers were separated and the aqueous layer was extracted with EtOAc (3×100 mL). The combined organic layers were washed with water (3×50 mL), sat. aq. solution of NaHCO3 (50 mL) and with brine (50 mL) then dried over Na2SO4, filtered and concentrated in vacuum to give a beige oil. This was purified by silica gel column chromatography (heptanes: EtOAc, 0-20% gradient) twice, to give (3-fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine as a thick pale-yellow oil, which slowly solidified upon standing (11.2 g, 31%).
A mixture of 5-(tert-butyl)-N-(3-fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (75.0 mg, 179.74 μmol), 5-chloro-7-(1-methylpyrazol-4-yl)imidazo[1,2-c]pyrimidine (42.00 mg, 179.74 μmol), K2CO3 (74.5 mg, 539.2 μmol) and Pd(dppf)Cl2 (6.58 mg, 8.99 μmol) were dissolved in dioxane (1.44 mL) and water (0.36 mL) and N2 was bubbled through the mixture for 5 min. The reaction mixture was heated to 100° C. under an atmosphere of N2 and stirred at 100° C. for 3 h. The reaction was concentrated and purified via column chromatography (gradient elution 0-100% [3:1 EtOAc:EtOH]:heptane) to afford 5-(tert-butyl)-N-(3-fluoro-2-methyl-4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (88 mg, 99.2% yield) as a light yellow solid. LCMS m/z=489.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.58 (t, J=5.77 Hz, 1H) 8.31 (s, 1H) 8.08 (s, 1H) 7.91 (s, 1H) 7.66-7.60 (m, 2H) 7.57 (br s, 1H) 7.35 (d, J=8.03 Hz, 1H) 4.59 (d, J=6.02 Hz, 2H) 3.87 (s, 3H) 2.35 (d, J=2.01 Hz, 3H) 1.44 (s, 9H).
5-(tert-butyl)-N-(2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide was obtained as a white solid, 74 mg, 82.1% yield, from 5-(tert-butyl)-N-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (Step 1, Example 55) and 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5), following the procedure described in Example 79, step 6. LCMS m/z=471.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.50 (t, J=5.90 Hz, 1H) 9.12 (d, J=1.00 Hz, 1H) 8.34 (s, 1H) 8.18 (d, J=2.51 Hz, 1H) 8.11 (d, J=0.75 Hz, 1H) 7.95 (d, J=5.02 Hz, 2H) 7.45 (d, J=8.53 Hz, 1H) 7.15 (dd, J=2.51, 1.00 Hz, 1H) 4.55 (d, J=6.27 Hz, 2H) 3.91 (s, 3H) 2.48 (s, 3H) 1.44 (s, 9H).
5-(tert-Butyl)-N-(3-fluoro-2-methyl-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide was obtained as a light yellow solid, 81 mg, 90.4% yield, from 5-(tert-butyl)-N-(3-fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (Example 79, step 5) and 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5), following the procedure described in Example 79, step 6. LCMS m/z=489.2 [M+H]+ 1H NMR (400 MHz, DMSO-d6) δ ppm 9.55 (t, J=6.15 Hz, 1H) 9.19 (d, J=1.00 Hz, 1H) 8.27 (s, 1H) 8.14 (d, J=2.26 Hz, 1H) 8.07 (d, J=0.75 Hz, 1H) 7.59 (t, J=7.53 Hz, 1H) 7.30 (d, J=8.03 Hz, 1H) 6.75 (t, J=2.13 Hz, 1H) 4.58 (d, J=5.77 Hz, 2H) 3.88 (s, 3H) 2.35 (d, J=2.01 Hz, 3H) 1.44 (s, 9H).
To a solution of tert-butyl (2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (359.1 mg, 0.977 mmol) in dioxane (30 mL) and H2O (5 mL) was added 4-chloropyrazolo[1,5-a]pyrazine (150 mg, 0.977 mmol) and K2CO3 (270 mg, 1.95 mmol) at 20° C. Pd(dppf)Cl2 (71.5 mg, 97.7 μmol) was added and the reaction was stirred at 90° C. for 3 h under N2. The mixture was filtered and concentrated under vacuum to give the crude, which was purified by chromatography column on silica gel (PE/EtOAc=3/1) to give tert-butyl (2-chloro-4-(pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (200 mg, 57.1% yield) as a yellow solid.
A solution of tert-butyl (2-chloro-4-(pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (200 mg, 0.557 mmol) in 4M HCl/EtOAc (20 mL) was stirred at 20° C. for 1 h. The mixture was concentrated under vacuum to give (2-chloro-4-pyrazolo[1,5-a]pyrazin-4-yl-phenyl)methanamine dihydrochloride (150 mg), as a white solid, which was used in the next step directly without further purification.
A solution of 5-tert-butyl-1,2,4-oxadiazole-3-carboxylic acid (200 mg, 1.18 mmol) in DCM (10 mL) and DMF (0.2 mL) was added thionyl chloride (559.3 mg, 4.70 mmol) at 15° C. and the reaction was stirred at 15° C. for 0.5 h. The mixture was filtered and concentrated under vacuum to give 5-tert-butyl-1,2,4-oxadiazole-3-carbonyl chloride (200 mg, crude) as white solid.
To a solution of (2-chloro-4-(pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (140 mg, 474.3 μmol) in DCM (30 mL) was added DIPEA (122.6 mg, 948.6 μmol) at 20° C. 5-tert-Butyl-1,2,4-oxadiazole-3-carbonyl chloride (Example 82 step 3, 134.2 mg, 711.5 μmol) was added and the reaction mixture was stirred at 20° C. for 1 h. The mixture was poured into water (50 mL) and extracted with DCM (50 mL×3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under vacuum. The crude product was purified by Prep-HPLC (Method D, 48-68% gradient) to give 5-(tert-butyl)-N-(2-chloro-4-(pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (88.9 mg, 45.6% yield) as a white solid. LCMS m/z=411.0 [M+H]+ 1H NMR: (400 MHz, DMSO-d6) δ=9.63-9.59 (m, 1H), 9.47 (m, 1H), 8.26 (s, 1H), 8.09-8.03 (m, 3H), 7.57-7.54 (m, 1H), 7.21 (s, 1H), 4.62 (d, J=6.0 Hz, 2H), 1.44 (s, 9H).
KOAc (8.13 g, 82.86 mmol) and Pd(dppf)Cl2 DCM (2.26 g, 2.76 mmol) were added to a solution of tert-butyl (4-bromo-3-fluorobenzyl)carbamate (8.40 g, 27.6 mmol) and (BPin)2 (14.03 g, 55.2 mmol) in dioxane (150 mL) and the reaction was stirred at 90° C. under N2 for 12 h. The mixture was concentrated to dryness to give crude product, which was purified by column chromatography on silica gel (PE/EtOAc=20/1) to give tert-butyl (3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (9.00 g, 83.5% yield) as a white solid. LCMS m/z=296.0 [M-CH4+H]+.
K2CO3 (472.7 mg, 3.42 mmol) and Pd(dppf)Cl2•DCM (93.1 mg, 114 μmol) were added to a solution of tert-butyl (3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (400 mg, 1.14 mmol) and 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 266.1 mg, 1.14 mmol) in dioxane (30 mL) and water (3 mL) and the mixture was stirred at 90° C. under N2 for 5 h. The mixture was concentrated to dryness and the crude product was purified by column chromatography (PE/EtOAc=1:4) to give tert-butyl (3-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (400 mg, 74.8% yield) as a brown solid.
A solution of tert-butyl (3-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (400 mg, 946.9 μmol) in HCl/EtOAc (4 M, 20 mL) was stirred at 20° C. for 1 h. The mixture was concentrated under vacuum to give (3-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (340 mg, 90.1% yield), as a yellow solid. It was used for the next step without purification.
To a solution of (3-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (80 mg, 223 μmol) in DCM (50 mL) was added DIPEA (86.45 mg, 668.9 μmol). 5-tert-Butyl-1,2,4-oxadiazole-3-carbonyl chloride (Example 82, step 3, 63.08 mg, 334.5 μmol) was added and the mixture was stirred at 20° C. for 1 h. The mixture was concentrated under vacuum and the crude was purified by Prep-HPLC (Method D, 43-63% gradient) to give 5-(tert-butyl)-N-(3-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (30 mg, 28.4% yield) as a brown solid. LCMS m/z=475.1 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ: 9.63 (t, J=5.0 Hz, 1H), 9.20 (s, 1H), 8.28 (s, 1H), 8.15 (s, 1H), 8.07 (s, 1H), 7.78 (t, J=5.0 Hz, 1H), 7.37 (t, J=5.0 Hz, 2H), 6.77 (s, 1H), 4.57 (d, J=5.0 Hz, 2H), 3.88 (s, 3H), 1.43 (s, 9H).
tert-Butyl (2,5-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate was obtained, 8.0 g, 89.5% yield, as a white solid, from tert-butyl (4-bromo-2,5-difluorobenzyl)carbamate and (BPin)2, following the procedure described in Example 83, Step 1. LCMS m/z=314.0 [M-CH4+H]+
K2CO3 (47.32 mg, 0.342 mmol) and Pd(dppf)Cl2 (12.53 mg, 17.12 μmol) were added to a solution of tert-butyl (2,5-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (82.17 mg, 0.223 mmol) and 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 40.0 mg, 0.172 mmol) in dioxane (8 mL) and water (1 mL) and the mixture was stirred at 90° C. under N2 for 2 h. The mixture was filtered and concentrated to dryness and the crude product was purified by column chromatography (PE/EtOAc=1:0 to 1/2) to give tert-butyl (2,5-difluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (40 mg, 53.1% yield) as a white solid. LCMS m/z=441.1 [M+H]+
A solution of tert-butyl (2,5-difluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (650 mg, 1.48 mmol) in HCl/EtOAc (4 M, 15 mL) and DCM (10 mL) was stirred at 20° C. for 1 h. The mixture was concentrated under vacuum to give (2,5-difluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (555 mg), as a white solid. It was used for the next step without purification. LCMS m/z=341.0 [M+H]+
To a solution of (2,5-difluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (80 mg, 235.1 μmol) in DCM (50 mL) was added DIPEA (151.9 mg, 1.18 mmol). 5-tert-Butyl-1,2,4-oxadiazole-3-carbonyl chloride (Example 82, step 3, 88.67 mg, 470.1 μmol) was added and the mixture was stirred at 20° C. for 1 h. The mixture was concentrated under vacuum and the crude was purified by Prep-HPLC (Method E, 40-70% gradient) to give 5-(tert-butyl)-N-(2,5-difluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (29 mg, 25.1% yield) as a white solid. LCMS m/z=493.0 [M+H]+ 1H NMR (400 MHz, DMSO-d6) δ: 9.55 (t, J=6.0 Hz, 1H), 9.20 (s, 1H), 8.27 (s, 1H), 8.14 (d, J=2.4 Hz, 1H), 8.05 (s, 1H), 7.67-7.62 (m, 1H), 7.43-7.38 (m, 1H), 6.79 (s, 1H), 4.57 (d, J=6.0 Hz, 2H), 3.86 (s, 3H), 1.41 (s, 9H)
To a solution of tert-butyl (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (Step 1, Example 14, 226.1 mg, 651.2 μmol) in dioxane (20 mL) and H2O (2 mL) was added 4-chloropyrazolo[1,5-a]pyrazine (100 mg, 651.2 μmol) and K2CO3 (180 mg, 1.30 mmol) at 20° C. Pd(dppf)Cl2 (47.65 mg, 65.1 μmol) was added and the reaction was stirred at 90° C. for 3 h under N2. The cooled mixture was filtered and concentrated under vacuum. The crude product was purified by column chromatography on silica gel (PE/EtOAc=4/1) to give tert-butyl (2-methyl-4-(pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (150 mg, 68.1% yield) as a yellow solid. LCMS m/z=339.0 [M+H]+
A solution of tert-butyl (2-methyl-4-(pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (150 mg, 443.3 μmol) in HCl/EtOAc (20 mL) was stirred at 20° C. for 1 h. The mixture was concentrated under vacuum to give (2-methyl-4-(pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (110 mg, crude) as a white solid, which was used in the next step without further purification. LCMS m/z=239.0 [M+H]+
To a solution of (2-methyl-4-(pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (100 mg, 364 μmol) in DCM (30 mL) was added DIPEA (94.1 mg, 727.9 μmol) and HATU (276.8 mg, 0.728 mmol). 5-(tert-Butyl)-1,2,4-oxadiazole-3-carboxylic acid (103 mg, 546 μmol) was added and the reaction was stirred at 20° C. for 1 h. The mixture was poured into water (50 mL) and extracted with DCM (50 mL×3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under vacuum to give the crude, which was purified by Prep-HPLC (Method D, 45-65% gradient) to give 5-(tert-butyl)-N-(2-methyl-4-(pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (55.7 mg, 39.2% yield) as a white solid. LCMS m/z=391.1 [M+H]+. 1H NMR: (400 MHz, DMSO-d6) δ=9.53-9.49 (m, 1H), 8.78 (d, J=4.4 Hz, 1H), 8.24 (d, J=2.4 Hz, 1H), 8.00 (d, J=4.4 Hz, 1H), 7.88-7.86 (m, 2H), 7.45-7.42 (m, 1H), 7.19 (d, J=1.6 Hz, 1H), 4.54 (d, J=6.0 Hz, 2H), 2.45 (s, 3H), 1.43 (s, 9H).
To a solution of tert-butyl (4-bromo-2-(difluoromethyl)benzyl)carbamate (4.20 g, 12.49 mmol) in dioxane (120 mL) was added (BPin)2 (3.33 g, 13.11 mmol), KOAc (3.68 g, 37.47 mmol) and Pd(dppf)Cl2 (9.14 g, 12.49 mmol) and the reaction was stirred at 85° C. for 16 h. The mixture was concentrated to dryness to give a residue which was purified by silica gel chromatography (PE:EtOAc, 100:0 to 85:5) to give tert-butyl (2-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (4.30 g, 62.9% yield) as clear semi-solid.
tert-Butyl (2-(difluoromethyl)-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate was obtained as a yellow solid, 800 mg, 74% yield, from tert-butyl (2-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate and 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5), following the procedure described in Example 83, step 2. LCMS m/z=455.1 [M+H]+
(2-(Difluoromethyl)-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride was obtained as a yellow solid, 700 mg, crude from tert-butyl (2-(difluoromethyl)-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate, following the procedure described in Example 85, step 2. LCMS m/z=355.0 [M+H]+
5-(tert-Butyl)-N-(2-(difluoromethyl)-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide was obtained as a yellow solid, 50.2 mg, 43% yield, from (2-(difluoromethyl)-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride and 5-(tert-butyl)-1,2,4-oxadiazole-3-carboxylic acid following a similar procedure to that described in Example 85, step 3. LCMS m/z=507.1 [M+H]+ 1H NMR (400 MHz, DMSO-d6) δ: 9.64-9.60 (m, 1H), 9.15 (s, 1H), 8.31-8.26 (m, 3H), 8.19 (s, 1H), 8.09 (s, 1H), 7.63 (d, J=8.0 Hz, 1H), 7.14-7.13 (m, 1H), 7.12 (s, 1H), 4.71 (d, J=6.0 Hz, 2H), 3.88 (s, 3H), 1.41 (s, 9H).
tert-Butyl (2,3-difluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate was obtained as a yellow solid, 100 mg, 27.9% yield, from tert-butyl (2,3-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate and 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5), following the procedure described in Example 83, step 2. LCMS m/z=441.1 [M+H]+.
To a solution of tert-butyl (2,3-difluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (100 mg, 227 μmol) in DCM (2 mL) was added HCl/EtOAc (15 mL, 4M) and the reaction was stirred at 25° C. for 1 h. The mixture was concentrated to give (2,3-difluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (80 mg, crude) as a yellow solid. LCMS m/z=341.0 [M+H]+
To a solution of (2,3-difluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (80 mg, 235.1 μmol) in DCM (30 mL) was added DIPEA (60.76 mg, 470.1 μmol), 2-(tert-butyl)-2H-tetrazole-5-carboxylic acid (80 mg, 470.14 mol) and HATU (179.24 mg, 470.1 μmol) and the reaction was stirred at 25° C. for 1 h. The mixture was diluted with water (30 mL) and extracted with DCM (15 mL×3). The combined organic layers were concentrated under vacuum and the residue was purified by Prep-HPLC (Method D, 42-62% gradient) to give 2-(tert-butyl)-N-(2,3-difluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-2H-tetrazole-5-carboxamide (37 mg, 32% yield) as a white solid. 1H NMR (500 MHz, DMSO-d6) δ: 9.71 (t, J=6.0 Hz, 1H), 9.24 (d, J=0.5 Hz, 1H), 8.28 (s, 1H), 8.18 (d, J=2.5 Hz, 1H), 8.08 (s, 1H), 7.62 (t, J=6.5 Hz, 1H), 7.40 (t, J=7.0 Hz, 1H), 6.87 (s, 1H), 4.67 (d, J=6.0 Hz, 2H), 3.88 (s, 3H), 1.74 (s, 9H).
To a solution of (2,3-difluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 87, step 2, 80 mg, 212.3 μmol) in DCM (30 mL) was added DIPEA (54.88 mg, 424.6 μmol) at 20° C. 5-(tert-Butyl)-1,2,4-oxadiazole-3-carboxylic acid (72.26 mg, 424.64 μmol) and HATU (97.13 mg, 254.78 μmol) were added and the reaction was stirred at 20° C. for 1 h. The mixture was poured into water (50 mL) and extracted with DCM (50 mL×3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under vacuum. The crude product was purified by Prep-HPLC (Method D, 53-73% gradient) to give 5-(tert-butyl)-N-(2,3-difluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (43.8 mg, 41.9% yield) as a yellow solid. LCMS m/z=493.1 [M+H]+ 1H NMR (400 MHz, DMSO-d6) δ: 9.66-9.62 (m, 1H), 9.24 (s, 1H), 8.29 (s, 1H), 8.18 (s, 1H), 8.08 (s, 1H), 7.65-7.61 (m, 1H), 7.41-7.31 (m, 1H), 6.87 (s, 1H), 4.64 (d, J=6.0 Hz, 2H), 3.89 (s, 3H), 1.43 (s, 9H).
The compounds in the following table were prepared from the appropriate carboxylic acid and amine listed below, following a similar procedure to that described in Example 88.
SM: 3-(tert-butyl)-1,2,4-oxadiazole-5-carboxylic acid and Amine 1 Prep-HPLC (Method D, 52-72% gradient) 39.6 mg, 28.2% yield as a yellow solid. LCMS m/z = 493.1 [M + H]+. 1H NMR (400 MHz, DMSO-d6) δ = 10.02 (t, J = 6.0 Hz, 1H), 9.25 (d, J = 0.8 Hz, 1H), 8.28 (s, 1H), 8.18 (d, J = 2.8 Hz, 1H), 8.08 (d, J = 0.8 Hz, 1H), 7.66-7.59 (m, 1H), 7.45 (t, J = 6.8 Hz, 1H), 6.87 (t, J = 2.4 Hz, 1H), 4.65 (d, J = 5.6 Hz, 2H), 3.89 (s, 3H), 1.37 (s, 9H)
SM: 2-(tert-butyl)oxazole-4-carboxylic acid and Amine 1 Prep-HPLC (Method D, 52-72% gradient) 55.6 mg, 52.4% yield as a yellow solid. LCMS m/z = 492.1 [M + H]+ 1H NMR: (400 MHz, DMSO-d6) δ = 9.23 (d, J = 1.2 Hz, 1H), 8.81 (t, J = 6.4 Hz, 1H), 8.56-8.53 (m, 1H), 8.27 (s, 1H), 8.17 (d, J = 2.4 Hz, 1H), 8.07 (d, J = 0.8 Hz, 1H), 7.63-7.57 (m, 1H), 7.34 (t, J = 6.8 Hz, 1H), 6.86 (t, J = 2.4 Hz, 1H), 4.59 (d, J = 6.4 Hz, 2H), 3.88 (s, 3H), 1.36 (s, 9H)
SM: 1-(tert-butyl)-1H-pyrazole-3-carboxylic acid and Amine 1 Prep-HPLC (Method D, 47-65% gradient) 68.0 mg, 48.6 % yield as a yellow solid. LCMS m/z = 491.0 [M + H]+1H NMR (400 MHz, DMSO-d6) δ = 9.24 (d, J = 0.8 Hz, 1H), 8.74 (t, J = 6.0 Hz, 1H), 8.29 (s, 1H), 8.18 (d, J = 2.8 Hz, 1H), 8.08 (s, 1H), 7.94 (d, J = 2.4 Hz, 1H), 7.65-7.59 (m, 1H), 7.36 (t, J = 6.4 Hz, 1H), 6.87 (t, J = 2.4 Hz, 1H), 6.67 (d, J = 2.4 Hz, 1H), 4.61 (d, J = 6.4 Hz, 2H), 3.89 (s, 3H), 1.59-1.55 (m, 9H)
SM: 2-(tert-butyl)-2H-1,2,3-triazole-4-carboxylic acid and Amine 1 Prep-HPLC (Method D, 48-68% gradient) 87.0 mg, 60.2% yield as a white solid. LCMS m/z = 492.1 [M + H]+1H NMR (400 MHz, DMSO-d6) δ: 9.24 (d, J = 0.8 Hz, 1H), 9.10 (t, J = 6.0 Hz, 1H), 8.28 (s, 1H), 8.21-8.16 (m, 2H), 8.08 (s, 1H), 7.62 (t, J = 6.8 Hz, 1H), 7.38 (t, J = 6.4 Hz, 1H), 6.88-6.85 (m, 1H), 4.63 (d, J = 6.0 Hz, 2H), 3.88 (s, 3H), 1.65 (s, 9H).
SM: 1-(tert-butyl)-1H-1,2,3-triazole-4-carboxylic acid and Amine 1 Prep-HPLC (Method E, 35-65% gradient) 40.0 mg, 34.6% yield as a yellow solid. LCMS m/z = 492.0 [M + H]+1H NMR (400 MHz, DMSO-d6) δ: 9.20 (s, 2H), 8.69 (s, 1H), 8.25 (s, 1H), 8.14 (d, J = 2.4 Hz, 1H), 8.04 (s, 1H), 7.57 (t, J = 6.8 Hz, 1H), 7.33 (t, J = 7.2 Hz, 1H), 6.83 (s, 1H), 4.61 (d, J = 5.6 Hz, 2H), 3.85 (s, 3H), 1.61 (s, 9H).
SM: 3-tert-butyl-1,2,4-oxadiazole-5-carboxylic acid and Amine 2 Prep-HPLC (Method E, 41-71% gradient) 68.7 mg, 59.3% yield as a white solid. LCMS m/z = 493.1 [M + H]+1H NMR: (400 MHz, DMSO-d6) δ: 9.89 (t, J = 5.6 Hz, 1H), 9.21 (d, J = 0.8 Hz, 1H), 8.27 (s, 1H), 8.14 (d, J = 2.4 Hz, 1H), 8.05 (s, 1H), 7.67-7.62 (m, 1H), 7.53-7.48 (m, 1H), 6.79 (t, J = 2.0 Hz, 1H), 4.57 (d, J = 5.6 Hz, 2H), 3.86 (s, 3H), 1.34 (s, 9H).
SM: 2-(tert-butyl)oxazole-4-carboxylic acid and Amine 2 Prep-HPLC (Method D, 51-71% gradient) 49.2 mg, 47.2% yield as a yellow solid. LCMS m/z = 492.1 [M + H]+1H NMR: (400 MHz, DMSO-d6) δ = 9.23 (s, 1H), 8.59-8.54 (d, J = 6.0 Hz, 1H), 8.55 (d, J = 6.8 Hz, 1H), 8.30 (d, J = 6.0 Hz, 1H), 8.18-8.14 (m, 1H), 8.08 (d, J = 6.4 Hz, 1H), 7.68-7.62 (m, 1H), 7.39-7.34 (m, 1H), 6.82 (s, 1H), 4.57-4.55 (m, 2H), 3.88 (d, J = 7.2 Hz, 3H), 1.36 (d, J = 6.8 Hz, 9H).
SM: 1-(tert-butyl)-1H-pyrazole-3-carboxylic acid and Amine 2 a yellow solid, 65 mg, 45.1%, LCMS m/z = 491.1 [M + H]+1H NMR (400 MHz, DMSO-d6) δ = 9.23 (d, J = 0.8 Hz, 1H), 8.71 (t, J = 6.0 Hz, 1H), 8.31 (s, 1H), 8.16 (d, J = 2.4 Hz, 1H), 8.09 (s, 1H), 7.94 (d, J = 2.4 Hz, 1H), 7.66 (dd, J = 5.6, 9.6 Hz, 1H), 7.36 (dd, J = 6.0, 10.4 Hz, 1H), 6.83 (t, J = 2.4 Hz, 1H), 6.68 (d, J = 2.4 Hz, 1H), 4.57 (d, J = 6.0 Hz, 2H), 3.89 (s, 3H), 1.57 (s, 9H).
SM: 2-(tert-butyl)-2H-1,2,3-triazole-4-carboxylic acid and Amine 2 Prep-HPLC (Method D, 46-66% gradient). 41.10 mg, 39.4% yield as a yellow solid. LCMS m/z = 492.1 [M + H]+ 1H NMR: (500 MHz, DMSO-d6) δ ppm 9.26-9.25 (m, 1H), 9.08 (t, J = 6.0 Hz, 1H), 8.32 (s, 1H), 8.22-8.17 (m, 2H), 8.13-8.10 (m, 1H), 7.70-7.66 (m, 1H), 7.44-7.40 (m, 1H), 6.85-6.82 (m, 1H), 4.60 (d, J = 7.0 Hz, 2H), 3.91 (s, 3H), 1.67 (s, 9H).
SM: 1-(tert-butyl)-1H-1,2,3-triazole-4-carboxylic acid and Amine 2 Prep-HPLC (Method D, 39-59% gradient) 62.9 mg, 48.4% yield as a yellow solid. LCMS m/z = 492.1 [M + H]+ 1HNMR (500 MHz, DMSO-d6) δ: 9.26-9.22 (m, 2H), 8.75 (s, 1H), 8.31 (s, 1H), 8.17 (d, J = 2.0 Hz, 1H), 8.10 (s, 1H), 7.69-7.66 (m, 1H), 7.40-7.36 (m, 1H), 6.85-6.84 (m, 1H), 4.60 (d, J = 6.5 Hz, 2H), 3.91 (s, 3H), 1.66 (s, 9H).
SM: 2-(tert-butyl)-2H-tetrazole-5-carboxylic acid and Amine 2 Prep-HPLC (Method D, 42-62% gradient) 61.20 mg, 52.0% yield as a white solid. LCMS m/z = 493.2 [M + H]+1H NMR: (500 MHz, DMSO-d6) δ ppm = 9.68 (t, J = 6.0 Hz, 1H), 9.24 (d, J = 1.0 Hz, 1H), 8.32 (s, 1H), 8.18 (d, J = 2.5 Hz, 1H), 8.10 (s, 1H), 7.71- 7.67 (m, 1H),7.48-7.44 (m, 1H), 6.84-6.83 (m, 1H), 4.64 (d, J = 6.0 Hz, 2H), 3.91 (s, 3H), 1.76 (s, 9H).
SM: 3-(tert-butyl)-1,2,4-oxadiazole-5-carboxylic acid and Amine 3 Prep-HPLC (Method D, 52-72% gradient) 50.1 mg, 38.9% yield as a yellow solid. LCMS m/z = 5-7.1 [M + H]+1H NMR (500 MHz, DMSO-d6) δ: 10.02 (t, J = 6.0 Hz, 1H), 9.20-9.19 (m, 1H), 8.34-8.31 (m, 3H), 8.23 (d, J = 2.5 Hz, 1H), 8.14-8.13 (m, 1H), 7.72 (d, J = 7.5 Hz, 1H), 7.60-7.37 (m, 1H), 7.18-7.16 (m, 1H), 4.76 (d, J = 6.0 Hz, 2H), 3.93 (s, 3H), 1.39 (s, 9H).
SM: 2-(tert-butyl)-oxazole-4-carboxylic acid and Amine 3 Prep-HPLC (Method D, 55-75% gradient) 40.0 mg, 36.1% yield as a pale white solid. LCMS m/z = 506.1 [M + H]+1H NMR (400 MHz, DMSO-d6) δ: 9.15 (s, 1H), 8.79 (t, J = 6.4 Hz, 1H), 8.54 (s, 1H), 8.30-8.25 (m, 3H), 8.18 (d, J = 2.4 Hz, 1H), 8.09 (s, 1H), 7.64-7.34 (m, 2H), 7.13-7.12 (m, 1H), 4.66 (d, J = 6.0 Hz, 2H), 3.88 (s, 3H), 1.34 (s, 9H).
SM: 5-(tert-butyl)-1,3,4-oxadiazole-2-carboxylic acid and Amine 3 as a yellow solid, 53 mg, 37.1%, Prep-HPLC (Method F, 44-66% gradient) LCMS m/z = 507.1 [M + H]+1H NMR: (400 MHz, DMSO-d6) δ: 9.95 (t, J = 6.0 Hz, 1H), 9.19 (d, J = 0.8 Hz, 1H), 8.33 (s, 2H), 8.30 (d, J = 8.0 Hz, 1H), 8.22 (d, J = 2.4 Hz, 1H), 8.12 (d, J = 0.8 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.63-7.33 (m, 1H), 7.16 (dd, J = 0.8, 2.4 Hz, 1H), 4.74 (d, J = 5.6 Hz, 2H), 3.91 (s, 3H), 1.41 (s, 9H).
SM: 1-(tert-butyl)-1H-pyrazole-3-carboxylic acid and Amine 3 Prep-HPLC (Method D, 49-69% gradient) 50.0 mg, 45.2% yield as a pale white solid. LCMS m/z = 505.2 [M + H]+ 1H NMR (400 MHz, DMSO-d6) δ: 9.15 (s, 1H), 8.70 (t, J = 6.0 Hz, 1H), 8.31-8.25 (m, 3H), 8.18 (d, J = 2.4 Hz, 1H), 8.09 (s, 1H), 7.91 (d, J = 2.4 Hz, 1H), 7.65-7.35 (m, 2H), 7.13 (d, J = 2.0 Hz, 1H), 6.65 (d, J = 2.0 Hz, 1H), 4.67 (d, J = 6.0 Hz, 2H), 3.88 (s, 3H), 1.54 (s, 9H).
SM: 2-(tert-butyl)-2H-1,2,3-triazole-4-carboxylic acid and Amine 3 Prep-HPLC (Method D, 51-71% gradient) 32.0 mg, 41.2% yield as a yellow solid. LCMS m/z = 506.3 [M + H]+1H NMR: (400 MHz, DMSO-d6) δ = 9.14 (s, 1H), 9.08 (t, J = 6.0 Hz, 1H), 8.28-8.26 (m, 3H), 8.19-8.15 (m, 2H), 8.08 (s, 1H), 7.64-7.61 (m, 1H), 7.48-7.30 (m, 1H), 7.13-7.10 (m, 1H), 4.70-4.68 (m, 2H), 3.88 (s, 3H), 1.62 (s, 9H)
SM: 1-(tert-butyl)-1H-1,2,3-triazole-4-carboxylic acid and Amine 3 Prep-HPLC (Method D, 44-64% gradient) 59.6 mg, 51.2% yield as a white solid. LCMS m/z = 506.1 [M + H]+1H NMR (400 MHz, DMSO-d6) δ: 9.24-9.20 (m, 1H), 9.14 (s, 1H), 8.70 (s, 1H), 8.30-8.24 (m, 3H), 8.18 (d, J = 2.4 Hz, 1H), 8.09 (s, 1H), 7.64-7.35 (m, 2H), 7.12 (d, J = 2.0 Hz, 1H), 4.70 (d, J = 6.0 Hz, 2H), 3.88 (s, 3H), 1.61 (s, 9H).
SM: 2-(tert-butyl)-2H-tetrazole-5-carboxylic acid and Amine 3 Prep-HPLC (Method D, 47-67% gradient) 33 mg, 50.9% yield as a yellow solid. LCMS m/z = 507.3 [M + H]+ 1H NMR (400 MHz, DMSO-d6) δ: 9.69 (t, J = 6.0 Hz, 1H), 9.15 (s, 1H), 8.31-8.25 (m, 3H), 8.18 (d, J = 2.4 Hz, 1H), 8.09 (s, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.62-7.34 (m, 1H), 7.13-7.08 (m, 1H), 4.74 (d, J = 6.0 Hz, 2H), 3.88 (s, 3H), 1.71 (s, 9H)
SM: 1-(tert-butyl)-1H-pyrazole-4-carboxylic acid and Amine 3 Prep-HPLC (Method G, 35-65% gradient) 47.9 mg, 42.1% yield as a white solid. LCMS m/z = 505.0 [M + H]+ 1H NMR: (500 MHz, DMSO-d6) δ: 9.19 (d, J = 0.5 Hz, 1H), 8.74 (t, J = 6.0 Hz, 1H), 8.38-8.30 (m, 4H), 8.23 (d, J = 2.5 Hz, 1H), 8.14 (s, 1H), 7.96 (s, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.61-7.36 (m, 1H), 7.18-7.16 (m, 1H), 4.70 (d, J = 6.0 Hz, 2H), 3.93 (s, 3H), 1.55 (s, 9H).
To a solution of (3-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 83, step 3, 80 mg, 223 μmol) in DCM (50 mL) was added DIPEA (86.45 mg, 669 μmol), 3-(tert-butyl)-1,2,4-oxadiazole-5-carboxylic acid (56.91 mg, 334.5 μmol) and HATU (85 mg, 223 μmol) and the mixture was stirred at 20° C. for 2 h. The mixture was concentrated under vacuum and the crude was purified by Prep-HPLC (Method D, 55-75% gradient) to give 3-(tert-butyl)-N-(3-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-5-carboxamide (41.8 mg, 39.5% yield) as a yellow solid. LCMS m/z=475.1 [M+H]+ 1H NMR (400 MHz, DMSO-d6) δ: 9.97 (t, J=4.0 Hz, 1H), 9.21 (s, 1H), 8.28 (s, 1H), 8.15 (s, 1H), 8.07 (s, 1H), 7.78 (t, J=8.0 Hz, 1H), 7.44-7.38 (m, 2H), 6.77 (s, 1H), 4.58 (d, J=4.0 Hz, 2H), 3.88 (s, 3H), 1.37 (s, 9H).
The compounds in the following table were prepared from (3-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 83, step 3) and appropriate heterocyclic carboxylic acid, following a similar procedure to that described in Example 108.
SM: 2-(tert-butyl)oxazole-4-carboxylic acid Prep-HPLC (Method D, 49-66% gradient) 44 mg, 41.7% yield, as a yellow solid. LCMS m/z = 474.1 [M + H]+ 1H NMR (400 MHz, DMSO-d6) δ: 9.19 (s, 1H), 8.82 (t, J = 4.0 Hz, 1H), 8.54 (s, 1H), 8.28 (s, 1H), 8.15 (s, 1H), 8.07 (s, 1H), 7.76 (t, J = 8.0 Hz, 1H), 7.35 (d, J = 8.0 Hz, 2H), 6.77 (s, 1H), 4.53 (d, J = 8.0 Hz, 2H), 3.88 (s, 3H), 1.36 (s, 9H).
SM: 4-(tert-butyl)oxazole-2-carboxylic acid 60 mg, 51.0% yield as a white solid. LCMS m/z = 474.1 [M + H]+1H NMR (500 MHz, DMSO-d6) δ: 9.48 (t, J = 5.0 Hz, 1H), 9.20 (s, 1H), 8.28 (s, 1H), 8.14 (s, 1H), 8.06 (d, J = 10.0 Hz, 1H), 7.77 (t, J = 5.0 Hz, 1H), 7.37 (t, J = 10.0 Hz, 2H), 6.78 (s, 1H), 4.54 (s, 2H), 3.88 (s, 3H), 1.26 (s, 9H).
SM: 1-(tert-butyl)-1H-pyrazole-3-carboxylic acid 39 mg, 33.3% yield as an orange solid. LCMS m/z = 473.0 [M + H]+1H NMR (400 MHz, DMSO-d6) δ: 9.20 (s, 1H), 8.74 (s, 1H), 8.29 (s, 1H), 8.15 (s, 1H), 8.08 (s, 1H), 7.94 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.36 (t, J = 4.0 Hz, 2H), 6.79 (s, 1H), 6.67 (s, 1H), 4.55 (d, J = 8.0 Hz, 2H), 3.89 (s, 3H), 1.57 (s, 9H).
SM: 1-(tert-butyl)-1H-1,2,3-triazole-4-carboxylic acid 51 mg, 42.8% yield as a white solid. Prep-HPLC (Method D, 42-62% gradient) LCMS m/z = 474.1 [M + H]+1H NMR (400 MHz, DMSO-d6) δ: 9.23 (t, J = 4.0 Hz, 1H), 9.19 (s, 1H), 8.71 (s, 1H), 8.27 (s, 1H), 8.14 (s, 1H), 8.06 (s, 1H), 7.76 (t, J = 8.0 Hz, 1H), 7.35 (t, J = 4.0 Hz, 2H), 6.77 (s, 1H), 4.57 (d, J = 8.0 Hz, 2H), 3.88 (s, 3H), 1.64 (s, 9H).
SM: 2-(tert-butyl)-2H-1,2,3-triazole-4-carboxylic acid Prep-HPLC (Method D, 47-67% gradient) 56 mg, 59.0% yield as a yellow solid. LCMS m/z = 474.1 [M + H]+ 1H NMR (400 MHz, DMSO-d6) δ: 9.20 (s, 1H), 9.08 (t, J = 4.0 Hz, 1H), 8.27 (s, 1H), 8.17-8.14 (m, 2H), 8.07 (s, 1H), 7.77 (t, J = 8.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 2H), 6.77 (s, 1H), 4.56 (d, J = 4.0 Hz, 2H), 3.88 (s, 3H), 1.65 (s, 9H).
SM: 2-(tert-butyl)-2H-tetrazole-5-carboxylic acid Prep-HPLC (Method D, 41-61% gradient) 60 mg, 69.3% yield as a yellow solid. LCMS m/z = 475.1 [M + H]+ 1HNMR (400 MHz, DMSO-d6) δ: 9.70 (t, J = 6.4 Hz, 1H), 9.20 (s, 1H), 8.28 (s, 1H), 8.15 (d, J = 2.4 Hz, 1H), 8.07 (s, 1H), 7.78 (t, J = 8.0 Hz, 1H), 7.40-7.37 (m, 2H), 6.77 (s, 1H), 4.60 (d, J = 6.0 Hz, 2H), 3.88 (s, 3H), 1.74 (s, 9H).
tert-Butyl ((5-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)pyridin-2-yl)methyl)carbamate was obtained, 85 mg, 77% yield as a light yellow solid, from tert-butyl ((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)methyl)carbamate and 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5), following the procedure described in Example 79, step 6. LCMS m/z=406.2 [M+H]+
tert-Butyl ((5-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)pyridin-2-yl)methyl)carbamate (85 mg, 209.6 μmol) was dissolved in MeOH (2.10 mL), HCl solution (1.25M in MeOH, 1.68 mL) was added and the reaction was stirred overnight at 50° C. The reaction was concentrated and vacuum dried to afford (5-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)pyridin-2-yl)methanamine hydrochloride (75 mg, crude) as a yellow solid. LCMS m/z=306.1 [M+H]+
A vial was charged with (5-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)pyridin-2-yl)methanamine hydrochloride (35 mg, 102.4 μmol), 2-(tert-butyl)-2H-tetrazole-5-carboxylic acid (20.91 mg, 122.9 μmol) and DCM (1.02 mL), followed by DIPEA (132.34 mg, 1.02 mmol) and the solution cooled to 0° C. HATU (46.85 mg, 122.9 μmol) was added in a single portion and the reaction was stirred overnight at rt. The reaction was concentrated and purified via column chromatography (gradient elution 0-100% [3:1 EtOAc:EtOH]:Heptane) to afford 2-(tert-butyl)-N-((5-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)pyridin-2-yl)methyl)-2H-tetrazole-5-carboxamide (40 mg, 84.5% yield) as a yellow solid. LCMS m/z=458.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.66 (t, J=6.10 Hz, 1H) 9.27 (d, J=2.44 Hz, 1H) 9.19 (s, 1H) 8.52 (dd, J=7.94, 2.44 Hz, 1H) 8.37 (s, 1H) 8.22 (d, J=2.44 Hz, 1H) 8.13 (s, 1H) 7.58 (d, J=7.94 Hz, 1H) 7.24 (dd, J=2.44, 1.22 Hz, 1H) 4.73 (d, J=6.10 Hz, 2H) 3.90 (s, 3H) 1.75 (s, 9H).
5-(tert-Butyl)-N-((5-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)pyridin-2-yl)methyl)-1,2,4-oxadiazole-3-carboxamide was obtained as a yellow solid, 45 mg, 74.3% yield, from (5-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)pyridin-2-yl)methanamine hydrochloride and 5-tert-butyl-1,2,4-oxadiazole-3-carboxylic acid, following the method described in Example 115, step 3. LCMS m/z=458.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.58 (t, J=6.10 Hz, 1H) 9.27 (d, J=1.83 Hz, 1H) 9.20 (s, 1H) 8.52 (dd, J=8.24, 2.14 Hz, 1H) 8.37 (s, 1H) 8.22 (d, J=2.44 Hz, 1H) 8.13 (s, 1H) 7.57 (d, J=7.94 Hz, 1H) 7.27-7.20 (m, 1H) 4.70 (d, J=6.10 Hz, 2H) 3.91 (s, 3H) 1.45 (s, 9H).
DABAL-Me3 (47.71 mg, 186.1 μmol) was added to a mixture of (2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 6, step 2, 40.0 mg, 124.1 μmol) and ethyl 5-tert-butyl-1,2,4-oxadiazole-3-carboxylate (36.90 mg, 186.14 μmol) in THF (1.24 mL) and the reaction was heated at 45° C. overnight. The mixture was diluted with MeOH (formed a thick gel) and filtered. The filtrate was concentrated and purified by column chromatography (gradient elution 0-75% [EtOAc:EtOH]:heptane) to afford 5-(tert-butyl)-N-(2-fluoro-4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-3-carboxamide (36.0 mg, 58.1% yield) as a light yellow solid. LCMS m/z=475.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.59 (t, J=6.10 Hz, 1H) 9.18 (d, J=1.22 Hz, 1H) 8.37 (s, 1H) 8.21 (d, J=2.44 Hz, 1H) 8.13 (s, 1H) 8.00 (dd, J=7.94, 1.83 Hz, 1H) 7.94 (dd, J=11.29, 1.53 Hz, 1H) 7.58 (t, J=7.94 Hz, 1H) 7.22 (d, J=1.83 Hz, 1H) 4.61 (d, J=6.10 Hz, 2H) 3.91 (s, 3H) 1.44 (s, 9H).
A mixture of tert-butyl (2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate (500 mg, 1.42 mmol), 4,6-dichloropyrazolo[1,5-a]pyrazine (267.65 mg, 1.42 mmol) and K3PO4 (2.0 M, 1.14 mL) were dissolved in dioxane (4.73 mL) and N2 was bubbled through the mixture for 5 min. Pd(t-Bu3P)2 (36.38 mg, 71.18 μmol) was added and the reaction mixture was stirred for 2 h at rt. The reaction was concentrated and was purified by column chromatography (gradient elution 0-100% EtOAc:heptane) to afford tert-butyl (4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)-2-fluorobenzyl)carbamate (460 mg, 86% yield) as a white oily solid. LCMS m/z=377.1 [M+H]+
tert-Butyl (2-fluoro-4-(6-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate was obtained as a yellow solid, 139 mg, 79.3% yield from tert-butyl (4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)-2-fluorobenzyl)carbamate and 1-methylpiperazine, following a similar procedure to that described in Example 23, step 2. The crude product was purified by column chromatography (gradient elution 0-100% [3:1 EtOAc:EtOH]:heptane w/1% TEA modifier). LCMS m/z=441.2 [M+H]+
(2-Fluoro-4-(6-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride was obtained as a yellow solid, 122 mg, crude, from tert-butyl (2-fluoro-4-(6-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate, following the procedure described in Example 23, step 3. LCMS m/z=341.1 [M+H]+
DABAL-Me3 (33.9 mg, 132.2 μmol) was added to a mixture of (2-fluoro-4-(6-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (30 mg, 88.1 μmol) and ethyl 3-(tert-butyl)-1,2,4-oxadiazole-5-carboxylate (132.2 μmol) in THF (0.88 mL) and the reaction was heated at 45° C. overnight. The mixture was diluted with NaHCO3 solution and DCM, and the layers separated. The aqueous layer was extracted with DCM, and the combined organic filtrates were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The material was purified by HPLC Method (C3, 5-55%) to afford 3-(tert-butyl)-N-(2-fluoro-4-(6-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,2,4-oxadiazole-5-carboxamide trifluoroacetate (8.30 mg, 15.5% yield,) as a yellow solid. LCMS m/z=493.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.97 (br t, J=6.1 Hz, 1H), 9.65 (s, 1H), 8.42 (s, 1H), 8.09 (d, J=2.4 Hz, 1H), 7.95 (br dd, J=7.9, 1.2 Hz, 1H), 7.87 (br dd, J=11.0, 1.8 Hz, 1H), 7.61 (br t, J=7.9 Hz, 1H), 7.14 (br d, J=2.4 Hz, 1H), 4.60 (br d, J=6.1 Hz, 2H), 4.31 (br d, J=12.8 Hz, 2H), 3.54 (br d, J=11.0 Hz, 2H), 3.24-3.06 (m, 2H), 2.86 (br s, 3H), 1.37 (s, 9H).
tert-Butyl (2-fluoro-4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate was obtained as an orange solid, 163 mg, 75.6% yield from tert-butyl (4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)-2-fluorobenzyl)carbamate (Example 118, step 1) and morpholine following the procedure described in Example 23, step 2. LCMS m/z=428.2 [M+H]+
(2-Fluoro-4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride was obtained as a red solid, 177 mg, from tert-butyl (2-fluoro-4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate following the procedure described in Example 23, step 3. LCMS m/z=328.1 [M+H]+
DIPEA (74.0 mg, 572.7 μmol) was added to a mixture of (2-fluoro-4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (30 mg, 67.5 μmol), potassium 5-tert-butyl-1,3,4-oxadiazole-2-carboxylate (16.94 mg, 80.9 μmol) and DCM (0.7 mL) and the solution cooled to 0° C. HATU (30.86 mg, 80.9 μmol) was added and the reaction was stirred overnight at rt. The reaction was diluted with water and passed through a phase separator. The aqueous layer was extracted with DCM, and the combined organic layers were concentrated. The crude product was purified by HPLC (Method A2, 5-60%) and lyophilised, to afford 5-(tert-butyl)-N-(2-fluoro-4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1,3,4-oxadiazole-2-carboxamide (0.3 mg, 0.8% yield) as a yellow solid. LCMS m/z=479.2 [M+H]+.
tert-Butyl (4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)-2-methylbenzyl)carbamate was obtained as a light yellow solid, 913 mg, 85% yield from tert-butyl (2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate and 4,6-dichloropyrazolo[1,5-a]pyrazine, following the procedure described in Example 118, step 1. LCMS m/z=373.1 [M+H]+
tert-Butyl (2-methyl-4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate was obtained as a yellow solid, from tert-butyl (4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)-2-methylbenzyl)carbamate and morpholine, following the procedure described in Example 119, step 1. LCMS m/z=424.3 [M+H]+
(2-Methyl-4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride was obtained as a yellow solid from tert-butyl (2-methyl-4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate following the procedure described in Example 119, step 2. LCMS m/z=324.2 [M+H]+
A vial was charged with (2-methyl-4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (40 mg, 100.9 μmol), 1-tert-butyltriazole-4-carboxylic acid (20.49 mg, 121.1 μmol), and DCM (1.01 mL), followed by DIPEA (110.75 mg, 856.9 μmol) and the solution was cooled to 0° C. HATU (46.17 mg, 121.1 μmol) was added and the reaction was stirred overnight at rt. The reaction was loaded directly onto a silica cartridge and purified by column chromatography (gradient elution 0-100% EtOAc:Heptane) to afford the product as a dark orange film. The material was re-purified by HPLC (Method C3, 10-95%) to give 1-(tert-butyl)-N-(2-methyl-4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1H-1,2,3-triazole-4-carboxamide trifluoroacetate (16 mg, 26.4% yield) as a yellow solid. LCMS m/z=475.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.04 (t, J=6.10 Hz, 1H) 8.71 (s, 1H) 8.13 (s, 1H) 8.01 (d, J=3.05 Hz, 1H) 7.89-7.83 (m, 2H) 7.41 (d, J=8.55 Hz, 1H) 7.03 (d, J=2.44 Hz, 1H) 4.52 (d, J=6.10 Hz, 2H) 3.81-3.74 (m, 4H) 3.38-3.35 (m, 4H) 2.45 (s, 3H) 1.64 (s, 9H)
tert-Butyl (2-methyl-4-(6-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate was obtained as an orange solid, 232 mg, 66.1% yield, from tert-butyl (4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)-2-methylbenzyl)carbamate (Example 120, step 1) and 1-methylpiperazine, following the procedure described in Example 119, step 1. The crude product was purified by column chromatography (gradient elution 0-100% [3:1 EtOAc:EtOH]:heptane w/1% TEA modifier). LCMS m/z=437.3 [M+H]+
(2-Methyl-4-(6-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine hydrochloride was obtained as a yellow solid, 226 mg, crude, from tert-butyl (2-methyl-4-(6-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate, following the procedure described in Example 119, step 2. LCMS/z=337.2 [M+H]+
DIPEA (163.1 mg, 1.26 mmol) was added to a solution of (2-methyl-4-(6-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine hydrochloride (50 mg, 148.6 μmol) and 1-tert-butyltriazole-4-carboxylic acid (30.17 mg, 178.3 μmol) in DCM (1.49 mL) and the solution was cooled to 0° C. HATU (68 mg, 178.3 μmol) was added in a single portion and the reaction was stirred overnight at rt. The reaction was diluted with water and passed through a phase separator. The aqueous layer was extracted with DCM, and the combined organic layers were concentrated in vacuo and the residue purified by HPLC (Method C3, 5-50%) afford 1-(tert-butyl)-N-(2-methyl-4-(6-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-1H-1,2,3-triazole-4-carboxamide trifluoroacetate (52 mg, 54.7% yield). LCMS m/z=488.3 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.06 (br t, J=6.1 Hz, 1H), 8.74-8.68 (m, 1H), 8.35 (s, 1H), 8.05 (br d, J=2.4 Hz, 1H), 7.91-7.81 (m, 2H), 7.42 (br d, J=7.9 Hz, 1H), 7.12-7.02 (m, 1H), 4.53 (br d, J=6.1 Hz, 2H), 4.30 (br d, J=13.4 Hz, 2H), 3.54 (br d, J=11.6 Hz, 2H), 3.20 (br d, J=11.6 Hz, 1H), 3.15-3.05 (m, 2H), 2.86 (br d, J=3.7 Hz, 3H), 2.46 (s, 3H), 1.68-1.26 (m, 9H).
Toluene (7.24 mL) was added to a mixture of tert-butyl (4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)-2-methylbenzyl)carbamate (Example 120, Step 1, 270 mg, 724.2 μmol), Pd2(dba)3 (66.31 mg, 72.4 μmol), Cs2CO3 (589.9 mg, 1.81 mmol) and tBuBrettPhos (70.20 mg, 144.8 μmol) and the solution was bubbled with N2 for 5 minutes. 2-Methoxyethanol (165.30 mg, 2.17 mmol) was added and the reaction was stirred overnight at 100° C. The cooled reaction was concentrated and the residue purified by silica gel column chromatography (gradient elution 0-100% EtOAc:Heptane) to afford tert-butyl (4-(6-(2-methoxyethoxy)pyrazolo[1,5-a]pyrazin-4-yl)-2-methylbenzyl)carbamate (155 mg, 51.9% yield) as a yellow solid. LCMS m/z=413.2 [M+H]+.
(4-(6-(2-Methoxyethoxy)pyrazolo[1,5-a]pyrazin-4-yl)-2-methylphenyl)methanamine dihydrochloride was obtained as a yellow solid, from tert-butyl (4-(6-(2-methoxyethoxy)pyrazolo[1,5-a]pyrazin-4-yl)-2-methylbenzyl)carbamate, following the method described in Example 23, step 3. LCMS m/z=313.1 [M+H]+
1-(tert-Butyl)-N-(4-(6-(2-methoxyethoxy)pyrazolo[1,5-a]pyrazin-4-yl)-2-methylbenzyl)-1H-1,2,3-triazole-4-carboxamide was obtained as an off-white solid, 19 mg, 31.2% yield, from (4-(6-(2-methoxyethoxy)pyrazolo[1,5-a]pyrazin-4-yl)-2-methylphenyl)methanamine dihydrochloride and 1-tert-butyltriazole-4-carboxylic acid following a similar procedure to that described in Example 120, step 4. LCMS m/z=464.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.06 (t, J=6.10 Hz, 1H) 8.72 (s, 1H) 8.42 (d, J=1.22 Hz, 1H) 8.10 (d, J=2.44 Hz, 1H) 7.92-7.84 (m, 2H) 7.43 (d, J=8.55 Hz, 1H), 7.15 (d, J=1.83 Hz, 1H) 4.53 (d, J=6.10 Hz, 2H) 4.45-4.37 (m, 2H) 3.74-3.67 (m, 2H) 3.32 (s, 3H) 2.46 (s, 3H) 1.64 (s, 9H).
DABAL-Me3 (47.56 mg, 185.5 μmol) was added to a mixture of (2-methyl-4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 120, step 3, 49.02 mg, 123.7 μmol) and ethyl 2-(tert-butyl)-2H-1,2,3-triazole-4-carboxylate (Example 37a, U.S. Ser. No. 10/377,719-B2, 36.6 mg, 185.5 μmol) in THF (1.24 mL) and the reaction was heated at 45° C. overnight. The reaction was carefully quenched with saturated NaHCO3 solution and diluted with DCM. The mixture was passed through a phase separator, and the aqueous layer was extracted with DCM. The combined organic layers were concentrated and purified by column chromatography (12 g column, gradient elution 0-100% EtOAc:Heptane) to afford a dark orange film. The material was re-purified via reverse phase HPLC (Method A2, 10-95%) and then lyophilised to give 2-(tert-butyl)-N-(2-methyl-4-(6-morpholinopyrazolo[1,5-a]pyrazin-4-yl)benzyl)-2H-1,2,3-triazole-4-carboxamide (1.30 mg, 2.2% yield) as a yellow solid. LCMS m/z=475.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 8.91 (t, J=5.80 Hz, 1H) 8.17 (s, 1H) 8.13 (s, 1H) 8.01 (d, J=2.44 Hz, 1H) 7.92-7.83 (m, 2H) 7.42 (d, J=7.94 Hz, 1H) 7.04 (dd, J=2.44, 1.22 Hz, 1H) 4.53 (d, J=6.10 Hz, 2H) 3.82-3.74 (m, 4H) 3.38-3.35 (m, 4H) 2.45 (s, 3H) 1.65 (s, 9H).
2-(tert-Butyl)-N-(2-methyl-4-(6-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-2H-1,2,3-triazole-4-carboxamide trifluoroacetate was obtained, 49 mg, 60.9% yield, from (2-methyl-4-(6-(4-methylpiperazin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine dihydrochloride (Example 121, step 2) and ethyl 2-(tert-butyl)-2H-1,2,3-triazole-4-carboxylate (Example 37a, U.S. Ser. No. 10/377,719-B2) following the procedure described in Example 118, Step 4. LCMS m/z=488.3 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 8.93 (br t, J=6.1 Hz, 1H), 8.35 (s, 1H), 8.17 (s, 1H), 8.06 (br d, J=2.4 Hz, 1H), 7.91-7.82 (m, 2H), 7.43 (br d, J=7.9 Hz, 1H), 7.08 (d, J=2.4 Hz, 1H), 4.53 (br d, J=6.1 Hz, 2H), 4.30 (br d, J=13.4 Hz, 2H), 3.54 (br d, J=11.6 Hz, 2H), 3.36 (br d, J=3.7 Hz, 2H), 3.25-3.05 (m, 3H), 2.87 (br d, J=3.7 Hz, 2H), 2.46 (s, 3H), 1.68-1.35 (m, 9H)
The compounds in the following table were prepared from the appropriate carboxylic acid and amine (as listed below), following a similar procedure to that described in Example 119, step 3.
2-(tert-butyl)oxazole-4-carboxylic acid and Amine 4. 2 mg, 5.6% yield LCMS m/z = 479.2 [M + H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.73 (br t, J = 6.1 Hz, 1 H), 8.55 (s, 1 H), 8.19 (s, 1 H), 8.04 (d, J = 2.4 Hz, 1 H), 8.02- 7.95 (m, 1 H), 7.95-7.77 (m, 4 H), 7.56-7.45 (m, 3 H), 7.09 (br d, J = 1.8 Hz, 1 H), 4.56 (br d, J = 6.1 Hz, 2 H), 3.82-3.72 (m, 4 H), 1.37 (s, 9 H).
potassium 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate and Amine 5. yellow film, 10 mg, 19.9% yield. LCMS m/z = 474.2 [M + H]+1H NMR (500 MHz, DMSO-d6) δ ppm 9.44 (t, J = 6.10 Hz, 1 H) 8.14 (s, 1 H) 8.02 (d, J = 2.44 Hz, 1 H) 7.90-7.85 (m, 2 H) 7.41 (d, J = 7.33 Hz, 1 H) 7.04 (d, J = 2.44 Hz, 1 H) 4.52 (d, J = 6.10 Hz, 2 H) 3.81-3.75 (m, 4H) 3.39-3.35 (m, 4 H) 2.44 (s, 3 H) 1.54 (s, 3 H) 1.41-1.36 (m, 2 H) 1.20-1.15 (m, 2 H).
5-tert-butyl-1,3,4-oxadiazole-2-carboxylic acid and Amine 6 yellow solid, 6.3 mg, 14.5% yield, LCMS m/z = 493.2 [M + H]+1H NMR (500 MHz, DMSO-d6) δ ppm 9.95-9.87 (m, 1 H), 8.39 (s, 1 H), 8.08 (br d, J = 2.4 Hz, 1 H), 7.94 (br dd, J = 7.9, 1.2 Hz, 1 H), 7.86 (br d, J = 11.0 Hz, 1 H), 7.65-7.56 (m, 1 H), 7.12 (s, 1 H), 4.60 (br d, J = 6.1 Hz, 2 H), 3.70- 3.40 (m, 5 H), 2.84 (s, 4 H), 1.40 (s, 9 H)
1-tert-butyltriazole-4-carboxylic acid and Amine 6 20 mg, 36.4% yield. LCMS m/z = 492.3 [M + H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.64 (s, 1 H), 9.16 (br t, J = 6.4 Hz, 1 H), 8.72 (s, 1 H), 8.41 (s, 1 H), 8.08 (d, J = 2.4 Hz, 1 H), 7.93 (br dd, J = 7.9, 1.8 Hz, 1 H), 7.86 (br dd, J = 11.0, 1.8 Hz, 1 H), 7.54 (br t, J = 7.9 Hz, 1 H), 7.14 (br d, J = 3.7 Hz, 1 H), 4.60 (br d, J = 6.1 Hz, 2 H), 4.31 (br d, J = 13.4 Hz, 2 H), 3.54 (br d, J = 11.6 Hz, 3 H), 3.35 (br s, 1 H), 3.25-3.09 (m, 3 H), 2.87 (br d, J = 4.3 Hz, 3 H), 1.64 (s, 9 H)
Amine 6 and 2-tert-butyloxazole-4-carboxylic acid yellow solid. LCMS m/z = 492.2 [M + H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.64 (s, 1 H), 8.75 (br t, J = 6.1 Hz, 1 H), 8.55 (s, 1 H), 8.41 (s, 1 H), 8.09 (d, J = 2.4 Hz, 1 H), 7.94 (br dd, J = 7.9, 1.2 Hz, 1 H), 7.85 (br dd, J = 11.0, 1.2 Hz, 1 H), 7.53 (br t, J = 7.9 Hz, 1 H), 7.12-7.17 (m, 1 H), 4.56 (br d, J = 6.1 Hz, 2 H), 4.31 (br d, J = 12.8 Hz, 2 H), 3.54 (br d, J = 11.0 Hz, 4 H), 3.36 (br s, 2 H), 3.26-3.05 (m, 4 H), 2.87 (br d, J = 3.7 Hz, 3 H), 1.44-1.15 (m, 9 H).
Amine 7 and 2-(tert-butyl)-2H-tetrazole-5-carboxylic acid 43 mg, 45.6% yield, LCMS m/z = 489.3 [M + H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.58 (br t, J = 6.1 Hz, 1 H), 8.35 (s, 1 H), 8.06 (br d, J = 3.1 Hz, 1 H), 7.92-7.73 (m, 2 H), 7.44 (br d, J = 8.5 Hz, 1 H), 7.08 (br d, J = 3.7 Hz, 1 H), 4.56 (br d, J = 6.1 Hz, 2 H), 4.30 (br d, J = 12.8 Hz, 2 H), 3.54 (br d, J = 11.6 Hz, 2 H), 3.35 (s, 3 H), 3.17-3.05 (m, 2 H), 2.86 (br d, J = 3.7 Hz, 2 H), 2.47 (s, 3 H), 1.74 (s, 9 H)
Amine 7 and potassium 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3- carboxylate 41 mg, 43.6% yield. LCMS m/z = 487.2 [M + H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.45 (br t, J = 6.1 Hz, 1 H), 8.36 (s, 1 H), 8.06 (d, J = 2.4 Hz, 1 H), 7.94-7.78 (m, 2 H), 7.42 (br d, J = 7.9 Hz, 1H), 7.08 (s, 1 H), 4.52 (br d, J = 6.1 Hz, 2 H), 4.30 (br d, J = 13.4 Hz, 2 H), 3.54 (br d, J = 11.6 Hz, 2 H), 3.39- 3.28 (m, 1 H), 3.26-3.04 (m, 2 H), 2.87 (br d, J = 3.7 Hz, 1 H), 2.45 (s, 1 H), 1.55 (s, 3 H), 1.41-1.30 (m, 2 H), 1.22-1.08 (m, 2 H)
Amine 8 and 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylic acid a yellow film, 8 mg, 13.1% yield, LCMS m/z = 463.2 [M + H]+1H NMR (500 MHz, DMSO-d6) δ ppm 9.45 (t, J = 5.80 Hz, 1 H) 8.43 (s, 1 H) 8.11 (d, J = 2.44 Hz, 1 H) 7.92-7.87 (m, 2 H) 7.43 (d, J = 8.55 Hz, 1 H) 7.15 (d, J = 2.44 Hz, 1 H) 4.52 (d, J-6.10 Hz, 2 H) 4.44-4.38 (m, 2H) 3.76-3.68 (m, 2 H) 3.33 (s, 3 H) 2.45 (s, 3 H) 1.55 (s, 3 H) 1.42-1.37 (m, 2 H) 1.19-1.15 (m, 2 H)
Amine 8 and 3-(1-methylcyclopropyl)-1,2,4-oxadiazole-5-carboxylic acid, yellow film, 1 mg, 1.7% yield, LCMS m/z = 463.2 [M + H]+1H NMR (500 MHz, DMSO-d6) δ ppm 9.86-9.78 (m, 1 H) 8.43 (s, 1 H) 8.11 (d, J = 2.44 Hz, 1 H) 7.89 (br s, 2H) 7.48-7.43 (m, 1 H) 7.15 (d, J = 2.44 Hz, 1 H) 4.53 (d, J = 6.10 Hz, 2 H) 4.44-4.38 (m, 2 H) 3.75-3.68 (m, 1 H) 3.44- 3.34 (m, 3 H) 2.45 (s, 3 H) 1.49 (s, 3 H) 1.22-1.17 (m, 2 H) 1.01-0.98 (m, 2 H)
A mixture of tert-butyl (4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (Example 23, Step 1, 200 mg, 557.4 μmol), RuPhos Pd G3 (69.93 mg, 83.6 μmol), azetidine hydrochloride (208.59 mg, 2.23 mmol), and NaOtBu (267.82 mg, 2.79 mmol) in toluene (4 mL) was stirred at 95° C. for 8 h under N2. The cooled mixture was concentrated in vacuum and the crude was purified by column chromatography on silica gel eluted with (PE/EtOAc=I/O to 2/1) to give tert-butyl (4-(6-(azetidin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (160 mg, 75.7% yield) as a yellow solid. LCMS m/z=380.1 [M+H]+
To a solution of tert-butyl (4-(6-(azetidin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (140 mg, 368.96 μmol) in DCM (12 mL) was added TFA (4 mL) dropwise and the mixture was stirred at 30° C. for 1 h. The mixture was concentrated in vacuum to give (4-(6-(azetidin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine trifluoroacetate (100 mg, crude) as a yellow solid, which was used in next step without further purification. LCMS m/z=280.0 [M+H]+
To a solution of (4-(6-(azetidin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)methanamine trifluoroacetate (80.0 mg, 286.4 μmol) in DCM (50 mL) was added DIPEA (111.04 mg, 859.2 μmol), then 5-tert-butyl-1,2,4-oxadiazole-3-carbonyl chloride (Example 82, step 3, 108.03 mg, 572.8 μmol) and the mixture was stirred at 20° C. for 1 h. The mixture was concentrated in vacuum and the crude was purified by Prep-HPLC (Method E, 42-72% gradient) to give N-(4-(6-(azetidin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-5-(tert-butyl)-1,2,4-oxadiazole-3-carboxamide (27.10 mg, 21.9% yield) as a yellow solid. LCMS m/z=432.1 [M+H]+ 1H NMR (400 MHz, DMSO-d6) δ: 9.57-9.56 (m, 1H), 8.01-7.98 (m, 2H), 7.95 (d, J=2.8 Hz, 1H), 7.85 (s, 1H), 7.50 (d, J=8.8 Hz, 2H), 6.99-6.98 (m, 1H), 4.53 (d, J=6.0 Hz, 2H), 3.92 (t, J=7.2 Hz, 4H), 2.36-2.33 (m, 2H), 1.42 (s, 9H).
Tert-butyl (4-(6-(dimethylamino)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate was obtained (60 mg, 25.0%) from methanamine and tert-butyl (4-(6-chloropyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (Example 23, Step 1) following a similar procedure to that described in
HCl/EtOAc (10.0 mL) was added to tert-butyl (4-(6-(dimethylamino)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)carbamate (60.0 mg, 163.3 μmol) and the reaction mixture was stirred at 30° C. for 2 h. The mixture was concentrated in vacuum to give 4-(4-(aminomethyl)phenyl)-N,N-dimethylpyrazolo[1,5-a]pyrazin-6-amine dihydrochloride (40 mg, crude) as a gray solid which was used for the next step without further purification. LCMS m/z=268.0 [M+H]+
5-Tert-butyl-1,2,4-oxadiazole-3-carbonyl chloride (Example 82, step 3, 37.25 mg, 197.5 μmol) was added to a solution of 4-(4-(aminomethyl)phenyl)-N,N-dimethylpyrazolo[1,5-a]pyrazin-6-amine dihydrochloride (40 mg, 131.7 μmol) and DIPEA (68.07 mg, 526.7 μmol) in DCM (45 mL) and the reaction was stirred at 30° C. for 3 h. The mixture was concentrated in vacuum and the residue was poured into water (120 mL). The aqueous was extracted with DCM (70 mL×3), the combined organic layers were dried over Na2SO4 and concentrated in vacuum. The crude product was purified by Prep-HPLC (Method D, 55-75% gradient) to give N-(4-(6-(azetidin-1-yl)pyrazolo[1,5-a]pyrazin-4-yl)benzyl)-5-(tert-butyl)-1,2,4-oxadiazole-3-carboxamide (30.0 mg, 47.8% yield) as a pale white solid. LCMS m/z=420.1 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ: 9.57-9.56 (m, 1H), 8.01-7.98 (m, 2H), 7.95 (d, J=2.8 Hz, 1H), 7.85 (s, 1H), 7.50 (d, J=8.8 Hz, 2H), 6.99-6.98 (m, 1H), 4.53 (d, J=6.0 Hz, 2H), 3.92 (t, J=7.2 Hz, 4H), 2.36-2.33 (m, 2H), 1.42 (s, 9H).
A mixture of tert-butyl N-(4-piperidylmethyl)carbamate 0.06 mg, 513.6 μmol), 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (60.0 mg, 256.8 μmol), and Cs2CO3 (167.33 mg, 513.56 μmol) were dissolved in DMSO (0.856 mL) and the reaction was stirred overnight at rt. The reaction was concentrated and purified by column chromatography (12 g column, gradient elution 0-75% [3:1 EtOAc:EtOH]:Heptane) to afford tert-butyl ((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)carbamate (100 mg, 94.6% yield) as a light brown solid. LCMS m/z=412.3 [M+H]+
tert-Butyl ((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)carbamate (82 mg, 199.3 μmol) was dissolved in MeOH (1.99 mL) and HCl solution (1.25 M in MeOH, 1.59 mL) was added and the reaction was stirred overnight at 50° C. The reaction was concentrated and vacuum dried to afford (1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride (93 mg, crude) as a red solid. LCMS m/z=312.2 [M+H]+
5-(tert-Butyl)-N-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide was obtained as a white solid, 20 mg, 44.8% yield, from potassium 5-(tert-butyl)-1,2,4-oxadiazole-3-carboxylate and (1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride following the procedure described in Example 115, step 3. LCMS m/z=464.3 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.00 (t, J=5.80 Hz, 1H) 8.45 (s, 1H) 8.14 (s, 1H) 7.98-7.88 (m, 2H) 6.92 (d, J=2.44 Hz, 1H) 4.54 (br d, J=13.43 Hz, 2H) 3.87 (s, 3H) 3.21 (t, J=6.41 Hz, 2H) 3.07 (br t, J=11.90 Hz, 2H) 1.99-1.90 (m, 1H) 1.80 (br d, J=10.99 Hz, 2H) 1.42 (s, 9H) 1.36-1.24 (m, 2H).
To a solution of ethyl (E)-2-amino-2-(hydroxyimino)acetate (2.5 g, 18.92 mmol) in DCM/DMF (v/v 20/1, 210 mL) was added 1-methylcyclopropanecarboxylic acid (2.08 g, 20.81 mmol), HATU (7.94 g, 20.81 mmol) and DIPEA (7.34 g, 56.76 mmol) and the reaction was stirred at 25° C. for 1 h. The mixture was poured into water (300 mL), extracted with DCM (100 mL×5) and the combined organic layers were evaporated under reduced pressure to afford ethyl (E)-2-(hydroxyimino)-2-(1-methylcyclopropane-1-carboxamido)acetate as a yellow oil, that was used directly in the next step.
A solution of ethyl (E)-2-(hydroxyimino)-2-(1-methylcyclopropane-1-carboxamido)acetate (5.30 g, 17.15 mmol) in pyridine (100 mL) was stirred at 100° C. for 17 h. The reaction solution was concentrated in vacuo, the residue was poured into HCl solution (1.0 M, 200 mL) and extracted with DCM (100 mL×3). The combined organic layers were concentrated to give the crude, which was purified by column chromatography (PE/EtOAc=30/1 to 10/1) to give ethyl 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate (1.40 g, 39.7% yield) as colorless oil.
To a solution of ethyl 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate (1.00 g, 4.86 mmol) in MeOH/H2O (v/v=10/1, 44 mL) was added NaOH (213.84 mg, 5.35 mmol) and the mixture was stirred at 25° C. for 2 h. The mixture was acidified to pH=6-7 with 2M HCl and then concentrated in vacuo. The crude product was freeze-dried to give 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylic acid (740 mg, crude) as white solid, which was used for the next step directly.
To a solution of 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylic acid (100 mg, 594.7 μmol) in DCM (30 mL) was added DMF (1.0 mL). SOCl2 (353.8 mg, 2.97 mmol) was added dropwise and the mixture was stirred at 25° C. for 1 h. The mixture was concentrated to give 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carbonyl chloride (120 mg, crude), which was used for the next step directly.
To a mixture of (1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride (Example 136, step 2, 80 mg, 230 μmol) in DCM (50 mL) was added DIPEA (89.17 mg, 690 μmol), then 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carbonyl chloride (85.83 mg, 460 μmol) and the reaction was stirred at 20° C. for 1 h. The reaction was concentrated in vacuum and the crude product was purified by prep-HPLC (Method E, 35-65% gradient) to give N-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide (48.0 mg, 45.2% yield) as a white solid. LCMS m/z=462.2 [M+H]+ 1HNMR: (400 MHz, DMSO-d6) δ: 8.91 (t, J=6.0 Hz, 1H), 8.41 (d, J=0.8 Hz, 1H), 8.10 (s, 1H), 7.94-7.87 (m, 2H), 6.91-6.84 (m, 1H), 4.50 (d, J=13.2 Hz, 2H), 3.83 (s, 3H), 3.16 (t, J=6.4 Hz, 2H), 3.03 (t, J=12.0 Hz, 2H), 1.96-1.82 (m, 1H), 1.76 (d, J=10.8 Hz, 2H), 1.50 (s, 3H), 1.36-1.31 (m, 2H), 1.30-1.19 (m, 2H), 1.15-1.10 (m, 2H).
To a mixture of (1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride (Example 136, step 2, 80.0 mg, 230 μmol) in DCM (50 mL) was added DIPEA (89.17 mg, 690 μmol), 1-tert-butyltriazole-4-carboxylic acid (77.82 mg, 460 μmol) and HATU (96.45 mg, 253 μmol) and the reaction was stirred at 20° C. for 1 h. The reaction was concentrated in vacuum and the crude was purified by prep-HPLC to give 1-(tert-butyl)-N-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1H-1,2,3-triazole-4-carboxamide (47.3 mg, 44.5% yield) as a white solid. LCMS m/z=463.1 [M+H]+ 1H NMR: (400 MHz, DMSO-d6) δ: 8.61 (s, 1H), 8.51 (t, J=6.0 Hz, 1H), 8.41 (s, 1H), 8.10 (s, 1H), 7.93-7.88 (m, 2H), 6.87 (d, J=1.6 Hz, 1H), 4.50 (d, J=13.2 Hz, 2H), 3.83 (s, 3H), 3.17 (t, J=6.4 Hz, 2H), 3.03 (t, J=11.6 Hz, 2H), 1.93-1.90 (m, 1H), 1.77 (d, J=12.4 Hz, 2H), 1.59 (s, 9H), 1.34-1.18 (m, 2H).
To a solution of tert-butyl 4-(hydroxymethyl)-2-methylpiperidine-1-carboxylate (3.50 g, 15.26 mmol) and TEA (7.72 g, 76.3 mmol) in DCM (150 mL) was slowly added TsCl (5.82 g, 30.52 mmol) followed by DMAP (372.86 mg, 3.05 mmol) and the reaction mixture was stirred at 20° C. for 12 h. The reaction mixture was concentrated in vacuo and the crude was purified by column chromatography (PE/EtOAc=4/1) to give tert-butyl 2-methyl-4-((tosyloxy)methyl)piperidine-1-carboxylate (5.0 g, crude) as clear oil. LCMS m/z=384.0 [M+H]+
To a solution of tert-butyl 2-methyl-4-((tosyloxy)methyl)piperidine-1-carboxylate (5.0 g, 13.04 mmol) and isoindoline-1,3-dione (3.84 g, 26.08 mmol) in DMF (100 mL) was added K2CO3 (3.60 g, 26.08 mmol) and the reaction mixture was stirred at 90° C. for 12 h. The mixture was concentrated under vacuum to remove THF and the crude was poured into saturated K2CO3 (100 mL) and extracted with EtOAc (100 mL×2). The combined organic layers were washed with water (100 mL), dried over Na2SO4, filtered and concentrated under vacuum. The crude was purified by column chromatography on silica gel (PE/EtOAc=4/1) to give tert-butyl 4-((1,3-dioxoisoindolin-2-yl)methyl)-2-methylpiperidine-1-carboxylate (5.0 g, crude) as a white solid. LCMS m/z=359.1 [M+H]+.
To a solution of tert-butyl 4-((1,3-dioxoisoindolin-2-yl)methyl)-2-methylpiperidine-1-carboxylate (1.00 g, 2.79 mmol) in DCM (20 mL) was added TFA (7.45 g, 65.34 mmol) and the mixture was stirred at 20° C. for 2 h. The mixture was concentrated under vacuum to give 2-((2-methylpiperidin-4-yl)methyl)isoindoline-1,3-dione trifluoroacetate (700 mg, crude) as clear oil, which was used without further purification. LCMS m/z=259.0 [M+H]+
To a solution of 2-((2-methylpiperidin-4-yl)methyl)isoindoline-1,3-dione trifluoroacetate (250.0 mg, 967.8 μmol) in NMP (2 mL) was added DIPEA (375.25 mg, 2.90 mmol), then 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 226.14 mg, 967.8 μmol) and the reaction was stirred under microwave irradiation at 180° C. for 2 h. The mixture was poured into H2O (100 mL) and extracted with EtOAc (100 mL×2). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under vacuum. The crude product was purified by column chromatography on silica gel (PE/EtOAc=1/9) to give 2-((2-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)isoindoline-1,3-dione (260 mg, 53.1% yield) as brown oil.
To a solution of 2-((2-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)isoindoline-1,3-dione (260 mg, 570.8 μmol) in EtOH (20 mL) was added NH2NH2·H2O (1.00 g, 19.98 mmol) and the reaction was stirred at 50° C. for 5 h. The mixture was concentrated under vacuum to give (2-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine (180 mg, crude) as a brown solid.
To a solution of this compound (180 mg, 553.15 μmol) and TEA (167.92 mg, 1.66 mmol) in DCM (30 mL) was added tert-butoxycarbonyl tert-butyl carbonate (241.45 mg, 1.11 mmol) and the reaction mixture was stirred at 20° C. for 3 h. The reaction mixture was concentrated under vacuum and the crude was purified by column chromatography (PE/EtOAc=1/4) to give tert-butyl ((2-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)carbamate (130 mg, 55.2% yield) as a brown solid.
A solution of this solid (130 mg, 305.5 μmol) in HCl/EtOAc (4 M, 10.0 mL) was stirred at 20° C. for 1 h. The mixture was concentrated under vacuum to give 2-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride (120 mg, crude) as a brown solid. LCMS m/z=326.1 [M+H]+
N-((2-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide was obtained as a yellow solid, 46 mg, 65% yield, from (2-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride and 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylic acid (Example 137, step 3) following the procedure described in Example 108.
LCMS m/z=476.1 [M+H]+1H NMR: (400 MHz, DMSO-d6) δ: 8.95-8.89 (m, 1H), 8.45-8.42 (m, 1H), 8.12 (s, 1H), 7.94 (s, 2H), 6.90-6.84 (m, 1H), 4.99-4.20 (m, 2H), 3.86 (s, 3H), 3.57-3.14 (m, 3H), 2.14-1.66 (m, 3H), 1.52 (d, J=4.0 Hz, 3H), 1.41-1.32 (m, 5H), 1.26-1.13 (m, 4H).
To a solution of (2-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride (Example 139, step 5, 150 mg, 414.5 μmol) in DCM (100 mL) was added DIPEA (160.71 mg, 1.24 mmol), 1-(tert-butyl)-1H-1,2,3-triazole-4-carboxylic acid (105.18 mg, 621.8 μmol) and HATU (158.04 mg, 414.51 μmol) and the reaction was stirred at 20° C. for 2 h. The mixture was concentrated under vacuum to give a brown crude, which was purified by Prep-HPLC (Method D, 38-58% gradient) to give 1-(tert-butyl)-N-((2-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1H-1,2,3-triazole-4-carboxamide (150 mg, crude) as a yellow solid. LCMS m/z=477.2 [M+H]+
This solid was further purified by SFC (Column: DAICEL CHIRALPAK AD (250 mm×30 mm, 10 μm), 0.1% NH3·H2O EtOH, Flow Rate (mL/min): 80, Column temp.: 35° C. to give:
1-(tert-butyl)-N-(((2S,4R)-2-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1H-1,2,3-triazole-4-carboxamide (stereochemistry arbitrarily assigned) (26 mg, 17.3% yield) as a white solid, LCMS m/z=477.1 [M+H]+. 1HNMR (400 MHz, DMSO-d6) δ=8.64 (s, 1H), 8.54 (t, J=6.0 Hz, 1H), 8.41 (s, 1H), 8.12 (s, 1H), 7.92 (d, J=4.0 Hz, 2H), 6.87 (s, 1H), 4.98 (t, J=6.0 Hz, 1H), 4.44 (d, J=14.0 Hz, 1H), 3.86 (s, 3H), 3.21-3.16 (m, 3H), 2.15 (s, 1H), 1.84-1.67 (m, 2H), 1.63 (s, 9H), 1.49-1.41 (in, 1H), 1.27-1.24 (in, 4H).
1-(tert-butyl)-N-(((2R,4R)-2-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1H-1,2,3-triazole-4-carboxamide (stereochemistry arbitrarily assigned) (18.50 mg, 12.3% yield) as a white solid, LCMS m/z=477.1 [M+H]+ 1HNMR (400 MHz, DMSO-d6) δ: 8.62 (s, 1H), 8.52 (t, J=6.0 Hz, 1H), 8.44 (s, 1H), 8.11 (s, 1H), 7.93-7.92 (m, 2H), 6.83 (s, 1H), 4.24-4.20 (m, 1H), 3.93-3.89 (m, 4H), 3.56-3.49 (m, 1H), 3.29-3.18 (m, 2H), 1.98-1.77 (m, 3H), 1.61 (s, 9H), 1.41-1.31 (m, 5H)
1-(tert-butyl)-N-(((2S,4S)-2-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1H-1,2,3-triazole-4-carboxamide (stereochemistry arbitrarily assigned) (21 mg, 14% yield) as a white solid, LCMS m/z=477.1 [M+H]+ 1HNMR (400 MHz, DMSO-d6) δ: 8.62 (s, 1H), 8.53 (t, J=6.0 Hz, 1H), 8.45 (s, 1H), 8.11 (s, 1H), 7.94-7.92 (m, 2H), 6.83 (s, 1H), 4.25-4.20 (m, 1H), 3.93-3.89 (m, 1H), 3.86 (s, 3H), 3.56-3.49 (m, 1H), 3.27-3.18 (m, 2H), 1.98-1.89 (m, 2H), 1.83-1.77 (m, 1H), 1.61 (s, 9H), 1.41-1.35 (m, 2H), 1.34-1.31 (m, 3H).
And 1-(tert-butyl)-N-((2-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1H-1,2,3-triazole-4-carboxamide(stereochemistry arbitrarily assigned), (17.0 mg, 11.3% yield) as a white solid. LCMS m/z=477.1 [M+H]+ 1HNMR (400 MHz, DMSO-d6) δ: 8.65 (s, 1H), 8.54 (t, J=6.0 Hz, 1H), 8.41 (s, 1H), 8.12 (s, 1H), 7.94-7.92 (m, 2H), 6.88 (s, 1H), 4.98 (t, J=6.0 Hz, 1H), 4.45 (d, J=14.0 Hz, 1H), 3.86 (s, 3H), 3.21-3.16 (m, 3H), 2.15 (s, 1H), 1.84-1.67 (m, 2H), 1.63 (s, 9H), 1.47-1.41 (m, 1H), 1.27-1.24 (m, 4H).
tert-Butyl ((3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)carbamate was obtained, from tert-butyl ((3-methylpiperidin-4-yl)methyl)carbamate and 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5) following the procedure described in Example 136, step 1. LCMS m/z=426.2 [M+H]+
(3-Methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride was obtained as a white solid, from tert-butyl ((3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)carbamate following the procedure described in Example 115, step 2. LCMS m/z=326.2 [M+H]+
5-(tert-Butyl)-N-((3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide was obtained as a white solid, 11 mg, 13% yield from (3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride and potassium 5-tert-butyl-1,2,4-oxadiazole-3-carboxylate, following the procedure described in Example 136, step 3. LCMS m/z=478.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.01-8.95 (m, 1H) 8.91 (t, J=6.41 Hz, 1H) 8.44 (s, 1H) 8.17-8.11 (m, 1H) 7.96-7.90 (m, 2H) 6.91 (d, J=1.83 Hz, 1H) 4.57-4.44 (m, 1H) 4.23-4.26 (m, 1H) 3.87 (s, 3H) 3.50 (dt, J=13.73, 4.43 Hz, 1H) 3.30-3.23 (m, 1H) 3.22-3.14 (m, 1H) 3.13-3.01 (m, 1H) 2.85-2.76 (m, 1H) 2.42 (br s, 1H) 2.17-1.99 (m, 1H) 1.81 (br d, J=10.38 Hz, 1H) 1.67-1.47 (m, 3H) 1.44-1.40 (m, 10H) 1.40-1.30 (m, 1H) 1.28-1.17 (m, 1H) 1.05 (d, J=6.10 Hz, 2H) 0.94 (dd, J=9.16, 6.71 Hz, 2H).
DIPEA (143.08 mg, 1.11 mmol) was added to a solution of (3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride (Example 144, step 2, 126 mg, 221.4 μmol) and potassium 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate (91.78 mg, 442.8 μmol) in DMF (2.21 mL). T3P® (422.7 mg, 664.3 μmol, 50% purity) was added and the reaction was stirred overnight at rt. Additional equivalents of potassium 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylate, DIPEA and T3P® were added and the reaction was stirred overnight at rt. The reaction was diluted with water, extracted with EtOAc (2×), the combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The material was purified by column chromatography (gradient elution 0-75% [3:1 EtOAc:EtOH]:Heptane) to afford a clear film. This was further purified by SFC:CHIRALPAK AD-H 30×250 mm, Sum Method: 40% (1:1) MeOH:DCM w/0.1% DEA in C02 (flow rate: 100 mL/min, ABPR 120bar, MBPR 40 psi, column temp 40° C.). The compounds were re-purified by column chromatography (4 g column, gradient elution 0-100% [3:1 EtOAc:EtOH]:Heptane) to afford the products as clear films.
Peak 1, N-(((3S,4R)-3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide, (4.0 mg, 3.8% yield, 99% purity). LCMS m/z=476.3 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ ppm 8.86 (br t, J=5.9 Hz, 1H), 8.44 (s, 1H), 8.13 (s, 1H), 7.96-7.92 (m, 2H), 6.91 (d, J=2.2 Hz, 1H), 4.53 (br d, J=13.2 Hz, 2H), 4.40 (br d, J=11.0 Hz, 2H), 3.87 (s, 3H), 3.48 (dt, J=12.8, 5.0 Hz, 2H), 3.19-3.12 (m, 2H), 3.06 (td, J=12.8, 2.2 Hz, 2H), 2.79 (br dd, J=13.2, 11.0 Hz, 2H), 1.80 (br dd, J=13.6, 3.3 Hz, 2H), 1.63-1.55 (m, 2H), 1.52 (s, 3H), 1.37-1.34 (m, 2H), 1.16-1.12 (m, 2H), 1.05 (d, J=5.9 Hz, 2H)
Peak 2, N-(((3S,4S)-3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide (2.0 mg, 1.9% yield, 99% purity) LCMS m/z=476.3 [M+H]+ 1H NMR (600 MHz, DMSO-d6) δ ppm 8.93 (br t, J=5.9 Hz, 1H), 8.44 (s, 1H), 8.14 (s, 1H), 7.99-7.90 (m, 2H), 6.91 (br d, J=2.2 Hz, 1H), 4.47 (br d, J=12.5 Hz, 2H), 4.31 (br d, J=11.7 Hz, 2H), 3.87 (s, 2H), 3.25-3.21 (m, 2H), 3.12-3.05 (m, 2H), 2.10 (br s, 1H), 2.04-1.96 (m, 1H), 1.60-1.56 (m, 2H), 1.54 (s, 3H), 1.41-1.35 (m, 2H), 1.17 (br d, J=2.2 Hz, 1H), 0.92 (br d, J=6.6 Hz, 3H)
Peak 3, N-(((3R,4R)-3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide (3.0 mg, 2.8% yield, 99% purity) LCMS m/z=476.3 [M+H]+ 1H NMR (600 MHz, DMSO-d6) δ ppm 8.93 (br t, J=5.9 Hz, 1H), 8.43 (s, 1H), 8.14 (s, 1H), 7.97-7.92 (m, 2H), 6.91 (d, J=1.5 Hz, 1H), 4.47 (br d, J=13.9 Hz, 2H), 4.31 (br d, J=11.7 Hz, 2H), 3.87 (s, 3H), 3.25-3.20 (m, 3H), 3.12-3.06 (m, 2H), 2.14-2.07 (m, 2H), 2.04-1.99 (m, 1H), 1.58 (br dd, J=9.5, 4.4 Hz, 2H), 1.54 (s, 3H), 1.40-1.35 (m, 3H), 1.20-1.13 (m, 4H), 0.92 (d, J=7.3 Hz, 4H)
Peak 4, N-(((3R,4S)-3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide (6.0 mg, 5.6% yield, 99% purity) LCMS m/z=476.3 [M+H]+ 1H NMR (600 MHz, DMSO-d6) δ ppm 8.86 (br t, J=5.9 Hz, 1H), 8.44 (s, 1H), 8.13 (s, 1H), 7.97-7.92 (m, 2H), 6.91 (d, J=2.2 Hz, 1H), 4.53 (br d, J=13.9 Hz, 2H), 4.45-4.36 (m, 2H), 3.87 (s, 3H), 3.48 (dt, J=13.2, 4.8 Hz, 1H), 3.19-3.12 (m, 2H), 3.10-3.01 (m, 2H), 2.79 (br dd, J=13.2, 10.3 Hz, 2H), 1.80 (br dd, J=13.2, 2.9 Hz, 2H), 1.63-1.56 (m, 2H), 1.52 (s, 4H), 1.38-1.34 (m, 2H), 1.34-1.28 (m, 1H), 1.17-1.13 (m, 2H), 1.05 (d, J=6.6 Hz, 3H)
To a solution of tert-butyl 4-(aminomethyl)-3-methylpiperidine-1-carboxylate (100 mg, 438 μmol) in DCM (20 mL) was added DIPEA (113.20 mg, 875.9 μmol) and 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carbonyl chloride (Example 137, step 4, 163.45 mg, 875.9 μmol) and the reaction was stirred at 20° C. for 1 h. The mixture was poured into water (50 mL) and extracted with DCM (50 mL×3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under vacuum. The crude was purified by column chromatography on silica gel (PE/EtOAc=1/1) to give tert-butyl 3-methyl-4-((5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamido)methyl)piperidine-1-carboxylate (120 mg, 72.4% yield) as a yellow solid. LCMS m/z=401.1 [M+Na]+
A solution of tert-butyl 3-methyl-4-((5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamido)methyl)piperidine-1-carboxylate (120 mg, 317.1 μmol) in HCl/EtOAc (20 mL) was stirred at 20° C. for 1 h. The mixture was concentrated under vacuum to give 5-(1-methylcyclopropyl)-N-((3-methylpiperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide hydrochloride (60 mg, crude) as a yellow solid, which was used without further purification. LCMS m/z=279.0 [M+H]+
To a solution of 5-(1-methylcyclopropyl)-N-((3-methylpiperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide hydrochloride (50 mg, 158.8 μmol) in IPA (10 mL) was added DIPEA (61.58 mg, 476.5 μmol) at 20° C. 4-Chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 74.22 mg, 317.7 μmol) was added and the mixture was stirred at 90° C. for 48 h. The reaction was concentrated under vacuum, the mixture was poured into water (20 mL) and extracted with DCM (20 mL×3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under vacuum. The crude was purified by Prep-HPLC (Method E, 38-65% gradient) to give N-((3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide (9.10 mg, 12.1% yield) as a white solid. LCMS m/z=476.1 [M+H]+ 1H NMR (400 MHz, DMSO-d6) δ: 8.95-8.90 (m, 1H), 8.43 (s, 1H), 8.14 (s, 1H), 7.95-7.93 (m, 2H), 6.91 (s, 1H), 4.49-4.29 (m, 2H), 3.87 (s, 3H), 3.28-3.21 (m, 4H), 2.11-2.00 (m, 2H), 1.58-1.51 (m, 5H), 1.39-1.36 (m, 2H), 1.18-1.16 (m, 2H), 0.92 (d, J=6.8 Hz, 3H).
A solution of cis-2-((3-methylpiperidin-4-yl)methyl)isoindoline-1,3-dione (800 mg, 2.23 mmol) in TFA (10 mL) and DCM (40 mL) was stirred at 20° C. for 1 h. The mixture was concentrated under vacuum to give cis-2-((3-methylpiperidin-4-yl)methyl)isoindoline-1,3-dione trifluoroacetate (600 mg, crude) as a yellow solid, which was used without further purification. LCMS m/z=259.0 [M+H]+
To a solution of cis-2-((3-methylpiperidin-4-yl)methyl)isoindoline-1,3-dione trifluoroacetate (600 mg, 1.62 mmol) in i-PrOH (20 mL) was added 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 300 mg, 1.28 mmol) and DIPEA (497.8 mg, 3.85 mmol) and the reaction was stirred at 90° C. for 48 h. The mixture was filtered and concentrated under vacuum. The crude product was purified by column chromatography on silica gel (PE/EtOAc=1/1 to 0/1) to give cis-tert-butyl (4-((1,3-dioxoisoindolin-2-yl)methyl)-3-methylpiperidine-1-carboxylate (330 mg, 56.6% yield) as a yellow solid. LCMS m/z=456.1 [M+H]+
To a solution of cis-tert-butyl (4-((1,3-dioxoisoindolin-2-yl)methyl)-3-methylpiperidine-1-carboxylate (330 mg, 724.5 μmol) in MeOH (20 mL) was added NH2NH2·H2O (300 mg, 85% purity) and the reaction stirred at 20° C. for 2 h. The mixture was concentrated under vacuum to give cis-2-((3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)isoindoline-1,3-dione (230 mg, crude) as a yellow solid, which was used directly without further purification. LCMS m/z=326.1 [M+H]+
To a solution of cis-2-((3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)isoindoline-1,3-dione (190 mg, 433.4 μmol) in DCM (50 mL) was added DIPEA (112.02 mg, 866.7 μmol) at 20° C. 2-(tert-Butyl)-2H-1,2,3-triazole-4-carboxylic acid (109.97 mg, 650.0 μmol) and HATU (247.82 mg, 650.0 μmol) were added and the reaction was stirred at 20° C. for 1 h. The mixture was poured into water (50 mL) and extracted with DCM (50 mL×3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under vacuum. The crude product was purified by Prep-HPLC (Method E, 33-63% gradient) to give cis-(3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine (180 mg, 85.4% yield) as a yellow solid. LCMS m/z=477.1 [M+H]+
This compound (180 mg, 377.7 μmol) was purified by SFC (column: Phenomenex-Cellulose-2 (250 mm×30 mm, 5 μm), 0.1% NH3·H2O, EtOH as mobile phase, from 55-55%, Flow Rate (mL/min): 70) to give:
Peak 1, 1-(tert-Butyl)-N-(((3S,4S)-3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1H-1,2,3-triazole-4-carboxamide (stereochemistry arbitrarily assigned) (66.6 mg, 37.0% yield) as a white solid. LCMS m/z=477.2 [M+H]+ 1H NMR (400 MHz, DMSO-d6) δ: 8.64 (s, 1H), 8.54-8.50 (m, 1H), 8.42 (s, 1H), 8.14-8.12 (in, 1H), 7.95-7.92 (m, 2H), 6.90 (d, J=1.6 Hz, 1H), 4.50-4.30 (m, 2H), 3.87 (s, 3H), 3.27-3.24 (m, 3H), 3.24-3.09 (m, 1H), 2.12-2.01 (m, 2H), 1.63 (s, 9H), 1.62-1.60 (m, 2H), 0.93 (d, J=7.2 Hz, 3H).
and Peak 2, 1-(tert-butyl)-N-(((3R,4R)-3-methyl-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1H-1,2,3-triazole-4-carboxamide (stereochemistry arbitrarily assigned) (54.0 mg, 30% yield) as a white solid. LCMS m/z 477.1 [M+H]+ 1H NMR (400 MHz, DMSO-d6) δ: 8.64 (s, 1H), 8.54-8.50 (i, 1H), 8.42 (s, 1H), 8.14-8.12 (m, 1H), 7.95-7.92 (m, 2H), 6.90 (d, J 1.6 Hz, 1H), 4.50-4.30 (i, 2H), 3.87 (s, 3H), 3.27-3.24 (m, 3H), 3.09-3.24 (m, 1H), 2.12-2.01 (m, 2H), 1.63 (s, 9H), 1.62-1.60 (m, 2H), 0.93 (d, J=7.2 Hz, 3H).
A mixture of benzyl (((3S,4R)-3-fluoropiperidin-4-yl)methyl)carbamate hydrochloride (500 mg, 1.65 mmol), 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 367.5 mg, 1.57 mmol) and DIPEA (813.06 mg, 6.29 mmol) were dissolved in DMF (3.30 mL) and the reaction was stirred at 90° C. overnight. The reaction was diluted with water and extracted with EtOAc (2×). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The material was triturated with EtOAc and filtered through a pad of Celite® and the solid collected. The filtrate was concentrated and purified by silica gel column chromatography (0-100% EtOAc:Heptane) to provide benzyl (((3S,4R)-3-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)carbamate (662.0 mg, 91% yield) as a tan solid. LCMS m/z=464.2 [M+H]+
A vial was charged with benzyl (((3S,4R)-3-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)carbamate (653.6 mg, 1.41 mmol), palladium (300.1 mg, 141 μmol) and MeOH (7.05 mL), purged and backfilled with H2 three times, then stirred under an atmosphere of H2 for 4 h. The reaction was filtered through a pad of Celite®, washed with MeOH and concentrated to afford ((3S,4R)-3-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine (441 mg, 95% yield) as a light yellow solid. LCMS m/z=330.2 [M+H]+
DIPEA (147.14 mg, 1.14 mmol) was added to a solution of ((3S,4R)-3-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine (75 mg, 227.7 μmol) and 1-(tert-butyl)-1H-1,2,3-triazole-4-carboxylic acid (57.79 mg, 341.6 μmol) in DMF (2.28 mL). T3P® (434.71 mg, 683.1 μmol, 50% purity) was added and the reaction stirred overnight at rt. The reaction was diluted with water and DCM and passed through a phase separator. The aqueous layer was extracted with DCM and the combined organic layers were concentrated. The residue was purified by HPLC (Method A2, 5-70%) The product containing fractions were concentrated, dissolved in MeCN (1 mL) and water (1 mL), and the resulting material was frozen in a dry ice/acetone bath and lyophilized to afford 1-(tert-butyl)-N-(((3S,4R)-3-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1H-1,2,3-triazole-4-carboxamide (56 mg, 50.7% yield) as a white solid. LCMS m/z=481.3 [M+H]+ 1H NMR (400 MHz, DMSO-d6) δ ppm 8.67 (s, 1H), 8.61 (t, J=5.9 Hz, 1H), 8.46 (d, J=0.8 Hz, 1H), 8.15 (s, 1H), 7.97-7.92 (m, 2H), 6.92 (dd, J=2.5, 0.8 Hz, 1H), 4.96 (br s, 1H), 4.88-4.76 (m, 2H), 4.67 (br d, J=12.0 Hz, 1H), 3.44-3.35 (m, 1H), 3.30-3.23 (m, 1H), 3.11-2.98 (m, 1H), 2.29-2.10 (m, 1H), 1.76-1.67 (m, 2H), 1.64 (s, 9H).
2-(tert-Butyl)-N-(((3S,4R)-3-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)oxazole-4-carboxamide was obtained as a white solid, 44 mg, 39.8% yield, from ((3S,4R)-3-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine (Example 152, step 2) and 2-tert-butyloxazole-4-carboxylic acid, following the procedure described in Example 152, step 3. LCMS m/z=481.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.49 (s, 1H), 8.46 (d, J=0.8 Hz, 1H), 8.20 (br t, J=6.0 Hz, 1H), 8.15 (s, 1H), 7.99-7.91 (m, 2H), 6.92 (d, J=2.5 Hz, 1H), 4.94 (br s, 1H), 4.88-4.76 (m, 2H), 4.66 (br d, J=11.8 Hz, 1H), 3.87 (s, 3H), 3.44-3.33 (m, 2H), 3.30-3.20 (m, 2H), 3.04 (br s, 1H), 2.27-2.08 (m, 2H), 1.69 (br s, 2H), 1.36 (s, 9H).
N-(((3S,4R)-3-Fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide was obtained as a white solid, 29 mg, 26.3% yield, from ((3S,4R)-3-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine (Example 152, step 2) and 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylic acid (Example 137, step 3), following the procedure described in Example 152, step 3. LCMS m/z=480.2 [M+H]+ 1H NMR (400 MHz. DMSO-d6) δ ppm 8.96-9.04 (m, 1H), 8.47 (s, 1H), 8.15 (s. 1H), 797-7.92 (m, 2H), 6.92 (d, J=2.5 Hz, 1H), 4.94 (br s, 1H), 4.87-4.76 (n, 2H), 4,67 (br d, J=15.1 Hz, 1 [H), 3.87 (s, 3H), 3.42-3.34 (m, 1H), 3.26 (s, 1H), 3.05 (s, 1H), 2.27-2.08 (m. 2H), 1.70 (br s, 2H), 154 (s, 3H), 1.42-1.34 (m, 2H), 1.21-1.11 (nm, 2H).
DIPEA (833.6 mg, 6.45 mmol) was added to a solution of tert-butyl cis-4-(aminomethyl)-3-fluoro-piperidine-1-carboxylate (499.42 mg, 2.15 mmol) and potassium 5-tert-butyl-1,2,4-oxadiazole-3-carboxylate (539.89 mg, 2.58 mmol) in DCM (21.5 mL) and the solution cooled to 0° C. HATU (983.60 mg, 2.58 mmol) was added in a single portion and the reaction was stirred overnight at rt. The reaction was concentrated and purified by column chromatography (40 g column, gradient elution 0-100% EtOAc:Heptane) to afford tert-butyl cis-4-((5-(tert-butyl)-1,2,4-oxadiazole-3-carboxamido)methyl)-3-fluoropiperidine-1-carboxylate (405 mg, 49% yield) as a white solid. LCMS m/z=407.2 [M+H]+
5-(tert-Butyl)-N-((cis-3-fluoropiperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide hydrochloride (403.7 mg, 1.05 mmol) was dissolved in MeOH (10.5 mL) and 1.25M HCl solution (in MeOH, 8.40 mL) and the reaction was stirred overnight at 50° C. The reaction was concentrated and the residue vacuum dried to afford 5-(tert-butyl)-N-((cis-3-fluoropiperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide hydrochloride (346 mg, crude) as a white solid. LCMS m/z=285.1 [M+H]+
A mixture of 5-(tert-butyl)-N-((cis-3-fluoropiperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide hydrochloride (50 mg, 155.9 μmol), 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 36.42 mg, 155.9 μmol) and DIPEA (80.58 mg, 623.5 μmol) were dissolved in DMF (311.7 uL) and the reaction was stirred at 80° C. overnight. The reaction was concentrated and the residue purified by HPLC (Method A2, 5-60%) afford 5-(tert-butyl)-N-((cis-3-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide (36 mg, 48.0% yield) as a beige solid. LCMS m/z=482.2 [M+H]+4. Separation of 5-(tert-butyl)-N-((cis-3-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide
5-(tert-Butyl)-N-((cis-3-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide (34 mg) was purified by SFC CHIRALPAK AD-H 30×250 mm, Sum Method: 45% IPA w/0.1% DEA in CO2 (flow rate: 100 mL/min, ABPR 120bar, MBPR 60 psi, column temp 40° C.) to provide:
Peak 1, 5-(tert-butyl)-N-(((3S,4R)-3-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide (5.0 mg, purity 98%). LCMS m/z=482.3 [M+H]+ 1H NMR (600 MHz, DMSO-d6) δ ppm 9.12-9.03 (m, 1H) 8.48 (s, 1H) 8.15 (s, 1H) 7.96 (d, J=3.67 Hz, 2H) 6.93 (d, J=2.20 Hz, 1H) 4.93 (br s, 1H) 4.87-4.77 (m, 2H) 4.67 (br d, J=11.74 Hz, 1H) 3.87 (s, 3H) 3.05 (s, 1H) 1.71 (br s, 2H) 1.43 (s, 9H) 1.23 (s, 3H) 0.85 (s, 1H)
And peak 2, 5-(tert-butyl)-N-(((3R,4S)-3-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide (4.0 mg, 98% purity). LCMS m/z=482.3 [M+H]+ 1H NMR (600 MHz, DMSO-d6) δ ppm 9.13-9.05 (m, 1H) 8.48 (s, 1H) 8.16 (s, 1H) 7.99-7.93 (m, 2H) 6.93 (d, J=1.47 Hz, 1H) 4.93 (br s, 1H), 4.87-4.78 (m, 2H) 4.67 (br d, J=13.21 Hz, 1H) 3.87 (s, 3H) 3.04 (br d, J=14.67 Hz, 1H) 1.71 (br s, 2H) 1.43 (s, 9H) 1.23 (s, 3H).
tert-Butyl 4-((5-(tert-butyl)-1,2,4-oxadiazole-3-carboxamido)methyl)-3,3-difluoropiperidine-1-carboxylate was obtained as a white solid, 558 mg, 54.6% yield from tert-butyl 4-(aminomethyl)-3,3-difluoro-piperidine-1-carboxylate and potassium 5-tert-butyl-1,2,4-oxadiazole-3-carboxylate following the procedure described in Preparation 155 and 156, step 1. LCMS m/z=452.2 [M+Na]+
tert-Butyl 4-((5-(tert-butyl)-1,2,4-oxadiazole-3-carboxamido)methyl)-3,3-difluoropiperidine-1-carboxylate (559.39 mg, 1.39 mmol) was dissolved in MeOH (13.90 mL), HCl solution (1.25M in MeOH, 11.12 mL) was added and the reaction was stirred overnight at 50° C. The reaction was concentrated and vacuum dried to afford crude 5-tert-butyl-N-[(3,3-difluoro-4-piperidyl)methyl]-1,2,4-oxadiazole-3-carboxamide hydrochloride (476 mg, crude) as a white solid. LCMS m/z=303.1 [M+H]+
A mixture of 5-(tert-butyl)-N-((3,3-difluoropiperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide hydrochloride (50 mg), 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 38.64 mg, 165.4 μmol) and DIPEA (85.50 mg, 661.6 μmol) were dissolved in DMF (330.78 uL) and the reaction was stirred at 80° C. overnight and a further 24 h at 100° C. The reaction was diluted with DMSO, passed through a syringe filter and purified by HPLC (Method C3, 5-60%) to afford 5-(tert-butyl)-N-((3,3-difluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide (30 mg, 36.3% yield) as a white solid. LCMS m/z=500.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.07 (br t, J=6.1 Hz, 1H), 8.56 (s, 1H), 8.19 (s, 1H), 8.00-7.96 (m, 1H), 7.00 (d, J=2.4 Hz, 1H), 4.73-4.63 (m, 2H), 4.51 (br d, J=13.4 Hz, 2H), 3.88 (s, 2H), 3.69-3.61 (m, 2H), 3.57 (br d, J=14.0 Hz, 1H), 3.48 (br s, 1H), 3.33 (ddd, J=13.4, 9.2, 6.7 Hz, 1H), 3.21 (br t, J=11.6 Hz, 2H), 1.99 (br d, J=14.0 Hz, 2H), 1.74-1.61 (m, 2H), 1.43 (s, 7H)
5-(tert-Butyl)-N-((3,3-difluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide (Example 157, 29 mg) was purified by chiral SFC (LUX Cellulose-4 LC 30×250 mm, 3 um), Method: 45% MeOH w/0.1% DEA in C02 (flow rate: 100 mL/min, ABPR 120bar, MBPR 40 psi, column temp 40° C.) to provide:
Peak 1, (S)-5-(tert-butyl)-N-((3,3-difluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide (10 mg, 34.5% yield) LCMS m/z=500.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.11-9.05 (m, 1H), 8.56 (s, 1H), 8.19 (s, 1H), 7.99 (d, J=2.4 Hz, 1H), 7.98 (s, 1H), 7.00 (br d, J=2.4 Hz, 1H), 4.66 (br d, J=14.7 Hz, 2H), 4.51 (br d, J=13.4 Hz, 2H), 3.88 (s, 3H), 3.70-3.61 (m, 2H), 3.26-3.19 (m, 1H), 2.01-1.97 (m, 1H), 1.74-1.66 (m, 1H), 1.43 (s, 9H)
And Peak 2, (R)-5-(tert-butyl)-N-((3,3-difluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide (10 mg, 34.5% yield). LCMS m/z=500.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.11-9.04 (m, 1H), 8.56 (s, 1H), 8.19 (s, 1H), 7.99 (d, J=2.4 Hz, 1H), 7.98 (s, 1H), 7.00 (br d, J=2.4 Hz, 1H), 4.67 (br s, 2H), 4.51 (br d, J=13.4 Hz, 2H), 3.69-3.60 (m, 2H), 3.57 (br d, J=14.0 Hz, 1H), 3.24-3.17 (m, 1H), 2.03-1.95 (m, 1H), 1.73-1.65 (m, 1H), 1.43 (s, 9H)
A mixture of tert-butyl ((4-fluoropiperidin-4-yl)methyl)carbamate (238.59 mg, 1.03 mmol), 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 200 mg, 855.9 μmol) and DIPEA (442.49 mg, 3.42 mmol) were dissolved in DMF (1.71 mL) and the reaction was stirred at 100° C. overnight. The reaction was diluted with water and extracted twice with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The material was purified by column chromatography (0-75% [3:1 EtOAc:EtOH]:Heptane) to afford tert-butyl ((4-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)carbamate (439 mg, impure) as an off-white solid. LCMS m/z=430.3 [M+H]+
(4-Fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride was obtained as a yellow solid, from tert-butyl ((4-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)carbamate, following the procedure described in Example 119, step 2. LCMS m/z=330.3 [M+H]+
DIPEA (128.50 mg, 994.3 μmol) was added to a solution of (4-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride (100 mg, 198.9 μmol) and potassium 5-tert-butyl-1,2,4-oxadiazole-3-carboxylate (62.42 mg, 298.3 μmol) in DMF (1.99 mL) T3P® (596.6 μmol, 355.13 uL, 50% purity) was added and the reaction was stirred overnight at rt. The reaction was diluted with water and DCM and passed through a phase separator. The aqueous layer was extracted with DCM and the combined organic layers were concentrated. The reaction was dissolved in minimal DMSO and purified by reverse phase HPLC (gradient elution 5-70% MeCN:H2O w/0.1% TFA modifier) and the product was dissolved in MeCN (1 mL) and water (1 mL), and the resulting material was frozen in a dry ice/acetone bath and lyophilized to afford 5-(tert-butyl)-N-((4-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide trifluoroacetate (47 mg, 38.9% yield,) as a light yellow solid. LCMS m/z=482.3 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.07 (t, J=6.41 Hz, 1H) 8.49 (s, 1H) 8.16 (s, 1H) 7.99-7.92 (m, 2H) 6.98 (d, J=2.44 Hz, 1H) 4.37 (br d, J=13.43 Hz, 2H) 3.87 (s, 3H) 3.62-3.51 (m, 2H) 3.45-3.35 (m, 2H) 1.96-1.79 (m, 4H) 1.42 (s, 9H).
N-((4-Fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxamide trifluoroacetate was obtained as a light yellow solid, 48 mg, 40.3% yield, from (4-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride (Example 160, step 2) and 5-(1-methylcyclopropyl)-1,2,4-oxadiazole-3-carboxylic acid (Example 137, step 3), following the procedure described in Example 160, step 3. LCMS m/z=480.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.01 (t, J=6.10 Hz, 1H) 8.49 (s, 1H) 8.16 (s, 1H) 7.99-7.93 (m, 2H) 6.97 (d, J=2.44 Hz, 1H) 4.37 (br d, J=12.82 Hz, 2H) 3.87 (s, 3H) 3.60-3.50 (m, 2H) 3.45-3.35 (m, 2H) 1.94-1.78 (m, 4H) 1.53 (s, 3H) 1.40-1.35 (m, 2H) 1.19-1.13 (m, 2H).
1-(tert-Butyl)-N-((4-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-1H-1,2,3-triazole-4-carboxamide trifluoroacetate was obtained as a light yellow solid, 51 mg, 43.1% yield, from (4-fluoro-1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methanamine dihydrochloride (Example 160, step 2) and 1-tert-butyltriazole-4-carboxylic acid, following the procedure described in Example 160, step 3. LCMS m/z=481.3 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.71 (s, 1H) 8.52 (t, J=6.41 Hz, 1H) 8.48 (s, 1H) 8.16 (s, 1H) 7.98-7.93 (m, 2H) 6.97 (d, J=2.44 Hz, 1H) 4.37 (br d, J=12.82 Hz, 2H) 3.87 (s, 3H) 3.62-3.52 (m, 2H) 3.47-3.36 (m, 2H) 1.94-1.79 (m, 4H) 1.63 (s, 9H).
To a solution of tert-butyl 4-(1-aminoethyl)piperidine-1-carboxylate (600 mg, 2.63 mmol) in DCM (50 mL) was added DIPEA (1.02 g, 7.89 mmol), 1-(tert-butyl)-1H-1,2,3-triazole-4-carboxylic acid (666.85 mg, 3.95 mmol) and then HATU (1.50 g, 3.95 mmol) and the reaction mixture was stirred at 20° C. for 4 h. The mixture was poured into water (200 mL) and extracted with EtOAc (100 mL×2). The combined organic layers were washed with brine (100 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by column chromatography on silica gel eluting with (PE/EtOAc=1/0˜1/1) to give tert-butyl 4-(1-(1-(tert-butyl)-1H-1,2,3-triazole-4-carboxamido)ethyl)piperidine-1-carboxylate (900 mg, 90.1% yield) as a white solid. LCMS m/z=380.2 [M+H]+
A solution of tert-butyl 4-(1-(1-(tert-butyl)-1H-1,2,3-triazole-4-carboxamido)ethyl)piperidine-1-carboxylate (900 mg, 2.37 mmol) in HCl/EtOAc (10 mL, 4M) was stirred at 20° C. for 1 h. The mixture was concentrated in vacuo to give 1-(tert-butyl)-N-(1-(piperidin-4-yl)ethyl)-1H-1,2,3-triazole-4-carboxamide hydrochloride (800 mg, crude) as a white solid, which was used in the next step without further purification. LCMS m/z=280.1 [M+H]+
To a solution of 4-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step X, 150 mg, 642 μmol) and 1-(tert-butyl)-N-(1-(piperidin-4-yl)ethyl)-1H-1,2,3-triazole-4-carboxamide (358.70 mg, 1.28 mmol) in IPA (50 mL) was added DIPEA (331.87 mg, 2.57 mmol) and the reaction mixture was stirred at 90° C. for 32 h. The mixture was concentrated in vacuo to give a crude product, which was purified by prep-HPLC (Method D, 33-53% gradient) to give 1-(tert-butyl)-N-(1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)ethyl)-1H-1,2,3-triazole-4-carboxamide (108.4 mg, 35.4% yield) as a white solid. LCMS m/z=477.2 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ: 8.69 (s, 1H), 8.47 (s, 1H), 8.31 (d, J=9.0 Hz, 1H), 8.21 (s, 1H), 8.00-7.98 (m, 2H), 7.05-7.04 (m, 1H), 4.57 (t, J=11.0 Hz, 2H), 3.95-3.88 (m, 4H), 3.17-3.07 (m, 2H), 1.90-1.80 (m, 3H), 1.63 (s, 9H), 1.40-1.32 (m, 2H), 1.17 (d, J=6.5 Hz, 3H).
tert-Butyl (((1R,5S,8r)-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)methyl)carbamate was obtained as a white solid, 445 mg, 95% yield from 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5) and tert-butyl N-(3-azabicyclo[3.2.1]octan-8-ylmethyl)carbamate hydrochloride, following the procedure described in Example 160, step 1. LCMS m/z=438.3 [M+H]+
((1R,5S,8r)-3-(6-(1-Methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)methanamine hydrochloride was obtained as a light yellow solid, from tert-butyl (((1R,5S,8r)-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)methyl)carbamate, following the procedure described in Example 119, step 2. LCMS m/z=338.2 [M+H]+
DIPEA (638.4 μL, 3.66 mmol) was added to a mixture of ((1R,5S,8r)-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)methanamine hydrochloride (300 mg, 731.1 μmol) and potassium 5-tert-butyl-1,2,4-oxadiazole-3-carboxylate (229.49 mg, 1.10 mmol) in DMF (3.66 mL). T3P® (2.19 mmol, 1.31 mL, 50% purity) was added and the reaction was stirred overnight at rt. The reaction was diluted with water and DCM and passed through a phase separator. The aqueous layer was extracted with DCM and the combined organic layers were concentrated. The crude was purified by column chromatography (gradient elution 0-75% [3:1 EtOAc:EtOH]:Heptane) to afford racemic material. This was further purified by SFC (LUX Cellulose-4 LC 30×250 mm, Sum Method: 45% EtOH w/0.1% DEA in C02 (flow rate: 100 mL/min, ABPR 120bar, MBPR 40 psi, column temp 40° C. to give Peak 1, 5-(tert-butyl)-N-(((1R,5S,8s)-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)methyl)-1,2,4-oxadiazole-3-carboxamide, 51 mg, LCMS m/z=490.0 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.12 (br t, J=5.80 Hz, 1H) 8.39 (s, 1H) 8.13 (s, 1H) 7.94 (s, 1H) 7.90 (d, J=2.44 Hz, 1H) 6.99 (d, J=1.83 Hz, 1H) 4.18 (br d, J=10.38 Hz, 2H) 3.86 (s, 3H) 3.69-3.59 (m, 4H) 2.84-2.75 (m, 1H) 2.28 (br s, 2H) 2.10-2.01 (m, 1H) 1.83-1.74 (m, 2H) 1.67-1.59 (m, 2H) 1.43 (s, 9H)
And Peak 2, 5-(tert-butyl)-N-(((1R,5S,8r)-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)methyl)-1,2,4-oxadiazole-3-carboxamide, 71 mg. LCMS m/z=490.0 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ ppm 9.09 (t, J=6.10 Hz, 1H) 8.40 (s, 1H) 8.13 (s, 1H) 7.93 (s, 1H) 7.90 (d, J=2.44 Hz, 1H) 6.96 (d, J=2.44 Hz, 1H) 4.42 (dd, J=12.82, 3.05 Hz, 2H) 3.86 (s, 3H) 3.21-3.13 (m, 4H) 2.25 (br s, 2H) 2.09 (t, J=7.94 Hz, 1H) 1.89-1.81 (m, 2H) 1.57-1.49 (m, 2H) 1.13 (t, J=7.02 Hz, 1H).
tert-Butyl ((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)azepan-4-yl)methyl)carbamate was obtained as an off-white solid, 167 mg, 91.7% yield from tert-butyl (azepan-4-ylmethyl)carbamate and 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5), following the procedure described in Example 160, step 1. LCMS mz=426.3 [M+H]+
(1-(6-(1-Methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)azepan-4-yl)methanamine dihydrochloride was obtained as a yellow solid, 179 mg, crude, from tert-butyl ((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)azepan-4-yl)methyl)carbamate, following the procedure described in Example 23, step 3.
5-(tert-Butyl)-N-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)azepan-4-yl)methyl)-1,2,4-oxadiazole-3-carboxamide trifluoroacetate was obtained as a light yellow solid, 61 mg, 41.4% yield, from (1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)azepan-4-yl)methanamine hydrochloride and 5-tert-butyl-1,2,4-oxadiazole-3-carboxylic acid, following the procedure described in Example 160, step 3. LCMS m/z=478.3 [M+H]+1H NMR (500 MHz, DMSO-d6) δ ppm 8.94 (t, J=5.80 Hz, 1H) 8.33 (s, 1H) 8.10 (s, 1H) 7.95-7.88 (m, 2H) 6.90 (d, J=1.83 Hz, 1H) 4.12-3.96 (m, 2H) 3.86 (s, 3H) 3.84-3.72 (m, 2H) 3.14 (t, J=6.71 Hz, 2H) 2.09-1.98 (m, 2H) 1.74 (br d, J=9.16 Hz, 3H) 1.55-1.45 (m, 1H) 1.41 (s, 9H) 1.24-1.12 (m, 1H).
1-(tert-butyl)-N-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)azepan-4-yl)methyl)-1H-1,2,3-triazole-4-carboxamide was obtained as a yellow solid, 70 mg, 46.7% yield, from (1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)azepan-4-yl)methanamine hydrochloride (Example 166, step 3) and 1-tert-butyltriazole-4-carboxylic acid, following the procedure described in Example 160, step 3. LCMS m/z=477.3 [M+H]+1H NMR (500 MHz, DMSO-d6) δ ppm 8.61 (s, 1H) 8.51 (t, J=5.80 Hz, 1H) 8.32 (s, 1H) 8.10 (s, 1H) 7.92 (s, 1H) 7.90 (d, J=2.44 Hz, 1H) 6.90 (d, J=1.83 Hz, 1H) 4.11-3.96 (m, 2H) 3.86 (s, 3H) 3.84-3.72 (m, 2H) 3.13 (t, J=6.71 Hz, 2H) 2.08-1.99 (m, 2H) 1.82-1.71 (m, 3H) 1.55-1.44 (m, 1H) 1.22-1.11 (m, 1H) 1.01-0.82 (m, 1H)
To a solution of benzyl 4-((2-oxopiperazin-1-yl)methyl)piperidine-1-carboxylate (3.00 g, 9.05 mmol) in IPA (30 mL) was added DIPEA (2.34 g, 18.10 mmol) and (Boc)20 (2.37 g, 10.86 mmol) and the reaction was stirred at 25° C. for 1 h. The solvent was removed under vacuum and the residue was purified by column chromatography on silica gel (from PE to PE:EtOAc=1:1) to give tert-butyl 4-((1-((benzyloxy)carbonyl)piperidin-4-yl)methyl)-3-oxopiperazine-1-carboxylate (1.20 g, 30.7% yield) as colorless oil.
To a solution of tert-butyl 4-((1-((benzyloxy)carbonyl)piperidin-4-yl)methyl)-3-oxopiperazine-1-carboxylate (800 mg, 1.85 mmol) in MeOH (20 mL) was added Pd/C (500 mg) and the reaction was hydrogenated at 15 psi and 30° C. for 12 h. The suspension was filtered and the filtrate was concentrated in vacuum to give tert-butyl 3-oxo-4-(piperidin-4-ylmethyl)piperazine-1-carboxylate (350 mg, crude) as a pale solid which was used for the next step without further purification.
To a solution of tert-butyl 3-oxo-4-(4-piperidylmethyl)piperazine-1-carboxylate (300 mg, 1.01 mmol) in butyl alcohol (10 mL) was added 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (Example 1, step 5, 236.0 mg, 1.01 mmol) and DIPEA (352.8 μL, 2.02 mmol) and the reaction was stirred at 110° C. for 10 h. The solvent was removed under vacuum and the residue was purified by column chromatography on silica gel (PE to DCM: MeOH=10:1) to give tert-butyl 4-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-3-oxopiperazine-1-carboxylate (200 mg, 40.0% yield) as a white solid.
To a solution of tert-butyl 4-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-3-oxopiperazine-1-carboxylate (80 mg, 161.8 μmol) in DCM (2.0 mL) was added HCl/EtOAc (20.0 mL) and the reaction was stirred at 25° C. for 1 h. The mixture was filtered to give 1-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)piperazin-2-one hydrochloride (60 mg, crude) as a white solid. LCMS m/z=395.1 [M+H]+
To a solution of 1-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)piperazin-2-one hydrochloride (80 mg, 185.7 μmol) in MeOH (10 mL) was added DIPEA (71.98 mg, 557 μmol) at 20° C. Isobutyraldehyde (20.08 mg, 278.5 μmol) and NaBH3CN (46.66 mg, 742.6 μmol) were added and the reaction was stirred at 20° C. for 10 h. The mixture was poured into water (50 mL) and extracted with DCM (50 mL×3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude was purified by Prep-HPLC (Method D, 11-31% gradient) to give 4-isobutyl-1-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)piperazin-2-one (32.7 mg, 35.2% yield) as a yellow solid. LCMS m/z=451.4 [M+H]+ 1H NMR (400 MHz, DMSO-d6) δ:11.41 (s, 1H), 8.49-8.39 (m, 1H), 8.20-8.14 (m, 1H), 8.00-7.94 (m, 2H), 6.98-6.93 (m, 1H), 4.52 (s, 2H), 3.98 (s, 2H), 3.86 (s, 3H), 3.74 (s, 2H), 3.46 (s, 1H), 3.11-2.98 (s, 5H), 2.49 (s, 2H), 1.93-1.83 (m, 4H), 1.29 (s, 2H), 1.00 (s, 6H).
4-(Cyclobutylmethyl)-1-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)piperazin-2-one was obtained as a white solid, 44.8 mg, 42.5% yield, from 1-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)piperazin-2-one hydrochloride (Example 168, step 4) and cyclobutanecarbaldehyde, following a similar method to that described in Example 168. The crude product was purified by Prep-HPLC (Method G, 35-65% gradient). LCMS m/z=485.2 [M+H]+ 1H NMR: (500 MHz, DMSO-d6) δ=8.44 (s, 1H), 8.14 (s, 1H), 7.96-7.92 (m, 2H), 6.91 (d, J=2.0 Hz, 1H), 4.52 (d, J=13.5 Hz, 2H), 3.87 (s, 3H), 3.30-3.26 (m, 2H), 3.21 (d, J=7.5 Hz, 2H), 3.06 (t, J=12.0 Hz, 2H), 2.95 (s, 2H), 2.59 (t, J=5.5 Hz, 2H), 2.52 (d, J=1.5 Hz, 1H), 2.38 (d, J=7.0 Hz, 2H), 2.05-1.98 (m, 3H), 1.89-1.82 (m, 1H), 1.81-1.75 (m, 1H), 1.72-1.61 (m, 4H), 1.30-1.22 (m, 2H).
To a solution of 1-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)piperazin-2-one hydrochloride (Example 168, step 4, 80 mg, 202.8 μmol) in MeOH (5.0 mL) was added propanal (47.11 mg, 811.2 μmol) and NaCNBH3 (50.98 mg, 811.2 μmol) and the reaction was stirred at 25° C. for 10 h. The mixture was concentrated in vacuo and the crude was purified by HPLC (Method D, 10-30%) to give 1-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-4-propylpiperazin-2-one (114.3 mg, 43.8% yield) as a white solid. LCMS m/z=437.2 [M+H]+. 1H NMR: (500 MHz, DMSO-d6) δ=11.5 (br s, 1H), 8.49 (s, 1H), 8.15 (s, 1H), 7.98-7.96 (m, 2H), 6.93 (s, 1H), 4.55-4.52 (m, 2H), 3.88 (s, 3H), 3.82-3.80 (m, 2H), 3.52-3.45 (m, 3H), 3.15-3.08 (m, 5H), 2.49-2.48 (m, 2H), 2.06-2.04 (m, 1H), 1.85-1.75 (m, 4H), 1.31-1.29 (m, 2H), 0.93 (t, 3H).
4-Methyl-1-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)piperazin-2-one was obtained as a white solid, 43.7 mg, 52.8% yield, from 1-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)piperazin-2-one hydrochloride (Example 168, step 4) and formaldehyde, following a similar procedure to that described in Example 170. The crude product was purified by HPLC (Method D, 23-32% gradient). LCMS m/z=409.3 [M+H]+ 1H NMR (500 MHz, DMSO-d6) δ=11.70 (s, 1H), 8.45 (s, 1H), 8.14 (s, 1H), 7.96-7.94 (m, 2H), 6.92 (d, J=2.0 Hz, 1H), 4.52 (d, J=13.5 Hz, 2H), 3.87 (s, 3H), 3.80 (s, 3H), 3.50 (d, J=12.0 Hz, 2H), 3.40 (d, J=7.5 Hz, 2H), 3.20 (d, J=6.0 Hz, 1H), 3.08 (d, J=7.0 Hz, 2H), 2.82 (s, 3H), 2.06-2.03 (m, 1H), 1.86-1.77 (m, 2H), 1.32-1.23 (m, 2H).
1-((1-(6-(1-Methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)-4-neopentylpiperazin-2-one was obtained as a white solid, 21.2 mg, 22.5% yield, from 1-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)piperazin-2-one hydrochloride (Example 168, step 4) and 2,2-dimethylpropanal, following a similar procedure to that described in Example 170. LCMS m/z=465.2 [M+H]+. 1H NMR: (500 MHz, DMSO-d6) δ=8.35 (s, 1H), 8.08 (s, 1H), 7.90-7.89 (m, 2H), 6.86 (s, 1H), 4.52-4.50 (m, 2H), 3.89 (s, 3H), 3.34-3.29 (m, 5H), 3.20-3.15 (m, 2H), 2.67-2.65 (m, 2H), 2.40-2.37 (m, 2H), 2.20-2.10 (m, 1H), 1.79-1.76 (m, 2H), 1.65-1.63 (m, 1H), 1.38 (s, 9H).
To a solution of 1-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)piperazin-2-one hydrochloride (Example 168, step 4, 60 mg, crude) in MeCN (15 mL) was added K2CO3 (63.07 mg, 456.31 μmol) and 2-iodopropane (51.71 mg, 304.2 μmol) and the reaction was stirred at 90° C. for 10 h. The solvent was removed under vacuum and the residue was purified by prep-HPLC (Method D, 10-30% gradient) to give 4-isopropyl-1-((1-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)piperidin-4-yl)methyl)piperazin-2-one (15.5 mg, 23.3% yield) as a white solid. LCMS m/z=437.1 [M+H]+ 1H NMR: (400 MHz, DMSO-d6) δ=8.45 (s, 1H), 8.14 (s, 1H), 7.97-7.92 (m, 2H), 6.91 (s, 1H), 4.52 (d, J=13.2 Hz, 2H), 3.87 (s, 3H), 3.86-3.62 (m, 4H), 3.55-3.43 (m, 3H), 3.30 (d, J=11.2 Hz, 1H), 3.20-3.02 (m, 3H), 2.05 (s, 1H), 1.93-1.81 (m, 2H), 1.30 (dd, J=2.4, 6.0 Hz, 8H).
The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured after monitoring the amount of phosphorylation of a fluorescein-labeled polyGAT peptide (Invitrogen PV3611) in the presence of active BTK enzyme (Upstate 14-552), ATP, and inhibitor. The BTK kinase reaction was done in a black 96 well plate (costar 3694). For a typical assay, a 24 μL aliquot of a ATP/peptide master mix (final concentration; ATP 10 PM, polyGAT 100 nM) in kinase buffer (10 mM Tris-HCl pH 7.5, 10 mM MgCl2, 200 μM Na3PO4, 5 mM DTT, 0.01% Triton X-100, and 0.2 mg/ml casein) is added to each well. Next, I pL of a 4-fold, 40× compound titration in 100% DMSO solvent is added, followed by adding 15 μL of BTK enzyme mix in 1× kinase buffer (with a final concentration of 0.25 nM). The assay is incubated for 30 minutes before being stopped with 28 μL of a 50 mM EDTA solution. Aliquots (5 uL) of the kinase reaction are transferred to a low volume white 384 well plate (Coming 3674), and 5 μL of a 2× detection buffer (Invitrogen PV3574, with 4 nM Tb—PY20 antibody, Invitrogen PV3552) is added. The plate is covered and incubated for 45 minutes at room temperature. Time resolved fluorescence (TRF) on Molecular Devices M5 (332 nm excitation; 488 nm emission; 518 nm fluorescein emission) is measured. IC50 values are calculated using a four parameter fit with 100% enzyme activity determined from the DMSO control and 0% activity from the EDTA control.
Table 1 shows the activity of the selected exemplary compounds of this invention in the in vitro Btk kinase assay, wherein each compound number corresponds to the example numbers in Examples 1-173. “†” represents an IC50 of greater than 1 μM and equal to or less than 10 μM. “††” represents an IC50 of greater than 10 nM and equal to or less than 1 μM (10 nM<IC50≤1 μM). “†††” represents an IC50 of greater than 1 nM and equal to or less than 10 nM (1 nM<IC50≤10 nM). “††††” represents an IC50 of less than 1 nM.
In Vitro whole blood CD69 Assay
Human heparinized venous blood from health donors was aliquoted into 96-well plate and “spiked” with serial dilutions of formula I compounds in DMSO or with DMSO without drug. The final concentration of DMSO in all wells was 0.1%. The plate was incubated at 37° C. for 30 min. Drug-containing samples were stimulated with 0.1 μg/mL mouse anti-human IgD-dextran (1A62) or 20 μg/mL polyclonal rabbit F(ab′)2 anti-human IgD. Phosphate-buffered saline (PBS) was added to the negative control unstimulated sample and the plates were incubated overnight (18 to 22 hours) at 37° C. Cells were stained with fluorochrome-conjugated anti-CD19 and anti-CD69 antibodies. Lyse/fix solution was used to remove red blood cells by hypotonic lysis and to fix the remaining cells, which were then analyzed by flow cytometry. CD19+ B cells were gated and analyzed for CD69 expression. The percentage of B cells expressing CD69 was plotted versus the log 10 of the concentration of the drug and the best-fit curves (variable Hill slope) were generated to obtain the IC50 value.
Table 2 shows the activity of the selected exemplary compounds of this invention in the in vitro whole blood CD69 assay, wherein each compound number corresponds to the example numbering set forth in the Examples 1-173 herein. “t” represents an IC50 of greater than 10 μM. “††” represents an IC50 of greater than 1 μM and equal to or less than 10 μM (1 μM<IC50≤10 μM). “†††” represents an IC50 of less than 1 μM.
This application claims the benefit of the filing date, under 35 U.S.C. § 119(e), of U.S. Provisional Application No. 63/277,879, filed on Nov. 10, 2021, the entire contents of which are incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2022/049618 | 11/10/2022 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63277879 | Nov 2021 | US |
